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Rhinovirus (RV) infections trigger exacerbations of chronic obstructive pulmonary disease (COPD) 
exacerbations and may precipitate secondary bacterial infections. Inhaled corticosteroids (ICS) are 
used commonly in COPD but are relatively ineffective in the context of virus-induced exacerbations 
and may also increase the risk of pneumonia. We hypothesised that, in a mouse model, ICS would 
suppress anti-viral and anti-bacterial immune responses leading to alteration of the airway 
microbiota and secondary bacterial infection following RV-induced exacerbation of COPD.  
Despite extensive optimisation, we were unable to define a representative mouse model of the 
deficient anti-viral and anti-bacterial responses that are indicative of human COPD. For this reason, 
and because of difficulties in measuring the airway microbiota in mice, we employed models of 
primary RV1B and Streptococcus pneumoniae infection as surrogates for viral exacerbation and 
bacterial colonisation in COPD. Fluticasone propionate (FP) administration prior to RV1B infection 
suppressed innate and adaptive immune responses leading to impaired virus control, in a dose 
dependent manner. This effect was causally related to suppression of type I interferon (IFN) as 
administration of recombinant IFN-β reconstituted IFN-stimulated gene expression and restored 
virus control. FP suppressed RV-induced airway inflammation but led to enhanced airway mucin 
production, effects that were unaltered by recombinant IFN-β. FP administration also suppressed 
innate responses to S. pneumoniae including expression of anti-bacterial cytokines and cathelicidin-
related anti-microbial peptide. High dose FP increased lung tissue bacterial loads with the opposite 
effect observed with lower dose FP despite similar anti-inflammatory effects. 
Our findings demonstrate beneficial anti-inflammatory effects of ICS during virus-induced COPD 
exacerbations but reveal some previously unrecognised detrimental effects including increased virus 
replication and enhanced mucin production. Additionally, we show that high dose ICS administration 
may increase bacterial loads and thus increase pneumonia risk but lower doses may conversely 
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Chapter 1: Introduction 
1.1 Chronic obstructive pulmonary disease 
1.1.1 Epidemiology 
Chronic obstructive pulmonary disease (COPD) is the most common chronic respiratory condition in 
adults, is a major cause of morbidity and is currently ranked as the 3rd leading cause of death 
worldwide.[1] COPD is also predicted to become the fifth leading cause of disability worldwide by 
2020.[2]  
Prevalence of COPD varies both within and between countries, which reflects differences in a 
number of factors including geographical and social factors, smoking patterns, environmental 
exposure to air pollution and access to healthcare.[3] According to the British Lung Foundation, an 
estimated 3.7 million people in the UK suffer from COPD [4] and the prevalence and burden of the 
disease are predicted to increase dramatically in the future due to persistent exposure to COPD risk 
factors and the increasingly ageing population. The financial burden to the UK National Health 
Service (NHS) of treating COPD was estimated to be over £800 million in 2011 with the total cost 
implications to the UK economy estimated to be around £2.7 billion per year when indirect costs 
such as working days lost are also considered.[5] 
1.1.2 Aetiology 
The development of COPD is multifactorial and related to a combination of genetic and 
environmental predisposing factors. There is overwhelming evidence that tobacco smoke is the main 
risk factor for COPD, especially in developed countries. In developing countries, outdoor air pollution 
and indoor smoke exposure from cooking and heating with organic fuels are also major causative 
contributors to development of COPD.[3, 6] 
Genetic factors that predispose to abnormal lung responses to environmental exposures are also 
believed to play a central role in development of COPD. The most extensively studied genetic 
abnormality is a deficiency in alpha-1 antitrypsin but this abnormality only accounts for 1-3% of 
patients with COPD.[7] Numerous other genetic abnormalities have been implicated in increasing 
COPD susceptibility, including mutations in genes encoding transforming growth factor β (TGF-β), 
tumour necrosis factor-α (TNF-α), serpin peptidase inhibitor, clade A alpha-1 antiproteinase, 
antitrypsin member 1 (SERPINA 1), interleukin (IL)-13 and matrix metalloproteinase (MMP)-9, among 
others.[8] 
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1.1.3 Definition and Diagnosis 
Definitions of COPD have evolved over time with the previous separately considered entities of 
chronic bronchitis (large airway inflammation and remodelling) and emphysema (destruction of the 
gas exchanging surfaces of the lung) more recently being replaced with an umbrella term of 
COPD.[9, 10] The diagnosis should be considered in patients with a suggestive medical history 
including dyspnoea, chronic cough and excessive sputum production and exposure to relevant risk 
factors for the disease. This clinical assessment should be combined with confirmation of post-
bronchodilator FEV1/FVC (forced expiratory volume in 1 second/forced vital capacity) < 0.70.[9]  
1.1.4 Immunology and Pathophysiology 
The major pathologic processes involved in development of COPD include remodelling and 
narrowing of the small airways, destruction of the lung parenchyma with pulmonary emphysema 
and inflammation of the central airways with chronic bronchitis.[11] 
1.1.4.1 Airway Inflammation 
Exposure to cigarette smoke and other inhaled irritants activates a distinct inflammatory cascade 
inducing lung epithelial cells and resident alveolar macrophages to produce a number of 
inflammatory mediators including TNF-α, IL-1β, CXCL8/IL-8 and granulocyte-macrophage colony 
stimulating factor (GM-CSF).[11, 12] These cytokines and chemokines act in a coordinated fashion to 
recruit additional inflammatory cells into the lungs, leading to a state of chronic airway 
inflammation, a central feature of COPD that has been demonstrated in tissue biopsy specimens and 
sputum analyses.[13, 14]  
Airway inflammation in COPD is characterised by an increase in a wide range of cell types including 
elevated macrophage numbers in the small airways and lung parenchyma [15] and increased T-
lymphocyte numbers in central airways, small airways and lung parenchyma, with an increased ratio 
of cytotoxic cluster of differentiation (CD)8+ T lymphocytes to CD4+ T helper cells.[16] Increased 
numbers of activated neutrophils are also observed in sputum and bronchoalveolar lavage (BAL) of 
patients with COPD, although increases are not observed in airway wall and lung parenchyma, likely 
reflecting the rapid transit of these cells through lung tissue.[11] Activated neutrophils secrete 
proteases such as neutrophil elastase, proteinase-3 and MMP-8 and -9 which may further contribute 
to alveolar destruction and also promote mucus hypersecretion.[11] 
Chapter 1: Introduction 
29 
 
1.1.4.2 Oxidative stress 
Oxidative stress also plays an important role in COPD. Increased oxidant burden from cigarette 
smoking leads to production of reactive oxidant species (ROS) by inflammatory cells and epithelium, 
which have wide-ranging effects in the airways leading to activation of multiple inflammatory genes 
and further amplification of the inflammatory response.[17] 
1.1.4.3 Mucus hypersecretion 
The inflammatory cell infiltration into lung tissue in COPD leads to abnormal tissue repair and 
remodelling that induces large airway mucous gland hyperplasia and goblet cell metaplasia in the 
small airways. This leads to a mucus hyper-secretory phenotype with increases in the amount and 
viscosity of mucus production. These processes may worsen airway obstruction [18] and lead to 
impairment of mucociliary clearance with retention of particulate matter and pathogens increasing 
susceptibility to respiratory infections.[19] 
1.1.4.4 Systemic Inflammation 
In addition to heightened airway inflammation, there is increasing recognition of the importance of 
systemic inflammation in COPD with reported increases in circulating levels of cytokines, chemokines 
and inflammatory cells.[20] This may contribute to disease systemic manifestations including 
skeletal muscle weakness, cardiovascular and metabolic disease and may also impact upon other 
comorbid diseases.[11] 
 
1.2 COPD exacerbations 
The natural course of COPD is punctuated by acute exacerbations which are described as episodes of 
symptomatic worsening that are beyond the normal day to day variations and require a change in 
medication.[9] Exacerbations are a major cause of morbidity, mortality and healthcare costs [21] and 
lead to accelerated lung function decline [22, 23] and reduced quality of life.[24] Data from the 
ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study 
demonstrated the presence of a frequent exacerbation phenotype which is more common as 
severity of airflow obstruction increases, with a history of prior exacerbations being the major factor 
associated with this phenotype.[25] 
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1.2.1 Aetiology of exacerbations 
COPD exacerbations have been associated with a number of aetiological factors including respiratory 
tract infection by bacteria and/or viruses [26, 27] and non-infectious aetiologies including air 
pollution [28], climatic factors such as air temperature [29] and cardiovascular events, particularly 
pulmonary embolism.[30]  
1.2.1.1 Viruses 
Respiratory viruses (most commonly rhinoviruses (RV)), are frequently detected in naturally 
occurring COPD exacerbations. Using molecular identification techniques, respiratory viruses have 
been identified in ~ 48-64% of naturally occurring exacerbations.[31-33]  Picornaviruses including 
rhinovirus are the most frequently detected pathogen.[34] Experimental infection studies have 
further confirmed a direct causal relationship between RV infection and COPD exacerbation with 
>90% of RV infected subjects experiencing an exacerbation of disease.[35]  
1.2.1.2 Bacteria 
Bacteria are also frequently detected during COPD exacerbations but a causal relationship between 
bacteria and exacerbation was previously debated when longitudinal studies showed no differences 
between rates of isolation of S. pneumoniae and H. influenzae by sputum culture in acute 
exacerbations and in stable disease.[36, 37]  However, more recent culture based studies have 
reported greater bacterial detection rates during exacerbation compared to stable state [31, 38, 39] 
and molecular typing has shown that acquisition of new bacterial strains may have a role in 
triggering exacerbations in COPD.[40] 
1.2.2 Human rhinoviruses 
1.2.2.1 Classification 
Rhinoviruses are positive-sense, single-stranded-RNA (ssRNA) viruses that are members of the family 
Picornaviridae and the genus Enterovirus.[41] RVs are classified according to serotype or, broadly, as 
‘major’ and ‘minor’ groups based on the receptor type used to gain entry into host cells. Major 
group RVs utilise the intracellular adhesion molecule 1 (ICAM-1) and minor group RVs utilise the low-
density lipoprotein receptor (LDL-R).[42, 43] 




RVs are the most frequent cause of the common cold and were first isolated from nasal samples of 
subjects with upper respiratory tract symptoms in the early 1960s.[44] RV infections are believed to 
account for ~70% of infectious agents detected in individuals displaying cold symptoms.[45] Other 
viral aetiological agents implicated in the common cold include influenza viruses A and B, 
coronaviruses, parainfluenza and respiratory syncytial viruses (RSV).[45]  
Previous studies have reported that adults are infected with RVs around 2-4 times per year with 
rates as high as 8-12 times per year observed in pre-school age children. Symptomatic infection rates 
decrease with older age, which is believed to be due to development of immune memory.[46] RV 
infections can occur throughout the year but peak during spring and early autumn in temperate 
climates.[47] Transmission of RV is likely to be secondary to both aerosol inhalation and spread via 
contaminated surfaces.[48, 49] 
1.2.2.3 Innate immune response to rhinovirus infection 
 RVs enter and replicate in epithelial cells lining the respiratory tract and trigger a cascade of distinct 
immune responses. Following entry of RV into epithelial cells, uncoating of the virus leads to release 
of viral RNA which is recognised by pattern recognition receptors (PRRs) including endosomal toll-
like receptors (TLR) 3, 7 and 8 and the intracellular RNA helicases retinoic acid inducible gene I (RIG-I) 
and melanoma differentiation-associated protein-5 (MDA5).[50-52] Following viral recognition, TLRs  
interact with adaptor molecules MyD88, TIR-domain containing adaptor-inducing interferon (IFN)-β 
(TRIF) and Mal and TRIF related adaptor molecule (TRAM) and RIG-I/MDA5 interact with 
mitochondrial anti-viral signalling protein (MAVS).[53, 54]  This triggers a signalling cascade that 
leads to activation of several key transcription factors including nuclear factor (NF)-B, interferon 
regulatory factor (IRF)-3 and IRF-7 and activating transcription factor (ATF)-2 [55, 56] These activated 
transcription factors then translocate to the nucleus and induce transcription of type I IFNs –α and –
β.[57, 58]  
The type I IFN response to RV infection is biphasic with initial IFN release triggered by detection of 
invading virus, through processes described above. The secondary step occurs where secreted type I 
IFNs bind to the type I IFN receptor complex (IFNAR-1 and -2), leading to activation of janus kinase 
(JAK) and tyrosine kinase proteins (TYK). These proteins then recruit and activate signal transducer 
and activator of transcription (STAT) proteins.[55] This leads to formation of a heterotrimeric 
complex containing IRF-9, known as interferon-stimulated gene factor-3 (ISGF3) which binds to 
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promoters of interferon-stimulated genes (ISGs) leading to their transcriptional activation.[59]  ISGs 
encode a range of proteins that selectively interfere with virus replication, protein synthesis or 
protein trafficking.[57] In addition to type I IFNs, the more recently described type III IFNs–λ1, -2 and 
-3 (IL-29, IL-28A and IL-28B respectively) may also have important roles in the innate anti-viral 
response to RV.[60]  
Type I IFN signalling is important for regulating function of natural killer (NK) cells which also 
participate in the innate anti-viral response by directly eliminating virally infected cells.[56, 61] Other 
innate components that have been shown to be important for the control of other respiratory 
viruses include macrophage function [62] and TNF-α expression [63] but whether these effects are 
directly relevant to control of RVs is unclear.   
1.2.2.4 Adaptive immune response to rhinovirus infection 
Adaptive immune responses are also an important component of host defence against respiratory 
virus infections. CD4+ and CD8+ T lymphocytes possess cytotoxic effector functions and several 
studies have shown that these cells have direct roles in the control of a number of viruses including 
influenza and RSV.[64-66] T cell responses in RV infections have not been extensively studied but a 
few studies have reported increased T cell recruitment to the airways in response to experimental 
RV infection in human and mouse models.[67-69] CD4+ T cells also provide help to B cells and are 
thus indirectly involved in production of antibody.[70] Pre-existing neutralising antibodies to RVs 
provide protection against infection and reduce symptoms in humans and may also provide 
protection against future RV infections.[71, 72] 
1.2.2.5 Disease 
Experimental RV infection studies in humans have been informative in defining the relationship 
between virus infection, inflammatory responses and symptoms. In healthy individuals, RV infections 
cause only mild upper respiratory tract symptoms including sore throat, rhinorrhea, cough and 
headache. Symptoms generally correlate with virus loads and begin around 12 hours (h) post-
challenge, peaking at day (d) 2-3 with resolution within 7-10d.[73-75]  
RV infection induces nasal mucus hypersecretion and plasma leakage and is associated with the 
production of pro-inflammatory cytokines including TNF-α IL-1β, IL-6 and chemokines CXCL8/IL-8, 
CCL3/macrophage inflammatory protein (MIP)-1α and CCL5/regulated on activation, normal T cell 
expressed and secreted (RANTES) in the upper airways, leading to a predominantly T helper-cell type 
1 (Th1) profile which limits virus shedding and symptoms.[76] Neutrophilia represents the major 
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cellular inflammatory component in RV infections and upper airway neutrophilia or neutrophil 
chemokine levels have been shown to correlate with symptom severity in several previous 
studies.[77-79]    
 
1.2.3 Mechanisms of rhinovirus-induced exacerbation in COPD 
1.2.3.1 Anti-viral immune responses 
Although RVs cause a mild self-limiting condition of the upper respiratory tract in healthy individuals, 
they can also infect the lower airways [80] and thus can precipitate acute disease exacerbations in 
patients with underlying COPD. As discussed, rhinoviruses are implicated in a large number of COPD 
exacerbations and the recently described human experimental model of RV infection [35] has 
allowed characterisation of disease-specific alterations in these mechanisms to be studied in COPD. 
As discussed, a robust IFN response is essential for resolution of RV infection in the airways and 
there is emerging evidence that these responses may be impaired in COPD. In vitro, cigarette smoke 
extract has been shown to impair RV-induction of IFNs –α and –β and ISGs in airway epithelial 
cells.[81, 82] BAL cells from patients with moderate COPD infected with RV ex vivo had impaired 
induction of IFN-β and a trend towards impaired IFN-α and –λ associated with impaired induction of 
ISG CXCL10/Interferon-gamma inducible protein 10kDa (IP-10).[35] Conversely, it has been reported 
that epithelial cells from COPD patients actually show enhanced type III IFN expression in response 
to RV infection.[83] Impairment of innate anti-viral immune responses may increase the 
susceptibility of patients with COPD to rhinovirus infections and/or lead to delayed RV clearance 
from the airways during established infection. This is supported by a study which reported that 
patients with COPD who were experimentally infected with RV16 had increased virus loads 
compared to healthy controls [35] and another in vitro study where airway epithelial cells from 
patients with COPD infected with RV29 had increased virus titres compared to cells from control 
subjects.[83] 
Very few studies have characterised the adaptive immune response to RV in COPD. Following 
experimental RV infection in COPD, CD8+ T cells were increased in BAL compared to baseline, an 
effect that was not observed in control subjects.[84] Reduced levels of immunoglobulin (Ig)G1 
antibody to the viral capsid protein of RV have also been shown to correlate with increased risk of 
acute exacerbations of COPD requiring hospitalisation.[85] 
Chapter 1: Introduction 
34 
 
1.2.3.2 Airway inflammation 
Recognition of RV by PRRs also leads to upregulation of pro-inflammatory mediators and cytokines 
that promote chemoattraction of inflammatory cells into the airways.[86] A number of studies 
assessing naturally occurring exacerbations in COPD have provided insight into the nature of airways 
inflammation during COPD exacerbations but few have examined specific inflammatory responses to 
viruses such as RV. COPD exacerbations represent a further amplification of the inflammatory 
process in the lungs from stable state. Regardless of aetiological cause, in comparison to stable 
state, exacerbations are associated with increases in cellular airways inflammation including 
neutrophilic and lymphocytic inflammation in sputum [31, 87, 88], increased neutrophil chemokine 
CXCL8/IL-8 [87, 89] and lymphocyte chemokines CXCL10/IP-10 [90] and CCL5/RANTES [87, 91] and 
exaggerated production of pro-inflammatory cytokines such as IL-6 [35, 91-93] and TNF- in the 
airways.[89, 91] 
Studies that have assessed the presence of viruses during exacerbations have reported that 
increased sputum IL-6 [93] and eosinophils [31, 91, 94] may specifically correlate with exacerbations 
in which a virus is present. Elevated levels of CXCL10/IP-10 in serum have also been identified as a 
marker of RV positive exacerbations in COPD but whether concurrent increases are observed in the 
airways is unknown.[95] The human model of experimental RV infection in COPD discussed above 
reported increased BAL neutrophil and lymphocyte numbers and increased sputum CXCL8/IL-8 
protein in patients with COPD compared to healthy controls. Additionally, virus loads also correlated 
with a number of sputum inflammatory indices in COPD including IL-6, CXCL8/IL-8, TNF-α and 
neutrophil numbers.[35] Some of the inflammatory mediators that have been shown to be increased 
during acute exacerbation of COPD compared to stable state or compared to infection in healthy 
controls are summarised in table 1.1. 
 
  




 Increased compared to stable 
COPD 
Increased compared to infection in 
healthy patients 
Inflammatory cells Neutrophils [31, 35, 87, 96] 
Lymphocytes [35, 87, 96] 





CCL5/RANTES [87, 91, 94] 
CCL4/MIP-1β  [91] 
CXCL8/IL-8 [35, 87, 89, 97] 
CXCL10/IP-10 [90] 
CCL2/monocyte chemotactic 
protein (MCP)-1 [96] 
Serum CXCL10/IP-10 [95] 
CXCL8/IL-8 [35] 
Cytokines IL-6 [32, 91, 93, 94] 
TNF-α [89, 91] 
IL-1β [91] 
 
Other mediators  Leukotriene B4 [96] 
Neutrophil elastase [35, 87] 
Eosinophilic cationic protein 
[87, 96] 
Myeloperoxidase [38, 97] 
Neutrophil elastase [35] 
Table 1.1 Inflammatory mediators increased during COPD exacerbations in comparison to stable state or in 
comparison to infection in healthy controls. 
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1.2.4 Mechanisms of bacterial exacerbation in COPD 
1.2.4.1 Bacterial colonisation 
Culture based studies have revealed the presence of bacteria in the lower respiratory tract of 
patients with COPD during clinical stability, an entity that has been previously termed 
‘colonisation’.[98] Isolated species can be broadly divided into two groups: potentially pathogenic 
microorganisms (PPMs) such as Haemophilus species, Streptococcus pneumoniae, Moraxella 
catarrhalis and Pseudomonas aeruginosa and non-potentially pathogenic microorganisms (non-
PPMs) such as components of the oropharyngeal and gastrointestinal flora including 
Corynebacterium, enterococci and Neisseria species.[99] 
The term ‘colonisation’ implies the presence of bacteria with no or minimal pathological significance. 
However, recent studies have shown that the presence of bacteria in the lungs is associated with 
host immune responses including increased neutrophilic airway inflammation [100, 101] and 
exaggerated production of inflammatory mediators such as TNF-α [101], IL-6 [102], IL-1β [102, 103], 
CXCL8/IL-8 [100, 102, 104-106], leukotriene-B4 [104, 106] and myeloperoxidase [104]. Bacterial 
infection in stable state is also associated with adverse clinical outcomes including increased risk of 
exacerbation [107, 108], impaired health status [102, 106] and accelerated lung function 
decline.[109, 110] This has led to postulation that ‘colonisation’ may represent a misnomer and 
alternative terms such as ‘chronic bronchial infection’ have subsequently been proposed.[98] 
1.2.4.2 Increased bacterial load 
Since COPD is associated with the presence of PPMs in the airways during clinical stability, studies 
have assessed the hypothesis that the occurrence of exacerbations may be related to increases in 
concentrations of existing PPMs, the ‘fall and rise’ or quantitative hypothesis of exacerbation 
pathogenesis.[111] This hypothesis is the subject of debate, as some studies have shown increased 
bacterial loads at exacerbation compared to stable state [38, 39] but one study conversely showed 
no difference or reduced concentrations of a number of PPMs at exacerbation.[112] 
1.2.4.3. Acquisition of new bacterial strain  
Studies that have employed molecular typing of bacterial isolates during stable state and 
exacerbation have led to development of the ‘new bacterial strain’ model of exacerbation 
pathogenesis. This states that acquisition of new strains of bacteria or antigenic change in a pre-
existing strain directly triggers acute exacerbations of COPD.[98] Sethi et al showed a two-fold 
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increase in exacerbation frequency in patients who had a new strain of one of four major PPMs (S. 
pneumoniae, H. influenzae, M. catarrhalis or P. aeruginosa) compared to patients in whom no new 
strains were isolated.[40] Furthermore, new strain exacerbations have also been shown to be 
associated with greater changes in airway inflammation and increased clinical symptom scores in a 
separate study by the same group.[113] 
1.2.4.4 Inflammatory responses during bacterial exacerbation 
Similar to virus-induced episodes, exacerbations associated with bacterial triggers also lead to 
enhanced airway inflammatory indices compared to stable state including increases in cellular 
airways inflammation [38, 91] and exaggerated production of chemokines and cytokines including 
TNF-α [96, 113], IL-6 [96], CXCL8/IL-8 [96], IL-1β [31] and leukotriene B4 [96]. Mechanisms of 
susceptibility to bacterial infection in COPD are discussed in section 1.3.2. 
1.2.4.5 The lower respiratory microbiome in COPD 
As discussed previously, our understanding of the role of bacteria in pathogenesis of exacerbations 
to date has been predominantly based on studies that use classical microbiological culture 
techniques or molecular typing of specific pre-determined bacterial strains. However, new culture-
independent molecular methods have revealed a diverse microbiota in the lower airways of healthy 
subjects and patients with chronic lung disease including the presence of bacteria that were not 
previously amenable to culture.[114-117] These culture-independent techniques are based on PCR 
amplification of the 16S rRNA gene, a highly conserved component of the bacterial genome. The 
gene consists of conserved and variable regions and, by using universal primers targeted at the 
conserved regions, the entire spectrum of microorganisms within a sample can be amplified with the 
variable regions allowing discrimination between different microorganisms.[118, 119]  
Studies using 16S rRNA sequencing to assess the lower respiratory microbiota in stable COPD have 
yielded conflicting results with one study showing increased community diversity in moderate to 
severe COPD vs. healthy controls [120] and other studies showing reduced or no change in 
diversity.[115, 116] Another study which assessed microbiota in endotracheal aspirates from 
intubated patients with COPD identified two distinct sub-groups, one group with a loss of bacterial 
community diversity and a second with increased diversity.[117] Studies have reported increased 
representation of Firmicutes phylum in severe COPD vs. smokers or healthy controls [115] and in 
severe vs. moderate COPD.[120] Proteobacteria have been reported to be more frequent in COPD 
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patients compared to healthy controls in one study [114] but less frequent in severe vs. moderate 
COPD in another study [120]. 
Only two studies to date have assessed the changes that occur in the lung microbiome from stable 
state to exacerbation in COPD. Huang et al assessed temporal changes in the airway microbiome of 
sequential sputum samples taken from patients with COPD at clinical stability and during 
exacerbation. An increase in Proteobacteria at exacerbation was observed that decreased with 
antibiotic therapy.[121] Similar findings were reported by a study that assessed the microbiota in 
sputum samples taken from subjects experimentally infected with RV16, where an increase in 
Proteobacteria, specifically H. influenzae was observed in patients with COPD but not in healthy 
controls.[122]   
 
1.3 Pneumonia in COPD 
 Patients with COPD are known to be at increased risk of developing bacterial pneumonia.[123-126] 
The distinction between bacterial exacerbation and pneumonia in COPD is based on the anatomical 
site of infection with exacerbations caused by infection of the larger airways and pneumonia 
affecting the lung parenchyma and smaller airways.[127, 128] Clinically, pneumonia can be identified 
by the presence of new consolidative changes on chest imaging. In reality, it can often be difficult to 
distinguish between a bacterial exacerbation and pneumonia in COPD and there is likely to be 
considerable overlap between these syndromes, especially since many studies of exacerbations in 
COPD do not routinely include chest imaging in the protocol.[98] The distinction between these two 
entities is clinically important because studies that have used radiographic definitions have reported 
worse outcomes for patients with COPD who present with pneumonia compared to non-pneumonic 
exacerbation.[129, 130]  
1.3.1 Aetiology of pneumonia in COPD 
Bacterial pathogens are the most common aetiological cause of pneumonia, although viruses have 
also been identified as potential causative agents.[131] The spectrum of microbial aetiology 
associated with pneumonia in COPD is similar to patients without chronic lung disease with S. 
pneumoniae frequently identified as the most common cause.[132, 133] However, H. influenzae and 
P. aeruginosa have been reported to be more common in COPD.[132-134]  
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1.3.2 Innate immune responses to Streptococcus pneumoniae 
Innate immune responses to bacterial respiratory pathogens have been most extensively studied in 
S. pneumoniae infection. S. pneumoniae is an encapsulated gram-positive diplococcus that belongs 
to the group α-Streptococci.[135] S. pneumoniae frequently colonises the upper respiratory tract in 
humans and, although most episodes of carriage are benign, the anatomical continuity of the 
nasopharynx with the lower airways makes pneumonia an ever-present risk.[136] The precise 
mechanisms that determine progression from nasopharyngeal colonisation to pneumonia are poorly 
understood, although factors such as human immunodeficiency virus (HIV) may predispose to 
increased risk.[137]  
As with RV infection, the first recognition of S. pneumoniae by the host is mediated by PRRs 
including TLRs and NOD-like receptors (NLRs) which recognise specific bacterial pathogen associated 
molecular patterns (PAMPs).[138] Components of the pneumococcal wall including lipoteichoic acid 
and lipoproteins are recognised by TLR2 which has been shown to be important in mouse models of 
disease as TLR2 deficient mice show reduced bacterial clearance following challenge with S. 
pneumoniae.[139] TLR4 was previously thought to be activated exclusively by products of Gram-
negative bacteria only but more recent data now suggests that TLR4 may be activated by 
pneumolysin, a pneumococcal virulence factor.[140] TLR9 is also believed to play a role in host 
recognition of S. pneumoniae and TLR9 deficient mice also have increased bacterial loads and 
reduced survival in response to pneumococcal challenge.[141]  
NLRs are the other major type of PRRs that are involved in bacterial recognition. Nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2) recognises bacterial peptidoglycan components 
and has been shown to promote macrophage recruitment and clearance of S. pneumoniae 
colonisation in mice.[142] NLR family, pyrin domain containing 3 (NLRP3) is another member of the 
NLR family that forms protein complexes called inflammasomes which are involved in post-
translational regulation of IL-1β production.[138] NLRP3 -/- mice have been shown to be more 
susceptible to pneumococcal pneumonia.[143]  
Recognition of S. pneumoniae by PRRs triggers intraceullar signaling cascades that lead to activation 
of transcription factors including NFB, STATs and IRF-3 and -7. NFB, in particular, plays an 
important role in pneumococcal infection and triggers expression of a number of proinflammatory 
genes.[144] Targeted disruption of the P50 subunit of NFB in mice increases susceptibility to 
pneumococcal infection [145] and polymorphisms of inhibitor of NF-B (IB) gene correlate with 
protection against invasive pneumococcal disease in humans [146]. Transcription factor activation 
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culminates in increased expression of proinflammatory mediators including cytokines such as IL-6, 
TNF-α and neutrophil chemokines such as CXCL8/IL-8 which all have important anti-bacterial roles. 
Anti-TNF-α antibody administration in a mouse model of pneumococcal pneumonia has been shown 
to increase systemic dissemination and accelerate mortality.[147] IL6 -/- mice show increased lung 
bacterial loads and mortality following pneumococcal infection [148] and selective depletion of 
neutrophils also increased bacterial lung loads in mice [149].   
Alveolar macrophages play a key role in initial phagocytosis of bacteria in the airways and also in 
coordinating the innate immune response to infection including amplification of TNF-α 
production.[150, 151] As infection progresses, macrophages cease to be involved in phagocytosis as 
neutrophils become the major phagocytosing cell.[151] Neutrophil action is crucial for S. 
pneumoniae clearance through a number of specific functions including chemotaxis, phagocytosis 
and direct microbial killing and selective depletion of neutrophils in mice leads to reduction in 
clearance of S. pneumoniae.[149] Other host defence mechanisms that have been shown to have 
important roles in bacterial lung infection include mucociliary clearance [152], complement [153] , 
type I and II IFNs [154, 155], IL-17 [156] and anti-microbial peptides (AMPs) such as cathelicidin 
[157], β defensin [158, 159] and surfactant protein-A [160]. 
 1.3.3 Impairment of anti-bacterial host defence in COPD 
The precise underlying pathophysiology of pneumonia in COPD has not been extensively studied. 
Therefore, whether similar mechanisms to the pathogenesis of bacterial exacerbations, such as 
increases in bacterial load of colonising species and/or new strain acquisition are also involved 
development of pneumonia in COPD is unclear. However, a number of studies have assessed some 
components of anti-bacterial innate responses in COPD and some of the reported impairments may 
potentially lead to increased risk of pneumonia.  
1.3.3.1 Pattern recognition receptor expression 
Conflicting data exists on the expression of bacterial PRRs TLR2 and TLR4 in COPD. Studies have 
reported decreased TLR2 expression on macrophages [161] and neutrophils [162] from patients with 
COPD and TLR4 has also been shown to be down-regulated on nasal epithelial cells in severe COPD  
[163]. These effects would potentially increase risk of pneumonia in COPD due to reduced bacterial 
recognition and suppressed initiation of anti-bacterial immune responses. However, other studies 
have shown increased expression of TLR2 on monocytes and sputum from patients with COPD.[164, 
165] TLR2 and TLR4 polymorphisms have additionally been shown to be associated with accelerated 
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lung function decline in COPD and this further suggests that these PRRs may play a role in disease 
progression, perhaps by increasing risk of bacterial infection.[166] There are no reported data 
suggesting that expression of NLRs is impaired in COPD, although polymorphisms of  NOD2 have 
been shown to be associated with lower FEV1 % predicted values.[167] 
1.3.3.2 Macrophage and neutrophil function 
As discussed in section 1.1.4.1, stable COPD is associated with increased absolute numbers of 
macrophages and neutrophils in the airways. Since these cells are responsible for phagocytic 
clearance of bacterial pathogens, it might be expected that phagocytosis would be enhanced rather 
than suppressed in COPD. However, accumulating evidence suggests that, although numbers of 
phagocytic cells are increased, function is markedly impaired in COPD.[168] Phagocytosis of 
potentially pathogenic species including S. pneumoniae and H. influenzae has been shown to be 
impaired in alveolar and monocyte-derived macrophages from patients with COPD.[169, 170] These 
defects appear to be specific to bacteria, since alveolar macrophages from patients with COPD have 
preserved capacity to phagocytose inert beads.[170-172] Additionally, defective efferocytosis has 
been shown in alveolar macrophages from patients with COPD compared to healthy controls.[171]  
Relatively few studies have assessed the phagocytic ability of neutrophils in COPD. Some studies 
have reported impaired phagocytosis of bacteria by peripheral blood neutrophils in COPD [173, 174] 
but these findings have not been replicated in other studies [175, 176]. Sapey et al reported specific 
functional defects in neutrophils from patients with COPD including reduced chemotaxis and poor 
migratory accuracy towards inflammatory sources.[177] 
1.3.3.3 Mucociliary clearance 
Optimal airway defence relies on an adequate balance between mucus production and clearance. As 
discussed in section 1.1.4.3, COPD is associated with defective mucus secretion with increased 
mucus viscosity and mucus retention. Tracheobronchial clearance following inhalation of 
radioaerosol has been shown to be impaired in COPD.[19] Impaired clearance may lead to 
accumulation of bacteria and thus increase susceptibility to exacerbations and pneumonia in COPD. 
Bacteria such as S. pneumoniae have also been shown to directly upregulate the airway mucin 
MUC5AC [178, 179] and thus lower airways colonisation may directly perpetuate mucus 
hypersecretion. In addition to altered quantity and quality of mucus in COPD, there is also evidence 
of impaired ciliary function in COPD which may further contribute to particle and pathogen retention 
and increased risk of bacterial infection.[180, 181] 
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1.3.3.4 Anti-microbial peptides 
AMPs are soluble anti-bacterial factors that are present in airway surface fluid and are secreted by 
epithelium and/or inflammatory cells.[182] Studies evaluating the production of AMPs in COPD have 
reported varying patterns of expression. During clinical stability, lower levels of salivary lysozyme 
[183] have been shown to correlate with increased risk of COPD exacerbation and sputum levels also 
fall with acquisition of new bacterial strains.[184] In contrast, lactoferrin levels appear to remain 
constant between stable state and exacerbation.[184] Secretory leucocyte protease inhibitor (SLPI) 
protein levels have been shown to be elevated in stable COPD [185] but decrease following bacterial 
infection [184] with lower levels reported to correlate with more frequent exacerbations in one 
study.[186]  Both increased [187] and decreased [185, 188] expression of human β-defensins have 
been reported in stable COPD. Cathelicidin/LL37 levels have been shown to be increased in the 
airways of patients with mild obstruction but reduced with more severe COPD.[189] Increased 
cathelicidin/LL37 levels have also been reported with colonisation or bacterial infection compared to 
stable state.[184] 
1.3.4 Coinfection and virus-induced secondary bacterial infection  
As discussed previously, both viruses and bacterial pathogens can trigger acute exacerbations of 
COPD. Dual virus and bacterial infection is reported in up to 25% of COPD exacerbations and this has 
led to the hypothesis that one infection may follow another so that they are infrequently detected 
together.[31, 190] A large body of evidence supports an association between influenza infection and 
secondary bacterial pneumonia triggered by S. pneumoniae, S. aureus or H. influenzae and several 
molecular mechanisms for these associations have been proposed.[191, 192] However, influenza is a 
lytic virus which causes significant necrosis to the airway epithelium [193] and therefore, 
mechanisms involved in influenza-induced secondary bacterial infection may not be directly 
applicable to rhinoviruses which do not cause similar epithelial damage.[194] 
1.3.4.1 Clinical studies 
The majority of studies assessing pathogens in naturally occurring infections in COPD have tested for 
viruses and bacteria in single samples obtained during exacerbation and rates of dual infection 
reported in these studies range from 8-25%.[31, 91, 195] Hutchinson et al performed sequential 
sampling at exacerbation onset and then 5-7 days later and found that, in 36% of exacerbations 
where a virus was detected, a bacterial species was identified in the second sample.[196] In another 
study by George et al, sequential sputum samples taken from patients with COPD during 
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exacerbation were analysed by PCR for rhinoviruses and bacterial pathogens S. pneumoniae, H. 
influenzae and M. catarrhalis. In patients with RV positive exacerbations but no bacteria detected at 
exacerbation onset, 73% were found to be subsequently positive for bacteria at d14 following 
exacerbation onset.[197] In the human experimental RV infection model, 60% of patients with COPD 
were shown to develop secondary bacterial infection identified by positive sputum culture, an effect 
that was not observed in healthy controls.[190] 
1.3.4.2 Alteration of the respiratory microbiome by virus infection 
Emerging evidence suggests that secondary bacterial infection may be precipitated by respiratory 
viruses through alterations in the respiratory microbiome. 16S rRNA sequencing of sputum samples 
from the human model of experimental RV infection in COPD showed a sixfold increase in 16S 
bacterial copy number at d15 post RV infection in COPD with a greater expansion of H .influenzae in 
patients with COPD compared to healthy controls.[122] A study by Leung et al reported that the 
oropharyngeal microbiota of patients coinfected with influenza and pneumonia had increased 
Pseudomonas representation compared to patients with pneumonia alone.[198] Studies have also 
shown alteration in the respiratory microbiota in response to influenza challenge in mice with 
concentration in two dominant communities containing Staphylococcus, Prevotella, Acinetobacter 
and Moraxella bacteria genera.[199] 
As discussed in section 1.2.4.5, there is evidence that the lower respiratory microbiota may be 
altered in stable COPD with increased representation of phyla such as Proteobacteria. Therefore, 
virus infection in patients with COPD may potentially lead to further dysregulation of the microbiota 
with expansion of existing species and increased risk of secondary bacterial infections and 
pneumonia.  
1.3.4.3 Mechanisms of rhinovirus-induced secondary bacterial infection 
A number of potential mechanisms for influenza-induced secondary bacterial infection have been 
identified but much less is known about the effect of rhinoviruses on bacterial infection. In vitro 
studies have reported that RV infection leads to increased adherence of S. pneumoniae, S. aureus 
and H. influenzae to nasal epithelial cells [200] and increased adherence of S. pneumoniae to 
tracheal epithelial cells [201]. Increased adherence may be mediated by upregulation of surface 
molecules such as platelet activating factor receptor (PAFR) or carcinoemryonic antigen-related cell 
adhesion molecule (CEACAM) facilitating increased binding of bacteria.[200, 201] Additionally, 
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studies have shown that RV can disrupt the barrier function of airway epithelial cells and directly 
increase transmigration of bacteria through cell layers in vitro.[202, 203] 
Impaired macrophage and neutrophil recruitment and function have been postulated as potential 
mechanisms underlying the increased risk of secondary bacterial infection following influenza 
infection.[204-207] Some of these effects may also be relevant to RVs, which have been shown to 
impair responses to bacterial products by alveolar macrophages in vitro [208] and a recent study 
also reported that RV1B suppressed neutrophil recruitment in response to secondary H. influenzae 
challenge in mice leading to impaired bacterial clearance.[209] 
Other potential mechanisms of RV-induced secondary bacterial infection in COPD include induction 
of proteases such as neutrophil elastase which can cleave AMPs such as SLPI and elafin, an effect 
that was suggested by data from the human experimental RV infection model where patients with 
COPD who developed bacterial infection had higher sputum levels of neutrophil elastase but lower 
levels of SLPI and elafin than bacteria-negative patients.[190] Several other mechanisms have been 
identified by studies of influenza-induced secondary bacterial infection including upregulation of IL-
10 [210], type I [211, 212] and type II [213] IFN signalling. Whether any of these mechanisms are 
relevant to RV-induced secondary bacterial infection is, to date, unclear.  
 
1.4 Management of COPD 
1.4.1 Overview of management in stable COPD 
Effective management of COPD should be individualised and multi-faceted with specific goals 
targeted towards symptomatic relief, improvement of exercise tolerance and health status, 
reduction of exacerbations and prevention of disease progression.[9] Management algorithms for 
COPD are evolving and the previous recommendations of treatment based solely on spirometric 
parameters are now recognised to be over-simplistic and potentially ineffective.[214] Recent 
guidelines from the Global Initiative in Obstructive Lung Disease (GOLD) recommend treatment 
based on stratification of patients according to a combination of clinically relevant factors including 
spirometry, frequency of exacerbations and breathlessness as assessed by the Medical Research 
Council (MRC) dyspnoea score or the COPD assessment test (CAT).[9] 
Broadly, management can be subdivided into nonpharmacologic and pharmacologic treatment. 
Nonpharmacologic approaches include smoking cessation (which can include pharmacologic 
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treatment), pulmonary rehabilitation and vaccination against influenza and pneumococcus.[9, 215] 
Pharmacologic strategies include bronchodilators (β2 adrenoreceptor agonists and anticholinergics), 
inhaled corticosteroids (ICS), phosphodiesterase inhibitors and oxygen therapy.[215] For very severe 
COPD, surgical options including lung volume reduction and lung transplantation can be considered 
in selected patients.[216] 
1.4.2 Inhaled corticosteroids  
1.4.2.1 Indications 
ICS are frequently used as therapeutic agents in COPD and are recommended in patients with FEV1< 
50% predicted and/or frequent exacerbations that are not adequately controlled by use of long 
acting β2 adrenoreceptor agonists (LABAs) alone.[9] Monotherapy with ICS is not recommended in 
COPD as it has been shown to be less effective than ICS/LABA combined.[9, 217] Despite these 
specific recommendations, there is evidence of more widespread use of ICS in patients with milder 
disease.[218-220] The most widely used ICS compounds in COPD are fluticasone propionate (FP) and 
budesonide with other compounds such as beclomethasone and ciclesonide infrequently used.[221, 
222] 
1.4.2.2 Mechanisms of action  
The molecular mechanisms underlying suppression of inflammation by ICS in airways diseases have 
been well characterised. The pharmacological actions of ICS are mediated by binding of the drug to 
the glucocorticoid receptor (GR) in the cell cytoplasm, forming a complex that subsequently 
translocates to the nucleus to interact with glucocorticoid response elements (GRE) located in the 
promoter region of target genes.[223, 224] Binding to GREs leads to an activation of the 
transcription of anti-inflammatory proteins (transactivation) and also leads to repressed expression 
of immune-regulatory genes (transrepression).[225] ICS may also have post-
transcriptional/translational effects such as degradation of mRNA and reduced inflammatory protein 
secretion.[226]  Effects of ICS on transcription of genes relevant to COPD are shown in table 1.2. 
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Increased transcription (transactivation) 
 Anti-inflammatory cytokines: IL-10, IL-12, IL-1 receptor antagonist 
 β2 adrenoceptors 
 IB  
 SLPI 
 Lipocortin 1 
 MAP kinase phosphatase-1 (MKP-1) 
Reduced transcription (transrepression) 
 Inflammatory cytokines: IL-1β, IL-6, IL-13, IL-15, TNF-α, GM-CSF 
 Chemokines: CCL5/RANTES, CXCL10/IP-10, CXCL8/IL-8, MCP-1 
 Inflammatory enzymes: cyclo-oxygenase-2 (COX-2), inducible nitric oxide synthase 
(iNOS) 
 Adhesion molecules: ICAM-1, vascular cell adhesion molecule-1 (VCAM-1) 
 Mediator receptors: neurokinin-1 receptors, bradykinin (B2) receptors 
 
Table 1.2: Effects of ICS on transcription of genes relevant to COPD 
(Adapted from Barnes (2011)[225] 
1.4.2.3 Anti-inflammatory effects of inhaled corticosteroids in stable COPD 
Although ICS are highly effective in reducing eosinophilic and Th2-mediated inflammation in asthma, 
COPD is believed to be associated with a resistance to the anti-inflammatory effects of ICS.[227] 
Histone deacetylase-2 (HDAC-2) is an enzyme that is recruited following activation of GRs and 
reverses histone acetylation leading to suppression of NFB- activated inflammatory genes.[228] 
The oxidative stress present in COPD reduces the expression and activity of HDAC-2 in lung tissue 
and alveolar macrophages and thus leads to resistance to ICS effects.[229] 
Despite the relative resistance to ICS therapy in COPD, several studies have reported suppressive 
effects on airway inflammation in stable state, although conflicting data exists.  Studies have 
reported suppressed neutrophilic inflammation by ICS in BAL [230, 231] but conversely increased or 
no effect on neutrophil counts in bronchial biopsies.[232-234] Reduced numbers of CD4+ and CD8+ 
lymphocytes have also been observed with ICS treatment [233, 235, 236] but other studies report no 
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or minimal effects.[234, 237, 238]  ICS treatment has been shown to increase macrophage numbers 
in BAL.[230, 231] 
1.4.2.4 Beneficial clinical effects associated with inhaled corticosteroid use 
Clinical studies have reported a number of potentially beneficial effects of ICS use in COPD. 
Reductions in exacerbation frequency have been reported in trials of ICS in patients with COPD with 
most studies reporting ~20-25% reduction.[217, 239, 240] The largest longitudinal study of ICS in 
COPD, the Towards a Revolution in COPD Health (TORCH) study reported a 25% reduction associated 
with combination fluticasone/salmeterol therapy. However, the group receiving salmeterol alone 
also had significantly reduced exacerbation rates compared to placebo and no difference was found 
between salmeterol alone and combined FP/salmeterol regarding severe exacerbation rates.[217] 
This has led some authors to speculate that the benefit on exacerbation reduction with combination 
therapy may be primarily related to the LABA component. Consistent with this hypothesis, some 
studies assessing budesonide or fluticasone therapy alone vs. placebo have reported no effect of ICS 
on exacerbation frequency.[241-243] Overall, the effect of ICS use on reducing exacerbation rates in 
COPD is relatively modest. 
Other potential beneficial effects associated with ICS therapy include increases in post-
bronchodilator FEV1 [217, 244] and improvements in health-related quality of life measures.[217, 
239, 245] No convincing data exists to suggest that ICS therapy has any significant effects on rate of 
lung function decline or mortality in patients with COPD.  
1.4.3 Effects of inhaled corticosteroids on respiratory virus infections  
As mentioned, respiratory virus infections are common triggers for acute exacerbations of COPD. 
Since ICS have been shown to have relatively modest effects on exacerbation frequency, there has 
been some speculation that they may have a relative lack of benefit in the context of acute 
respiratory virus infections in particular.[57]  
1.4.3.1 Effects of corticosteroids on innate anti-viral responses  
Emerging evidence suggests that corticosteroids may suppress innate anti-viral immune responses. 
In vitro studies have shown suppression of RV-induction of IFN-α by budesonide in peripheral blood 
mononuclear cells [246] and suppression of RV–induction of ISG CXCL10/IP-10 by budesonide in 
bronchial epithelial cells.[247] Additionally, dexamethasone administration has been shown to 
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inhibit IFN–induced ISGs in bone-marrow derived macrophages.[248] The specific components of 
type IFN signalling affected by steroids have not been fully characterised. 
1.4.3.2 Effects of corticosteroids on virus control  
The in vivo consequences of this potential impairment of anti-viral immune responses by ICS on virus 
control have also not been extensively studied. Gustafson et al reported that oral prednisolone 
administration prior to experimental RV challenge in healthy subjects led to increased viral titres in 
nasal lavage [249] and Puhakka et al showed prolonged virus shedding with intranasal FP 
administration during naturally occurring colds [250]. In a mouse model, systemic administration of 
hydrocortisone in combination with pneumovirus infection increased viral replication.[251] 
Conversely, Singam et al showed in a mouse model of allergic asthma that nebulised FP 
administration reduced virus loads following RSV challenge [252] and Bauer et al showed no effect 
of oral dexamethasone administration on virus titres in cigarette-smoke exposed mice infected with 
influenza [253]. None of these studies have performed detailed evaluations of the in vivo effects of 
corticosteroids on anti-viral innate immune responses and/or correlated impairment with changes in 
virus loads.  
1.4.3.3 Effects of corticosteroids on virus-induced airway inflammation 
Studies that have assessed the effects of inhaled corticosteroids on virus-induced airway 
inflammation have reported conflicting results.  Intranasal administration of FP in a long-term house 
dust mite (HDM)-induced mouse model of asthma with RV1B infection led to suppressed BAL 
eosinophil numbers but had no effect on numbers of neutrophils, lymphocytes or macrophages in 
BAL.[254] Another study assessed oral prednisolone therapy administration in combination with 
influenza or RSV infection, also in a mouse model of HDM-induced asthma. Prednisolone had no 
effect on virus-induced BAL macrophage or neutrophil recruitment but reduced eosinophils in 
response to RSV infection and lymphocytes in response to influenza or RSV infection.[255] A study 
that assessed inhaled budesonide in a human model of experimental RV-induced asthma 
exacerbations showed only minimal effects on cellular airways inflammation.[67] These studies have 
therefore further reinforced the belief that ICS may be ineffective at specifically reducing virus-
induced airway inflammation. 
1.4.3.4 Effect of corticosteroids on adaptive immunity 
Very few studies have assessed the effects of ICS on components of the adaptive immune response 
to respiratory virus infection. Grunberg et al evaluated the effect of inhaled budesonide treatment in 
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asthmatic patients experimentally infected with RV16 and showed no significant effect on CD4+ or 
CD8+ T cell numbers in airway epithelium.[67] To date, there are no studies that have assessed the 
effect of corticosteroids on antibody production following respiratory virus infection. 
 
1.4.4 ICS use and pneumonia 
An increased risk of pneumonia associated with use of ICS in COPD has been reported by a number 
of recent studies and this signal has raised considerable concern about the potential safety of these 
commonly used therapies. Several large randomised controlled trials have reported a consistent and 
statistically significant increased incidence of pneumonia associated with use of FP in COPD, either 
as monotherapy or in combination with LABA.[217, 256-259] TORCH, the largest study to date,  
included 4788 patients over a 3 year follow-up and reported 19.6% incidence of pneumonia 
associated with FP/Salmeterol vs. 12.9% with placebo (p<0.001).[217] A recent study which assessed 
a novel FP derivative compound, fluticasone furoate, in combination with the LABA vilanterol, also 
reported increased frequency of pneumonia.[260] Evaluation of alternative ICS/LABA combinations 
containing budesonide have shown a less consistent association with pneumonia, with one study 
reporting increased risk [245] but others showing no effect [261-263]. Although an earlier industry 
funded meta-analysis concluded that budesonide use was not associated with increased pneumonia 
risk [264], a more recent Cochrane review that included 43 studies reported an increased risk of 
pneumonia hospitalisation associated with use of either FP or budesonide [265]. The association of 
ICS use with pneumonia risk has also been evaluated in population based cohort studies which have 
reported an increased incidence of pneumonia with an estimated relative risk between 26–
70%.[222, 266-270] Some of these studies have additionally suggested that the risk may be dose 
dependent with increasing doses associated with greater risk.[266, 267, 270] 
Although the risk of pneumonia with ICS has been reported by a number of studies, some have 
questioned this association due to a number of potential methodological limitations and 
confounding factors. Very few existing studies have been designed to specifically assess pneumonia 
as an endpoint with most trials relying on a physician diagnosis of pneumonia rather than the gold 
standard of radiographic imaging.[271] Diagnosis of pneumonia on clinical grounds alone has been 
shown to have poor sensitivity and specificity [272, 273] and this has led to suggestions that some 
episodes of non-pneumonic COPD exacerbation may have been misreported as pneumonia, thus 
leading to an over-estimation of risk. Results of observational studies may be further confounded by 
Chapter 1: Introduction 
50 
 
over-representation of unmeasured factors such smoking, immunisation history, functional status 
and co-morbidities that could influence the risk of pneumonia in ICS-users. 
Intriguingly, although several clinical trials show an increased risk of development of pneumonia 
with ICS use in COPD, many have not reported a corresponding increase in pneumonia-related 
mortality.[217, 257] Observational studies of patients admitted with community-acquired 
pneumonia (CAP) provide further weight to this theory by demonstrating that ICS use causes either 
reduced mortality [269, 274, 275] or at least has no effect on outcome in patients with COPD.[221] A 
recent study also showed that prior treatment with ICS reduces the risk of development of 
parapneumonic effusions in patients with CAP.[276] In contrast, some observational studies have 
shown an increase in pneumonia hospitalisations and pneumonia-related mortality associated with 
ICS use.[222, 267] 
 
1.4.5 Effects of ICS on anti-bacterial host defence mechanisms and bacterial infection 
As discussed above, studies of ICS use in COPD report an increased risk of development of 
pneumonia and a variable effect on pneumonia-related mortality. Interestingly, ICS use in asthma 
has not been shown to correlate with a similar increased risk of pneumonia.[277] The reasons for 
this are unclear but may be theoretically related to a number of factors including higher drug doses 
used in COPD, greater frequency of colonising bacteria in the lower airways and/or differences in 
effects of ICS on immune responses in asthma and COPD.  
1.4.5.1 Innate anti-bacterial immune responses 
A number of studies have assessed the effect of corticosteroids on various components of anti-
bacterial host-defence in the lungs and some of the reported impairments may contribute to the 
increased risk of pneumonia observed in clinical practice. MacRedmond et al reported that FP 
downregulates TLR4 mRNA and protein in an airway epithelial cell line in vitro.[163]  As discussed, 
severe COPD is also associated with reduced TLR4 expression and therefore ICS and COPD may 
interact synergistically to lead to impaired expression of TLR, reduced bacterial recognition and 
suppressed initiation of anti-bacterial immune responses which may increase risk of pneumonia. 
Conversely, TLR2 has been shown to be enhanced by dexamethasone with an 8-fold increase in 
mRNA expression observed in an airway epithelial cell line.[278] A study which assessed the effect of 
dexamethasone on expression of NLRs, the other major family of PPRs for S. pneumoniae, showed 
an increase in NLRP3 mRNA and protein expression in macrophage cell lines.[279]  
Chapter 1: Introduction 
51 
 
The effect of corticosteroids on phagocytosis by macrophages is unclear with some studies showing 
an impairment of function [280-282] and others reporting no effect [170, 283]. Phagocytosis of E.coli 
by neutrophils ex vivo has been reported to be unaffected by hydrocortisone [284] and studies have 
also shown no effect of fluticasone on production of reactive oxygen species by neutrophils [285] 
and dexamethasone on formation of neutrophil extracellular traps [286]. A number of in vitro 
studies in various cell types and in vivo studies have shown that corticosteroids can suppress 
induction  of number of inflammatory cytokines and chemokines that are known to have roles in 
anti-bacterial host defence including IL-6 [283, 287-289], TNF-α [288-291], CXCL8/IL-8 [287, 288] and 
type I IFNs (discussed previously in section 1.4.3.1).  
Variable effects of corticosteroids on AMP expression have been reported. In vitro, dexamethasone 
had no effect on spontaneous release of lactoferrin or lysozyme in nasal explants in one study [292] 
but a 40% reduction in lactoferrin was reported in another study [293]. Thompson et al showed a 
reduction in BAL lactoferrin and lysozyme levels in patients with COPD treated with 6 weeks of 
beclomethasone compared to placebo control.[231] Conversely, Schoonbrood et al showed no 
effect on sputum lactoferrin levels following 4 weeks treatment with beclomethasone.[294] In vitro, 
SLPI mRNA expression in airway epithelial cells has been shown to be induced by administration of 
FP [295] but these effects have not been replicated in vivo with no effect of FP treatment on sputum 
levels of SLPI shown in patients with COPD [296] and no effect of FP treatment on BAL levels of SLPI 
reported in healthy controls [297]. Biphasic effects of corticosteroids have been shown on 
expression of surfactant protein-A in vitro with induction at low drug concentration but inhibition 
with prolonged exposure to high concentrations.[298] In vivo, ICS treatment has been associated 
with increased expression of surfactant proteins-A and -B in a mouse model [299] and increased 
surfactant protein-D in induced sputum from patients with COPD [300]. β-defensin 2 has been 
shown to be inhibited by corticosteroids in vitro [301, 302] and in vivo [302] while cathelicidin-
related antimicrobial peptide (CRAMP, the mouse homolog of human LL37/cathelicidin) has been 
shown to be suppressed by budesonide administration in mice [303].  
The effects of corticosteroids on mucociliary clearance have not been extensively studied. High dose 
prednisolone administration has been shown to impair mucociliary clearance in rats [304] but 
nebulised budesonide had no effect on mucociliary clearance in human asthmatics [305]. Varying 
effects of corticosteroids on expression of mucins have been reported with some in vitro studies 
reporting suppression of baseline MUC5AC expression [306] and suppression of MUC5AC induced by 
P.aeruginosa or H. influenzae in airway epithelial cell lines [307, 308]. Conversely in vivo studies have 
shown no effect of intranasal corticosteroids on MUC5AC expression in nasal epithelium [309] and 
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no effect of ICS on MUC5AC and MUC5B expression in bronchial biopsies from asthmatic patients 
[310] while dexamethasone has been shown to increase IL-13 induced MUC5AC in vitro in human 
bronchial epithelial cell lines [311]. 
Some of the possible impairments in anti-bacterial host defence in COPD (as discussed in section 
1.3.2) and in relation to ICS use are summarised in figure 1.1. 
 
Figure 1.1: Potential mechanisms of impaired anti-bacterial host-defence associated with ICS use and COPD.                                                                                                                                                                         
Abbreviations: COPD chronic obstructive pulmonary disease; IL interleukin  TLR toll-like receptor; TNF tumour 
necrosis factor. Blue dashed arrow represents anti-bacterial impairment related to COPD. Red dashed arrow 
represents anti-bacterial impairment related to inhaled corticosteroid use. 
 
1.4.5.2 Bacterial clearance  
As discussed in the previous section, ICS may impair or enhance a number of anti-bacterial host 
defence factors in the lungs. Only a few studies have assessed the in vivo effects of ICS 
administration on bacterial clearance in mouse models and they report conflicting findings. Chu et al 
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showed that nebulised administration of FP during M. pneumoniae infection in mice reduced 
bacterial loads in lung tissue.[312] Barbier et al similarly showed that intranasal FP administration 
led to ~50% reduction in bacterial loads in mice infected with S. pneumoniae and additionally 
showed that FP administration reduced in vitro invasion of airway epithelial cells by S. 
pneumoniae.[313] Conversely, Patterson et al showed increased bacterial burden in lung tissue and 
blood associated with nebulised FP administration in a mouse model of Klebsiella pneumoniae 
infection [283] and Wang et al showed a similar effect with nebulised budesonide following P. 
aeruginosa infection in an ovalbumin-induced mouse model of asthma [303]. These studies suggest 
that ICS may either accelerate or impair bacterial clearance from the lungs but variation in a number 
of factors including dose and type of ICS administered, bacterial pathogen and strain of mouse used 
may all influence the observed effects. The relevance of these animal studies to ICS use in patients 
with COPD is unclear and there are no existing human models of experimental bacterial respiratory 
infection in COPD to translate these findings into. 
1.4.5.3 Bacterial colonisation and the lower respiratory microbiome 
In addition to studies that have assessed the effects of ICS in models of bacterial pneumonia, other 
studies have focussed on whether ICS have any effects on colonising bacteria in the lungs during 
clinical stability. A study that used culture based techniques showed that ICS use in children with 
asthma increased oropharyngeal colonisation by S. pneumoniae.[314] Other studies which have 
employed molecular techniques have shown that ICS use in COPD is associated with increased 
sputum bacterial loads measured by quantitative PCR in stable state.[315]  Pragman et al showed 
segregation of bacterial communities associated with use of ICS by performing 16S pyrosequencing 
in BAL samples from patients with COPD.[120] Similarly, Huang et al observed a trend towards 
greater richness and diversity of the microbiota in samples from ICS-exposed vs. non-exposed 
patients with COPD.[316] These studies all provide intriguing evidence that ICS use may potentially 
alter the respiratory microbiota in COPD, leading to proliferation of existing PPMs and subsequent 
increased risk of bacterial pneumonia. 
1.4.5.4 Virus-induced secondary bacterial infection 
As discussed in section 1.3.3, there is evidence that a primary respiratory virus infection may directly 
precipitate secondary bacterial infection. Whether ICS use can influence virus-induced secondary 
bacterial infection and interact to favour development of pneumonia is unclear. In the Investigating 
New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) study, pneumonia was shown 
to occur more frequently following an unresolved exacerbation in COPD patients taking ICS but the 
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aetiology of exacerbations could not be determined.[317] This finding raises speculation that ICS use 
in COPD may potentiate pneumonias that follow viral exacerbations. Jamieson et al showed that 
dexamethasone treatment led to increased bacterial loads in the liver during sequential infection 
with intranasal influenza and intravenous Listeria monocytogenes in mice.[318]  
 
1.5 Animal models of COPD exacerbation 
As discussed above, COPD is a complex, heterogeneous disorder and human studies have previously 
focused on characterising the underlying disease pathogenesis. There has also been interest in 
development of clinically relevant animal models of COPD to enable controlled investigation of 
pathogenic pathways involved in stable disease and during acute exacerbations. However, there 
remains an incomplete understanding of the different disease phenotypes in humans and therefore, 
developing a clinically relevant model in animals has been somewhat challenging.  
1.5.1 Models of stable COPD 
Most existing animal models of COPD have been reported in mice and broadly employ three main 
strategies: inhalation of noxious stimuli (most commonly cigarette smoke), instillation of tissue-
degrading proteinases such as elastase or genetic manipulation.[319]   
Models using genetic manipulation include gene knockout mouse strains such as tissue inhibitor of 
metalloproteinases-3 (TIMP-3) -/- [320] or surfactant protein-D -/- [321] or transgenic strains over-
expressing mediators such as IL-13 and IFN-γ.[322, 323] Although these models have provided some 
insight into COPD pathogenesis and susceptibility, it is recognized that the disease in humans is 
caused by a combination of genetic susceptibility and environmental exposures and therefore, the 
relevance of these monogenetic approaches to clinical disease may be questionable. 
Cigarette smoke based models have the advantage of using the primary disease-causing agent in 
humans. Smoke can be administered by whole–body exposure or nose-only dosing protocols.[324] 
Regardless of the method of exposure, studies have consistently shown that cigarette smoke induces 
a number of pathophysiological changes that are indicative of COPD including enhanced cellular 
airways inflammation, increased BAL inflammatory mediator production, increased oxidative stress 
and mucus hypersecretion.[325-330] Although these features may be representative of those seen 
in healthy human smokers or early stage COPD, the overt emphysematous tissue destruction seen in 
advanced disease cannot be recreated with use of cigarette smoke exposure in mice, even if 
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administration occurs for prolonged periods.[331] It has been estimated that cigarette smoke 
exposure induces pathology associated with mild COPD (GOLD stage 1).[331] Given that most cases 
of COPD in humans are not diagnosed until the disease has become more severe (usually GOLD 
stage 2 or above)[332, 333], cigarette exposure models may be considered irrelevant to the 
spectrum of patients commonly encountered in clinical practice. In particular, acute exacerbations of 
disease become more frequent as the disease progresses [25] and, therefore, other methods of 
modelling COPD may be more appropriate when studying pathophysiological mechanisms involved 
in exacerbations.  
Instillation of elastase into the airways produces a rapid onset of emphysematous tissue destruction 
in the lungs and may be considered to be the best and most rapid method for modelling severe 
disease and therefore, the optimum method for producing a phenotype relevant to patients 
encountered in clinical practice.[319, 331] Additionally, elastase administration in mice also 
produces other disease-relevant features including increased airway inflammation, mucus hyper-
secretion and impaired lung function.[334-337] However, elastase does not model all the 
complicated events associated with exposure to cigarette smoke, which contains over 4000 
chemicals and >1015 free radicals per inhalation [331] and therefore administration of a single 
substance is an over-simplified method of modeling COPD. Some studies have also reported models 
of chronic lipopolysaccharide (LPS) administration leading to features of airway inflammation, 
remodelling, emphysema and altered lung function in mice [338, 339] but these models are 
generally believed to be even less representative of human disease as they fail to accurately recreate 
a number of key features.  
1.5.2 Models of viral exacerbation 
Several studies have combined models of stable COPD with viral challenge to directly mimic acute 
exacerbation. Most studies have used cigarette smoke exposure prior to infection with either 
influenza or respiratory syncytial virus (RSV). Studies vary in terms of duration of smoke exposure 
and also with regards to the specific virus used. However, most studies report that cigarette smoke 
exposure leads to enhanced virus-induced airway inflammation.[253, 340, 341] Conversely, Han et al 
reported that 21 days of cigarette smoke exposure led to suppressed cytokine production and 
airway inflammation in response to challenge with pandemic H1N1 influenza [342] and Robbins et al 
reported suppressed inflammation with low dose influenza but enhanced inflammation when higher 
doses of virus were combined with cigarette smoke exposure [343]. Studies that have assessed the 
effect of cigarette smoke on virus loads have reported varying effects with one study showing 
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increased virus titres [341], another showing reduced titres [343] and two reporting no effect [253, 
342]. Other endpoints that are relevant to COPD exacerbation such as mucus hyper-secretion and 
lung function impairments have not generally been reported in the existing cigarette smoke 
exacerbation models. 
Despite being the most frequently identified viral cause for COPD exacerbation, no existing studies 
have assessed the effect of cigarette smoke exposure on RV infection in mice. The only published 
mouse model of RV-induced exacerbation in COPD reported that weekly intranasal administration of 
porcine pancreatic elastase combined with LPS for four weeks, followed by RV1B infection, led to 
increased lung tissue mRNA expression of TNF-α, IL-13 and MUC5AC, increased airway hyper-
responsiveness (AHR) to methacholine (MCH) challenge, deficient type I IFN responses and delayed 
virus clearance from the airways.[344] These features are similar to those reported in human studies 
of naturally occurring exacerbations and those induced by the experimental RV infection human 
COPD model, as discussed previously. 
1.5.3 Models of bacterial infection  
1.5.3.1 Bacterial exacerbation 
A number of studies have also combined cigarette smoke exposure or elastase (+/- LPS) 
administration with bacterial challenge to model exacerbation. Cigarette smoke models have 
reported enhanced inflammation and increased bacterial clearance in response to challenge with H. 
influenzae [345] or P. aeruginosa.[346]  Models of elastase administration have reported suppressed 
inflammation in response to S. pneumoniae [347] with other studies showing enhanced 
inflammation to H. influenzae [348] or S. pneumoniae [349]. Ganesan et al reported that H. 
influenzae infection following combined four dose elastase/LPS administered led to delayed 
bacterial clearance, increased airway inflammation, enhanced expression of MUC5AC and 
exaggerated AHR.[350] 
1.5.3.2 Colonisation 
An alternative approach to modelling COPD adopted by some studies has been to try to recreate the 
lower respiratory bacterial colonisation component of the disease. A major problem in establishing 
models of chronic lung infection is that common human PPMs are rapidly cleared by the rodent 
immune system, typically within 24-48h of administration when low infecting doses are 
instilled.[351] Haste et al reported a model of low dose S. pneumoniae infection in CBA/Ca mice 
where recoverable numbers of pneumococci were present at 7d post-infection and showed that the 
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dose and strain of bacteria and also the strain of mouse used can impact upon whether chronic 
infection can be successfully established.[352] Other studies have attempted to encase bacteria in 
agar beads to restrict in vivo phagocytosis and have shown longer term persistence of bacteria in the 
airways.[353, 354] 
1.5.3.3 Lower respiratory microbiome in mice 
Studies have also started to characterise the lower respiratory microbiota in samples including BAL, 
lung tissue and nasal lavage taken from specific pathogen free mice and have shown the presence of 
similar phyla to those identified in humans including Proteobacteria, Firmicutes and Bacteroidetes. 
[355, 356] Krone et al used 16S pyrosequencing to show that the microbiota in nasal lavage differed 
between young and elderly mice and also showed that challenge with S. pneumoniae led to a 
decrease in microbial community diversity.[356] Goulding et al used clone library sequencing of BAL 




1.6 Aim, Hypothesis and Thesis Outline 
1.6.1 Aim and Hypothesis 
The overall aim of this project was to investigate the effects of ICS therapy on rhinovirus-induced 
secondary bacterial infection in COPD. The central hypothesis was that ICS suppress anti-viral and 
anti-bacterial host defence responses and thus predispose to secondary bacterial infection following 
RV-induced exacerbation of COPD. Focussed aims and hypotheses are presented at the start of each 
of the results chapters.   
1.6.2 Thesis Outline 
In the Introduction section of this chapter, the background to the topics covered within this thesis is 
outlined including COPD, the role of RVs and bacteria in precipitating COPD exacerbations and 
secondary bacterial pneumonias and the effects of ICS on anti-viral and anti-bacterial host-defence. 
Chapter 2 details the materials and methods used. This is followed by the results chapters: Chapter 3 
describes experiments to define a representative mouse model of RV-induced COPD exacerbation; 
Chapter 4 investigates the effects of inhaled corticosteroid administration on RV infection in mice; 
Chapter 5 investigates the effects of inhaled corticosteroid administration on respiratory bacterial 
infection in mice. Finally, in Chapter 6, the results presented in the thesis are discussed and plans for 
future work are outlined. 
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Chapter 2: Materials and methods                                                                                                 
2.1 Materials 
Details of commonly used buffers and cell/virus culture media are shown in table 2.1. Further 
miscellaneous reagents are also given in table 2.2. 
Medium / Buffer Composition 
Ammonium-chloride-
Potassium (ACK) lysis buffer 
0.155M Ammonium chloride (Sigma-Aldrich, Shaftesbury, UK), 
10mM potassium bicarbonate (Sigma-Aldrich) and 0.1mM 
disodium ethylenediaminetetraacetic acid (EDTA; Invitrogen, 
Paisley, UK) in dH20. Filter-sterilised through a 0.22µm filter. 
BAL fluid 12mM lidocaine hydrochloride monohydrate (Sigma-Aldrich) 
and 5.5 mM EDTA (Invitrogen) in phosphate buffered saline 
(PBS; PAA Laboratories, Yeovil, UK). 
10%/2% Dulbecco’s 
Modified Eagles Medium 
(DMEM)  medium 
10%/2% (v/v) foetal calf serum (FCS, PAA) in DMEM (PAA) with 
20µM HEPES buffer (Invitrogen) and 1% sodium bicarbonate 
(v/v) (Gibco, Paisley, UK).  
ELISA wash buffer 0.05% (v/v) Polyethylene glycol sorbitan monolaurate 
(‘Tween20’; Sigma-Aldrich) in PBS. 
ELISA reagent diluent 
 
1% bovine serum albumin (w/v) (BSA; Sigma-Aldrich) in PBS. 
Fluorescence activated cell 
sorting (FACS) buffer 
1% (w/v) BSA (Sigma-Aldrich) and 0.01% (w/v) sodium azide in 
PBS. 
Lung/BAL cell culture 
medium 
100µg/ml streptomycin (Sigma-Aldrich), 100 units/ml penicillin 
(Sigma-Aldrich), 5% FCS (v/v) (PAA), 2mM L-glutamine, 20 µM  
HEPES buffer (Invitrogen) in Roswell Park Memorial Institute 
1640 medium (RPMI; PAA). 
Lung digestion buffer Lung/BAL cell culture medium containing 1mg/ml collagenase 
type XI (Sigma-Aldrich) and 80 units/ml bovine pancreatic 
DNAse type IV (Sigma-Aldrich). 
4% Paraformaldehyde (PFA) 4% solution (w/v) of paraformaldehyde (Sigma-Aldrich) in 
water. Stirred at 55oC for 30 minutes. pH 7.2-7.4. Filter 
sterilised through a 0.22µm filter. 
10%/2% RPMI medium 10%/2% (v/v) heat inactivated FCS (PAA) in RPMI (PAA) 
supplemented with 20µM HEPES buffer (Invitrogen); 0.075% 
(v/v) sodium bicarbonate (Invitrogen), 100 units/ml penicillin 
(Invitrogen) and 100µg/ml streptomycin (Invitrogen) 
Tris -EDTA (TE) buffer 1M Tris Base (Sigma-Aldrich) with 0.5M EDTA (Invitrogen) in 
dH2O 496ml. 
Table 2.1 Buffers and Media 
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Reagent Details Supplier 
DNA ladder 1kB plus DNA ladder 
10bp-12kB DNA standard 
Invitrogen 
Elastase Porcine pancreatic elastase. 
High purity, crystallised 
Merck, Nottingham, UK 
Fluticasone propionate 5mg powder  Sigma-Aldrich 
Isofluorane ‘Isofluorane-Vet’ 100% (w/w) Merial, Harlow, UK 
LPS LPS from Escherichia coli 
026:B6. Lyophilised powder, 
purified by phenol extraction 
Sigma-Aldrich 
Pentobarbitone Pentoject Pentobarbitone 
sodium 20% (w/v) 
AnimalCare Ltd, York, UK 
Polyinosinic-polycytidylic 
acid (poly(I:C)) 
Long synthetic analog of 
dsRNA 
Invitrogen 
Poly(I:C) (HMW)/LyoVec MDA5 agonist (transfected 
poly(I:C)) 
Invitrogen 
RNALater RNA stabilisation buffer Qiagen, Crawley, UK 
Recombinant IFN-β Mouse IFN-β, carrier free R & D Systems, Abingdon, UK 
Streptavidin–Horse radish 
peroxidase (HRP) 
ELISA grade Streptavidin-HRP 
conjugate (streptavidin from 
Streptomyces avidinii) 
Invitrogen 
Tetra methyl benzidine 
(TMB) substrate 
3,3’,3,5’ TMB single solution 
chromagen 
Invitrogen 
Table 2.2 Miscellaneous reagents 
  




2.2.1 Virological techniques 
2.2.1.1 RV1B propagation 
The minor group (LDL-R binding) human Enterovirus rhinovirus A, serotype 1B was obtained from the 
American Type Tissue Culture Collection (ATCC, Teddington, UK) and passaged 7 times in Ohio Hela 
cells (European Collection of Cell Cultures, Health Protection Agency, Porton Down, UK) to create 
laboratory working stocks. Working stocks were periodically neutralised with HRV-specific antisera 
(ATCC) to confirm serotype. 
25 x 175 cm2 flasks of Ohio HeLa cells were grown to approximately 90% confluence in 10% DMEM 
medium (v/v) at 37oC with 5% CO2. Cells were washed twice with PBS and infected with 10ml of 2 x 
107 50% tissue culture infectious dose (TCID50) working stock RV1B in 2% DMEM medium (v/v). 
Flasks were then incubated at room temperature for 1h with gentle shaking before addition of a 
further 10ml 2% DMEM medium (v/v) with subsequent incubation at 37oC with 5% CO2 for a further 
24h or until close to 100%. Cytopathic effect (CPE) was observed. The cells and medium were then 
harvested, concentrated to 36ml in PBS by repeated centrifugation at 2,700 x g at 4oC and stored at -
80oC. 
2.2.1.2 Virus purification    
 The cell pellet/PBS mixture was freeze-thawed twice to lyse cells and then centrifuged at 2,700 x g 
for 15 minutes at 4oC to remove cellular debris. Virus was precipitated from the supernatant by 
adding 2.8g Polyethylene Glycol-6000 (Sigma-Aldrich) and 4ml of 5M (final concentration) NaCl, 
followed by incubation on ice for 1h. The virus was then pelleted by centrifugation at 2,700 x g for 15 
minutes and was then re-dissolved in 15ml of PBS and further centrifuged to remove insoluble 
matter. The supernatant was filtered through a 0.2µm syringe filter and then concentrated to ~ 
2.5ml by repeated centrifugation at 2,500 x g, at 4oC using a 100,000MW 15ml Amicon centrifugal 
filtration device (Milipore, Billerica, USA). Purified RV1B stocks were stored at -80oC.  
2.2.1.3 Virus titration 
As separate virus batches were used for each study, these were assessed for infectivity by in vitro 
culture before use in vivo. Ohio Hela cells were seeded in 96 well plates at 1.5 x 104 cells per well in 
150µl 10% DMEM medium (v/v). RV1B stocks were serially diluted to give concentrations from 10-1 
to 10-8 and 50µl of each dilution was added to 8 replicate wells of HeLa cells. Plates were incubated 
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at 37oC in 5% CO2 for 96h and then assessed for CPE by light microscopy. The Spearman-Karber 
formula was used to calculate the TCID50.[357] 
2.2.1.4 Virus inactivation 
Purified virus stocks were inactivated for use as a control inoculum by irradiation with 1200µJ/cm2 
ultraviolet (UV) light using a UV crosslinker (CX-2000; UVP, Cambridge, UK).  
2.2.2 Animal models and methods 
2.2.2.1 Mice 
8-10 week old female C57BL/6 mice were purchased from Charles River (Margate, UK) and housed in 
individually ventilated cages in specific pathogen-free conditions within the CBS facility at St. Mary’s 
campus, Imperial College London. All work was completed in accordance with UK Home office 
guidelines (UK project licence PPL 70/7234).  During all experiments, animal welfare was monitored 
at least twice daily and any mice that displayed signs of significantly impaired health status were 
euthanised.  
2.2.2.2 Anaesthesia 
For all intranasal challenges, mice were lightly anaesthetised in an exposure box with inhaled 
isofluorane and oxygen at 2 litres per minute (Merial). Terminal anaesthesia was achieved by 
intraperitoneal injection of 0.2ml 20% (w/v) pentobarbitone solution (Pentoject). 
2.2.2.3 RV1B infection 
Mice were challenged intranasally with 50µl inoculum containing 2x106 TCID50 RV1B or UV-
inactivated RV1B (UV-RV1B), or mock infected with PBS. Mice were culled by terminal anaesthesia 
performed at various time-points post challenge.  
2.2.2.4 RV-induced exacerbation of COPD model 
Mice were challenged intranasally with 1.2 units of porcine pancreatic elastase (Merck) on d1 and 
with 70 endotoxin units of LPS from Escherichia coli 026:B6 (Sigma-Aldrich) on d4 of the week for up 
to 4 consecutive weeks.  In an alternate model, mice were treated with a single dose of 1.2 units of 
elastase alone. Mice treated with intranasal PBS instead of elastase or LPS were used as controls. For 
exacerbation, mice were infected intranasally with 50µl inoculum containing 2 x 106 TCID50 RV1B or 
UV-inactivated RV control, either 7d after final LPS challenge in the case of combined elastase and 
LPS models or 10d after elastase challenge in the single dose elastase model. The four dose 
elastase/LPS  RV-induced exacerbation of COPD mouse model is outlined schematically in figure 2.1 
and the nomenclature used for each treatment group is explained in table 2.3.  
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Table 2.3 Four dose combined elastase/LPS COPD RV exacerbation model, treatment group nomenclature 
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The single dose elastase RV-induced exacerbation of COPD model is outlined in figure 2.2 and the 
nomenclature used for each treatment group is explained in table 2.4. 
Figure 2.2 Single dose elastase RV-induced exacerbation of COPD model  
 
Group Elastase RV1B 
Infection 
 




























Table 2.4 Single dose elastase RV-induced exacerbation of COPD model, treatment group nomenclature 
 
2.2.2.5 FP and RV1B infection model 
FP powder (Sigma-Aldrich) was resuspended at a concentration of 357µg/ml in dimethyl sulfoxide 
(DMSO; Sigma-Aldrich) and then diluted 1:1000 in PBS. Mice were treated intranasally with 50µl of 
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this solution (equating to approximately 1mg/kg FP dose) or vehicle DMSO diluted 1:1000 in PBS as 
control. One hour after FP or vehicle administration, mice were infected intranasally with 50µl RV1B 
(5 x 106 TCID50) or UV-inactivated RV1B control. The FP and RV1B model is outlined in figure 2.3 and 
the nomenclature used for each treatment group is explained in table 2.5.  
Figure 2.3 FP and RV1B infection model  
 
Group Fluticasone propionate RV1B  Infection 
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2.2.2.6 Recombinant IFN-β administration; FP and RV1B infection model 
Mice were intranasally dosed with 1mg/kg FP or vehicle DMSO, 1h prior to infection with 50µl RV1B 
(5 x 106 TCID50) or UV-inactivated RV1B control, as described for the FP and RV1B infection model 
(section 2.2.2.5). One hour following RV1B or UV-RV1B challenge, mice were then additionally 
treated intranasally with 50µl of PBS containing 104 units of recombinant IFN-β (R & D systems). This 
model is outlined in figure 2.4 and the nomenclature used for each treatment group is explained in 
table 2.6. 



































































































Table 2.6 Recombinant IFN-β in FP and RV1B infection model, treatment group nomenclature 
 
2.2.2.7 FP and Streptococcus pneumoniae infection model 
Mice were dosed intranasally with FP (1mg/kg) or vehicle DMSO, as described for the FP and RV1B 
infection model (section 2.2.2.5), 1h prior to infection with 50µl of S.pneumoniae (2.5 x 105 colony 
forming units (CFU)) capsular serotype 2 strain (D39). This strain had been cultured previously at 
37oC in Todd-Hewitt broth (Oxoid, Basingstoke, UK) supplemented with 0.5% yeast extract (w/v) 
(Sigma-Aldrich) and aliquots of known concentration had been stored at -80oC in 10% glycerol (v/v) 
(Sigma-Aldrich). This model is outlined in figure 2.5 and the nomenclature used for each treatment 
group is explained in table 2.7. 
 
Chapter 2: Materials & Methods  
68 
 






























Table 2.7 FP and S. pneumoniae infection model, treatment group nomenclature 
 
2.2.2.8 Airway hyper-responsiveness assessment  
AHR was assessed using an unrestrained whole body plethysmography system (Electromedical 
Measurement Systems (EMMS; Alton, UK). Mice were challenged for 1 minute with increasing doses 
of acetyl-β-methyl-choline chloride (methacholine) (Sigma-Aldrich) in H20 up to a maximum of 
100mg/ml and enhanced pause (Penh) was assessed over the following 5 minute period. Data were 
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acquired and analysed using eDaq v1.8 software (EMMS) and are presented as Penh average for 5 




)  x ( 
Te
𝑅𝑡
 − 1) 
  
PEF = Peak Expiratory flow (ml/s) 
PIF = Peak Inspiratory flow (ml/s) 
Te = Expiratory Time (Total) 
Rt = Relaxation Time (time take for expiration of 65% total expiratory volume) 
 
2.2.3 Sample recovery and processing 
2.2.3.1 Bronchoalveolar lavage 
Mice were cannulated via the trachea and lavaged with 1.5ml of BAL fluid. For 16S sequencing work, 
a modified protocol was adopted with use of autoclaved polytetrafluoroethylene (PTFE) tubing (VWR 
chemicals, Lutterworth, UK) and autoclaved instruments. Cells and supernatants from recovered 
fluid were separated by centrifugation at 12,000 x g for 1 minute. Cells were treated with 1ml ACK 
buffer for 30 seconds to lyse red blood cells and then resuspended in 1ml of 10% RPMI medium 
(v/v). BAL supernatants were stored at -80oC until use. Total live BAL cell counts were assessed by 
trypan blue (Sigma-Aldrich) exclusion.  
2.2.3.2 Nasal lavage 
Nasal lavage was performed by cannulation via the trachea upward to the nasopharynx. The nasal 
cavity was gently perfused back to front with 1.0 ml of PBS via the catheter, and the lavage fluid was 
collected at the nares. Autoclaved tubing and instruments were used, as described for BAL. 
2.2.3.3 Differential cell counts 
100µl of cells from the 1ml total BAL suspension (from section 2.2.3.1) was spun down (110 x g, 5 
minutes) onto Shandon Cytoslides using a cytocentrifuge (Shandon Cytospin 3; Thermo Scientific, 
Basingstoke, UK). Slides were air-dried and stained with Quick Diff kit (Reagena, Toivala, Finland) 
and, using light microscopy, approximately 300 cells per slide were differentially counted blind to 
experimental conditions. 
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2.2.3.4 Isolation of lung cells for flow cytometry 
The left lung was excised post BAL and crudely dissociated in gentleMACS C-tubes (Militenyi Biotech, 
Bisley, UK) containing 5ml of lung digestion buffer using the gentleMACS Dissociator system 
(Militenyi Biotech) followed by incubation for 45 minutes at 37oC (5% CO2). A second step of 
mechanical dissociation was then carried out to general a single cell suspension and cells were 
pelleted by centrifugation (445 x g for 10 minutes). Erythrocytes were lysed in 5ml ACK buffer for 5 
minutes and then neutralised using 10ml PBS. Finally, cells were filtered through a 100µm cell 
strainer, washed in PBS and resuspended in 10% RPMI medium (v/v). Total live lung cell counts were 
determined by light microscopy using trypan blue exclusion. 
2.2.3.5 Lung tissue processing for RNA extraction 
The right apical lung lobe was excised post BAL, rinsed in sterile PBS and stored at -80oC in RNAlater 
(Qiagen).  
2.2.3.6 Lung tissue processing for measurement of bacterial loads  
For quantification of bacterial loads in the S.pneumoniae mouse model, the left lung was excised  
post BAL using autoclaved instruments, rinsed in sterile PBS and placed into 1ml sterile PBS. Samples 
were processed immediately, as described in section 2.2.9.1. For 16S quantitative PCR, the right 
upper lobe, the left lung or both lungs were excised post BAL, immediately placed into an autoclaved 
1.7ml tube and snap frozen in liquid nitrogen followed by storage at -80oC. 
2.2.3.7 Nuclear protein extraction 
The left lung was excised post BAL, immediately placed into a 1.7ml tube and snap frozen in liquid 
nitrogen followed by storage at -80oC. Lung tissue was manually homogenised whilst immersed in 
liquid nitrogen using a mortar and pestle. Nuclear Protein was then extracted using a nuclear 
extraction kit (Active Motif, La Hulpe, Belgium) according to manufacturer’s instructions and samples 
stored at -80oC. 
2.2.3.8 Histological evaluation of lungs. 
For histological evaluation, following BAL, the lungs were perfused with PBS via the heart and 
inflated with 4% paraformaldehyde (w/v) (PFA) and then immersion fixed in 4% PFA for 24h. Further 
processing was carried out by the St Mary’s Hospital Cellular Pathology Service (Imperial College NHS 
Trust, London). Lungs were embedded in 4% paraffin and 5μm thick sagittal sections were stained 
with hematoxylin and eosin (H&E) or periodic acid Schiff (PAS) reagent. Alveolar chord length was 
determined by measuring the diameter of air spaces in 10 random fields per slide using Zeiss 
Axiovision software (version 4.8.3.0; Carl Zeiss, Oberkochen, Germany). PAS stained lung sections 
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were scored using a modified system, as previously described [358] and 10-20 airways were counted 
per section. All counting was performed blind to experimental conditions 
2.2.3.9 Blood sampling 
For measurement of RV-specific antibodies in the RV1B mouse model, peripheral blood was 
collected from the carotid arteries into microtainer serum separation tubes (BD Biosciences, Oxford, 
UK) and whole blood was allowed to coagulate for 1h at room temperature. Serum was then 
separated by centrifugation at 13,000 x g for 2 minutes and stored at -80oC. 
For measurement of bacterial loads in blood in the S.pneumoniae model, samples were obtained by 
cardiac puncture and immediately transferred into lithium heparin microtainer blood collection 
tubes (BD Biosciences). Samples were processed immediately, as described in section 2.2.9.2. 
2.2.4 Flow cytometry 
2.2.4.1 Surface staining of BAL and lung leukocytes. 
1 x 106 lung cells or 1 x 105 BAL cells were plated into a 96 v-well plate and incubated in 50µl of 5µg 
/ml of Fc Block in FACS buffer (anti-mouse CD16/CD32, BD Biosciences) for 15 minutes at room 
temperature. Fluorochrome-conjugated antibodies specific for cell surface markers diluted in 50µl 
FACS buffer per well were directly added to cells with further incubation for 30 minutes at 40C in the 
dark. The antibodies used and their working concentrations are displayed in table 2.8. Cells were 
then washed in PBS and stained with live/dead cell marker (Invitrogen) at 1:1000 dilution in PBS for 
20 minutes at 4oC in the dark. Cells were then washed with PBS and fixed by addition of 100µl per 
well of 2% formaldehyde (v/v) (Sigma-Aldrich) in PBS for 20 minutes at room temperature in the 
dark. Cells were again washed with PBS, resuspended in FACS buffer and stored at 4oC in the dark, 












Specificity Clone Conjugate Final concentration 
Hamster anti-mouse 
CDε3 
500A2 Pacific Blue 1µg/ml 
Rat anti-mouse 
CD4 
RM4-5 APC 0.25µg/ml 
Rat anti-mouse 
CD8a 
53-6.7 Alexa Fluor 488 0.5µg/ml 
Rat anti-mouse 
C19 
1D3 PerCP-Cy5.5 0.25µg/ml 
Hamster anti-mouse 
CD69 
H1.2F3 FITC 1µg/ml 
Mouse anti-mouse 
NK1.1 
PK136 PE 1µg/ml 
Table 2.8 Antibodies used for flow cytometry and working concentrations 
 
2.2.4.2 Flow cytometry data acquisition and analysis 
Stained cells were acquired on an LSR II flow cytometer (BD Biosciences) and analysed using FlowJo 
software (version 10.0.6 ; Tree Star, Ashland, USA). Representative gating strategies used for analysis 



















































Figure 2.6 Representative flow cytometry gating; Lung and BAL lymphocytes in RV infection model 
Abbreviations: FSC-A Forward scatter area; SSC-A Side scatter area; SSC-H Side scatter height 
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2.2.5 Enzyme-linked immunosorbent assay (ELISA) 
2.2.5.1 BAL soluble mediators  
Protein levels of chemokines and cytokines were assessed in BAL fluid, diluted as required. All ELISAs 
were carried out using reagents from Duoset kits (R&D Systems), according to manufacturers’ 
instructions. All steps were performed at room temperature and plates were washed 3 times with 
ELISA wash buffer between steps. Briefly, the primary antibody was incubated in a 96-well plate 
(Nunc MaxiSorp, ThermoScientific) overnight at room temperature and blocked with 1% BSA in PBS 
(w/v) (reagent diluent) for 2h. One hundred µl of sample or standard (recombinant protein serially 
diluted 1:2 in reagent diluent) was added and incubated for 2h. Biotin conjugated detection antibody 
in reagent diluent was then added with further incubation for 2h. HRP conjugated to streptavidin 
(Invitrogen) was added at 0.2µg/ml in reagent diluent and incubated for 15 minutes. Seventy-five µl 
of TMB substrate (Invitrogen) was then added and development of colour monitored before addition 
of equal volume of 1M H2SO4 to stop the reaction.  
IFN-α and -β protein levels in BAL were assessed using specific kits (R&D Systems/PBL Interferon 
Source, Piscataway, USA) with plates pre-coated with capture antibody. For the IFN-β ELISA, 
sample/standard, secondary antibody and HRP were simultaneously incubated for 1h. For the IFN-α 
ELISA, sample/standard was simultaneously incubated with detection antibody for 1h at room 
temperature with shaking at 450rpm, followed by overnight incubation at 4oC. Subsequently, plates 
were washed and incubated with HRP conjugate for 2h, prior to reaction development. 
2.2.5.2 Mucin proteins 
MUC5AC and MUC5B proteins in BAL were measured after adhesion to a 96 well plate by allowing 
samples to evaporate at 37oC overnight. Plates were washed 3 times with ELISA wash buffer 
between steps. The following day, plates were blocked for 2h at room temperature with 2% BSA/PBS 
(w/v). For measurement of MUC5AC, the detection antibody used was biotinylated anti-MUC5AC 
(ThermoScientific) at 400 ng/ml in 0.2% BSA/PBS (w/v) and subsequent steps were as described in 
section 2.2.5.1. For the MUC5B assay, detection antibody was mouse anti-MUC5B clone EH-
MUC5Ba, as previously described.[359] Bound anti-MUC5B antibody was detected with peroxidase-
conjugated goat anti-mouse IgG (Sigma-Aldrich) diluted 1:1000 in 0.2% BSA/PBS. Standard curves for 
mucin ELISAs were generated by serial 1:2 dilutions of BAL supernatants previously taken from 
ovalbumin-induced hyper-allergic mice. 
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2.2.5.3 RV-specific IgG 
96 well plates were coated with 50µl per well of concentrated RV1B or HeLa cell lysate, diluted 1:100 
in PBS and incubated at 4oC overnight. Plates were washed 3 times with ELISA wash buffer between 
all steps. Plates were blocked with 100µl 5% (w/v) skimmed milk powder (Marvel, Knighton, UK) 
dissolved in PBS at room temperature for 2h. 50µl serum diluted 1:50 in 5% skimmed milk/PBS was 
added with further incubation at room temperature for 2h. Biotinylated rat anti-mouse IgG1 or 
IgG2a detection antibodies (BD Biosciences) were then added and incubated at room temperature 
for 2h. Subsequent stages were as described in section 2.2.5.1. For analyses, values generated for 
HeLa cell lysate coated wells were subtracted from that of RV coated wells for each sample. 
2.2.5.4 Nuclear DNA-binding ELISAs 
Activation of transcription factors GR, NFB p65 subunit and IRF-3 were assessed in lung tissue using 
commercially available DNA binding assays (Active Motif). 20 µg per well of nuclear protein 
(extracted as described in section 2.2.3.7) was added per well and the assay was carried out 
according to manufacturers’ instructions. 
2.2.5.5 ELISA analyses 
Plates were analysed by a Spectramax Plus plate reader (MDS Analytical Technologies, Wokingham, 
UK) at 450nm with corrections made for plate and background absorbance at 540nm and 
concentrations calculated from the standard curve. Data were analysed using Softmax Pro software 
(version 5.2; Molecular Devices, Sunnyvale, USA). The lower limits of detection for ELISA assays are 
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Assay Lower limit of detection 
CRAMP 0.32 ng/ml 
CCL5/RANTES 31.2 pg/ml 
CCL17/TARC 31.2 pg/mL 
CCL22/MDC 7.81 pg/ml 
CXCL1/KC 15.6 pg/ml 
CXCL2/MIP-2 15.6 pg/ml 
CXCL9/MIG 15.6 pg/ml 
CXCL10/IP-10 62.5 pg/ml 
IFN-α 15.6 pg/ml 
IFN-β 15.6 pg/ml 
IFN-λ 31.2 pg/ml 
IL-6 15.6 pg/ml 
Pentraxin-3 21.8 pg/ml 
TNF-α 31.2 pg/ml 
Table 2.9: Lower limit of detection for ELISA assays  
 
2.2.6 Neutralisation assay 
Neutralisation of RV1B was measured in Ohio HeLa cells on 96 well plates.  HeLa cells were grown 
until ~90% confluent. Pooled sera for each given treatment group (sampled as described in section 
2.2.3.9) at d14 post-challenge were incubated with purified RV1B or medium control at room 
temperature with shaking for 1h and then added to HeLa cells with further incubation at 37oC for 48-
72h. Protection from CPE was measured by crystal violet cell viability assay. Cells were stained with 
0.1% (w/v) crystal violet (Sigma-Aldrich) at room temperature for 10 minutes. Cells were then 
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washed with water, air-dried and crystal violet was solubilised with 1% sodium dodecyl sulphate 
(SDS) solution (w/v). Absorbance was measured by a Spectramax Plus plate reader at 560 nm. 
2.2.7 Quantitative PCR 
2.2.7.1 RNA extraction and cDNA preparation 
Lung lobes which had been stored in RNAlater were removed and lysed in RLT buffer by bead milling 
using a TissueLyser LT (Qiagen). RNA was extracted using an RNeasy kit (Qiagen) according to 
manufacturers’ instructions. Briefly, cellular debris was removed by centrifugation at 13,000 x g for 3 
minutes. RNA was precipitated with 70% ethanol and then bound to an RNeasy spin column 
(Qiagen), washed and contaminating DNA removed using DNAse I (Qiagen). RNA was eluted in 35µl 
RNase-free water.  
For conversion to cDNA, 10µl RNA was added to a reaction mix containing 10µM random hexamer 
primers (Promega, Southampton, UK), 0.5mM deoxynucleotide triphosphates (dNTPs) and 
0.2units/µl reverse transcriptase (both from Omniscript kit, Qiagen) and incubated at 37oC for 1h. 
2.2.7.2 Bacterial DNA extraction 
To extract bacterial DNA present in lavage or lung tissue samples, the FastDNA Spin Kit for Soil 
(MPBiomedicals, Cambridge, UK), was used according to manufacturers’ instructions. BAL or nasal 
lavage samples were centrifuged at 20,000 x g for 30 minutes to pellet cell debris and bacteria. The 
pellet was then resuspended in 998µl sodium phosphate buffer and added to a lysing matrix E tube 
with 122µl MT buffer (all MPBiomedicals) and homogenised using a Precellys24 high-throughput 
tissue homogeniser (Precellys, Ann Arbor, USA) at a speed of 6,800rpm with two cycles of 30 
seconds. For lung tissue, the sample was added directly to 998µl sodium phosphate buffer and 122µl 
MT buffer in a lysing matrix E tube and homogenised as described above. Protein was then removed 
from the supernatant by addition of protein precipitation solution (MPBiomedicals) followed by 
centrifugation at 14,000 x g for 5 minutes. From the resultant supernatant, DNA was bound by 
addition of matrix beads. The beads/DNA were then washed with ethanol after which DNA was 
eluted into 100µl DNase/Pyrogen Free water (MPBiomedicals). The extracted DNA was stored at -
80oC until further use. 
2.2.7.3 Taqman quantitative PCR 
Taqman quantitative PCR was carried out using 1µl cDNA or appropriately diluted plasmid standard, 
added to a reaction mix of 6.25µl Quantitect Probe PCR Mastermix (Qiagen) with primers and 
FAM/TAMRA-labelled probes specific for the 5’-untranslated region of RV, 18S ribosomal RNA or the 
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the gene of interest (table 2.10) in a total volume of 12.5µl per well of a qPCR plate (MicroAmp fast 
96-well reaction plate; Applied Biosystems, Paisley, UK). The reaction was run on a 7500 Real-Time 
PCR System (Applied Biosystems) for 45 cycles with the following conditions: 1 cycle of 50oC (2 
minutes) and 95oC (10 minutes); 45 cycles at 95oC (15 seconds) and 60oC (1 minute). The cycle at 
which fluorescence of free FAM in the sample passed a threshold value (Ct) appropriate to the data, 
as set by the user, was determined. cDNA for 18s ribosomal RNA was diluted 1:100 in dH20 prior to 
analysis. All samples were analysed in duplicate. 
Gene/virus copy number was quantified by comparison to a plasmid DNA standard and normalised 
to 18s ribosomal RNA levels. The lower limit of detection for all Taqman assays was 10 copies/µl 
cDNA. When no standard was available (as it was not possible to clone some qPCR products) the 
relative quantity was calculated first by normalisation to an endogenous control (to 18s rRNA copies 
using the 2-ΔΔCt method) and then subsequently normalised to the mean of the control group giving 
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Assay Sequence (5’ – 3’) Concentration 































































































































Table 2.10 Taqman quantitative PCR primers and probes 
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2.2.7.4 SYBRGreen quantitative PCR 
SYBRGreen quantitative PCR for bacterial DNA content of all extracted samples was carried out using 
the 7500 Real-Time PCR System (Applied Biosystems). Tripicate reactions were performed for each 
sample using on 1µl template per reaction. For creation of the standard curve a 1:10 dilution series 
(1 x 108 to 1 x 102 copies/µl) of Pseudomonas aeruginosa PAO1 full length 16S rRNA gene cloned into 
PCR II vector (Invitrogen) was used. In addition to template, each PCR reaction mix contained 0.2µl 
of forward primer 520F (10µm; 5'- AYTGGYDTAAAGNG -3'), 0.2 µl reverse primer 802R (10µm; 5'- 
TACNVGGGTATCTAATCC -3’), 5µl SYBR Fast Universal master mix (Kapa Biosystems, Woburn, USA) 
and 3.6µl H2O. PCR cycling conditions were: 1 cycle of 90
oC for 3 minutes, followed by 40 cycles  of 
95oC (20 seconds), 50oC (30 seconds), 72oC (30 seconds) and melt conditions of 1 cycle of 95oC (15 
seconds) and 1 cycle of 60oC (1 minute) followed by dissociation at 95oC (15 seconds).  The lower 
limit of detection for SYBRGreen quantitative PCR was 1000 copies/µl cDNA. 
2.2.8 16S rRNA sequencing methods 
2.2.8.1 Amplicon preparation 
The 16S rRNA gene was amplified using the reverse primer 
5’CCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNNNNNNNNCCGTCAATTCMTTTRAGT-3’ and the 
forward primer 5’-CCTATCCCCTGTGTGCCTTGGCAGTCTCAGCCTACGGGAGGCAGCAGCAG-3’. The 
reverse primers contain the A adaptor sequence for 454 pyrosequencing (underlined) followed by a 
12 nucleotide multiplex identifier barcode (represented as NNNNNNNNNNNN) used to tag each PCR 
product and then the bacterial primer 926R (italicised). The forward primer lacks the barcode but 
contains an adaptor sequence (underlined) followed by the bacterial primer 357F (italicised). Twenty 
five μl PCR reactions were set up with 1μl of template (extracted DNA), 1μl Forward Primer (10μM), 
1μl Reverse primer (10μM), 0.5μl dNTP mix (10mM), 1μl BSA (20 mg/ml), 6.5μl Glycine Betaine 
(1.3M), 2.5μl Faststart 10 x Buffer, 0.2μl FastStart HiFidelity Polymerase (5units/μl)(all Sigma-Aldrich) 
and 11.25μl H2O. Cycling conditions were: 1 cycle of 95
oC for 2 minutes, 30 cycles of 94oC (20 
seconds), 50oC for (30 seconds) and 72 oC (5 minutes).  
2.2.8.2 Gel electrophoresis 
To confirm amplification and that no PCR contamination had occurred, amplicons were visualised on 
1% agarose gels (w/v). These were prepared by addition of 1g agarose (Sigma-Aldrich) to 100ml of TE 
Buffer with 5µl of Gel Red (Biotium, Cambridge, UK). The mixture was heated until the agarose 
dissolved and left to cool until a temperature of approximately 60oC was reached. The mixture was 
then poured onto an agarose gel slab, a well comb inserted and the gel left to set at room 
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temperature for 1h. When loading the gel, 10µl of 100bp DNA ladder (Invitrogen) was loaded into 
the well of one lane of the gel to allow the length of DNA fragments to be determined post 
electrophoresis. 5µl of each amplicon was mixed with 1µl of loading dye (Invitrogen) before loading 
onto gel. Bands were visualised using the EpiChemi3 Darkroom UV transilluminator system (Ultra-
Violet Products Inc., Upland, USA). 
2.2.8.3 Amplicon purification 
Quadruplicate PCR products were pooled together to ensure sufficient DNA for sequencing. The 
AMPure XP kit (Agencourt, Takeley, UK) was used to purify the pooled amplicon products with a 
ratio of 0.7 magnetic beads to PCR product, giving a size selection that removes oligonucleotides 
smaller than ~250 base pairs. The purified PCR amplicons were then washed with ethanol, eluted 
from the magnetic beads and stored at -80oC until further use. 
2.2.8.4 Amplicon quantification, dilution and pooling 
Purified amplicons were quantified using the Quant-iT PicoGreen dsDNA assay kit (Invitrogen) 
according to manufacturers’ instructions. A standard curve was created from phage λ DNA standard 
(Invitrogen) in TE buffer to allow DNA concentration of each amplicon to be determined. DNA 
samples of sufficient quantity for subsequent sequencing (>2.5ng/µl) were pooled together in 
equimolar concentrations. The Amplicon pool was then purified (as described in section 2.2.8.3) and 
quantified using the Quant-iT PicoGreen  dsDNA assay. The amplicon pool was then diluted to a 
concentration of 105 molecules/µl prior to setting up the emulsion PCR. 
2.2.8.5 Emulsion PCR 
Emulsion PCR was carried out according to the manufacturers’ instruction. Briefly, a live amp 
mixture was made consisting of 382.5µl H2O, 515µl additive, 297.5µl amp mix, 80µl amp primer, 70µl 
enzyme mix, 2µl PPiase (all Roche). The live amp mixture was then added to a Turrex stirring tube 
containing 4ml emulsion oil (both Roche), 30µl of the amplicon pool diluted to 105 molecules/µl and 
DNA capture beads (Roche). The contents were mixed using an Ultra Turrax Tube Drive (Roche) for 5 
minutes at 2,000 rpm. The emulsion mix was then transferred to a 96 well plate and amplification 
performed with the following cycling conditions: 1 cycle of 94oC (4 minutes); 50 cycles of 94oC (30 
seconds) and 60oC (10 minutes). 
2.2.8.6 16S pyrosequencing 
Single direction pyrosequencing was carried out using the 454 Life Sciences GS Junior (Roche), 
according to manufacturers’ instructions. The barcoded sequence reads were processed using 
Quantitative Insights into Microbial ecology (QIIME) sotware package (version 1.7.0), as previously 
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described.[361] Sequence reads containing ambiguous bases, primer sequence mismatches, 
homopolymer runs or mean quality score of <25 were removed. Remaining sequences were 
clustered into Operational Taxonomic Units (OTUs) at 97% identity, aligned to full length 16S rRNA 
sequences and then assigned a taxonomic identity using the Ribosomal Database Project Classifier 
[362] via the Silva reference database.[363] 
 
2.2.9 Bacterial culture methods 
2.2.9.1 Measurement of S. pneumoniae colony forming units in lung tissue 
Lung tissue was homogenised by bead milling using a TissueLyser LT (Qiagen) and then serial tenfold 
dilutions of the homogenate were made in sterile PBS up to a maximum dilution of 1:10,000.  One 
hundred µl of each dilution was plated onto a separate Columbia horse blood agar plate (Oxoid, 
Basingstoke, UK) using a sterile spreader (Thermo Scientific). Plates were incubated for 18h at 37oC 
and colonies were counted on plates where 50-300 distinct colonies were present. The total number 
of CFUs was determined as the number of colonies x dilution factor x the original cell suspension 
volume. 
2.2.9.2 Measurement of S. pneumoniae colony forming units in blood 
Heparinised blood samples (taken as described in section 2.2.3.9) were tenfold serially diluted in PBS 
up to a maximum dilution of 1:10,000. One hundred µl of each dilution was then plated onto 
Columbia horse blood agar plates and processed as described in section 2.2.9.1. 
 
2.2.10 Measurement of bacterial phagocytosis by BAL macrophages 
2.2.10.1 Fluorescein isothiocyanate labelling of S. pneumoniae 
S.pneumoniae D39 (1 x 106 CFU) was heat killed by incubation at 60oC for 1h. Bacteria were 
centrifuged at 12,000 x g for 3 minutes and washed with 1ml of ice-cold 1% BSA/Hank’s balanced 
salt solution (w/v) (HBSS; Sigma-Aldrich).  Bacteria were again centrifuged at 12,000 x g for 3 
minutes and the resulting pellet resuspended in 100µl fluorescein isothiocyanate (FITC) isomer I 
solution at 0.1 mg/ml in PBS (Sigma-Aldrich). The solution was mixed on a rotator at 4oC for 30 
minutes. Nine hundred µl of ice-cold 1% BSA/HBSS was then added with further centrifugation at 
12,000 x g for 3 minutes. The bacterial pellet was resuspended in 1ml ice-cold 1% BSA/HBSS and 
again centrifuged at 12,000 x g for 3 minutes.  Resuspension in 1%BSA/HBSS followed by 
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centrifugation was repeated 3 further times until supernatant was clear of residual FITC. Labelled 
bacteria were stored at -20oC until use. 
2.2.10.2 Ex vivo bacterial phagocytosis assay 
BAL samples from 5 mice taken 4h after treatment with 50µl FP 1mg/kg or vehicle DMSO control (as 
described in section 2.2.2.5) were pooled and cells were pelleted by centrifugation at 12,000 x g for 
1 minute. Cells were treated with 1ml ACK buffer for 30 seconds to lyse red blood cells and then 
resuspended in 1ml of 10% RPMI medium (v/v). Total live BAL cell counts were assessed by trypan 
blue exclusion and 1 x 105 cells per group were removed into a separate 1.7ml tube for use in the 
assay. FITC-labelled S.pneumoniae (1 x 106 CFU) was added to each tube and a control tube of BAL 
cells with unlabelled heat-killed S.pneumoniae was also prepared. 50µl ice-cold mouse serum (taken 
from untreated C57/BL6 mice, as described in section 2.2.3.9) was added to each tube. Tubes were 
rotated end-over-end on a shaker for 25 minutes at ∼8 rpm followed by centrifugation at 250 x g for 
8 minutes. The pellet was then resuspended in 1ml ice cold HBSS. Centrifugation and resuspension 
then occurred a further five times to remove extracellular bacteria. Finally, the pellet was 
resuspended in 200µl ice-cold 5% FCS/PBS (v/v). 
2.2.10.3 Visual assessment of phagocytosis by fluorescence microscopy 
A 100µl aliquot of final macrophage/bacteria suspension from section 2.2.10.2 was removed and 
mixed with ethidium briomide to a final concentration of 50µg/ml. Ten µl of this suspension was 
then placed immediately onto a microscope slide and overlayed with a coverslip. Slides were kept in 
the dark and viewed within 2h (under oil immersion for 1000x magnification) using a fluorescence 
microscope (LSM 5 Pascal Laser Scanning microscope, Carl Zeiss) with a long-pass FITC filter.  
2.2.10.4 Measurement of phagocytosis by flow cytometry 
1x105 cells of the final macrophage/bacteria suspension from section 2.2.10.2 was plated into a 96 v-
well plate and incubated with live/dead cell marker (Invitrogen) at 1:1000 dilution in PBS for 20 
minutes. Cells were then washed with PBS and fixed by addition of 100µl per well of 2% 
formaldehyde (v/v) (Sigma-Aldrich) in PBS for 20 minutes at room temperature in the dark. Cells 
were again washed with PBS, resuspended in FACS buffer and stored at 4oC in the dark, prior to 
analysis within 4h. Data were acquired and analysed as described in section 2.2.4.2.  
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2.2.11 In vitro methods 
2.2.11.1 BEAS2B cell culture 
The epithelial cell line BEAS2B was cultured in 175cm2 tissue culture flasks in 10% RPMI medium 
(v/v) at 37oC with 5% CO2. Cells were passaged when approximately 90% confluent. 
2.2.11.2 Transfection of BEAS2B cells with reporter constructs 
Transfections were performed on 12 well culture plates (Nunc). BEAS2B cells were grown and 
transfected when 80-90% confluent. A reaction mix of reporter plasmid (IFNβ-luciferase) at 
0.8µg/well was diluted in serum-free RPMI containing internal control vector (Renilla, 0.2µg/well) 
and incubated for 3 minutes at room temperature. Superfect (Qiagen) at 3µl/well was added to the 
mix with further incubation for 15 minutes at room temperature. The mix was then diluted 1:5 with 
serum-free RPMI. Cells were washed twice with PBS and 475ml of the mix was added to each well. 
Cultures were then incubated at 37oC for 3h with 5% CO2. The transfection mixture was then 
removed, cells washed twice with PBS and 1ml 2% RPMI medium (v/v) added to each well. 
2.2.11.3 Treatment of BEAS2B cells with FP and receptor agonists 
FP (Sigma-Aldrich) was dissolved in DMSO at a stock concentration of 0.1 M, and stored at −20 °C. 
Twenty four hours following transfections, cells were treated with FP at 1nM and 10nM 
concentrations in 1ml of 2% RPMI medium (v/v). Control wells were treated with 2% RPMI medium 
alone. One hour following FP treatment, 5µg/ml TLR3 agonist (Poly(I:C); Invitrogen) or 250ng/ml 
MDA5 agonist (transfected Poly(I:C); Invitrogen) in 1ml 2% RPMI medium was added to cells. 2% 
RPMI medium alone was used as negative control for either agonist. 
2.2.11.4 Dual-luciferase reporter assay system 
At 24h following treatment with agonist, cells were washed with PBS and then lysed in 100µl of 1 x 
passive lysis buffer (Promega). Cells were then collected, subjected to two freeze-thaw cycles and 
centrifuged at 16,200 x g for 1 minute to pellet cell debris. Twenty µl of each sample was assessed 
for relative light units (RLU) using a Dual Luciferase kit (Promega) according to the manufacturers’ 
instructions. Relative promoter activity was calculated by dividing the RLU of the reporter plasmid 
(IFN-β-Luc) over the RLU of the internal control vector (Renilla).  
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2.2.12 Statistical analysis 
For animal experiments, group sizes of at least 4 mice per experimental condition were used. All 
data shown is representative of at least 2 independent experiments with individual figures depicting 
data from a single experiment (unless otherwise indicated). Data were analysed using Prism (version 
4, Graphpad Software, San Diego, USA) and expressed as group mean, displaying error bars as 
standard error of the mean (SEM). Data were analysed by Kruskal-Wallis test with differences 
between groups assessed by Dunn’s post-test when three or more groups were compared at a single 
time-point. Two–way ANOVA was used for comparison between multiple groups at more than one 
timepoint with significant differences between groups assessed by Bonferroni’s multiple comparison 
test. For in vitro data, mean +/- SEM of 3 independent experiments is shown. Data were analysed by 
Kruskal-Wallis test with differences between groups assessed by Dunn’s post-test. Differences were 
considered significant when p<0.05. Specific p values are indicated in figure legends. 
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Chapter 3: Results - Characterisation of a mouse model of RV-induced COPD exacerbation  
3.1 Introduction 
Rhinovirus (RV) infections are common triggers for acute exacerbations of chronic obstructive 
pulmonary disease (COPD).[27, 364] Inflammatory responses during RV-induced exacerbations of 
COPD are poorly characterized. Some insight has been gained from naturally occurring COPD 
exacerbation studies, but these studies are limited by potential confounding factors such as varying 
time between virus infection and presentation, and treatments being initiated prior to sampling. A 
recently described human experimental RV infection model in COPD has allowed controlled 
measurement of a range of inflammatory parameters and provided a clearer understanding of the 
relationship between virus infection, anti-viral innate responses and airways inflammation.[35] In 
comparison to stable state, exacerbations are associated with increased neutrophilic [31, 35, 87, 88, 
91] and lymphocytic [35, 84, 87, 88, 96] cellular airways inflammation, exaggerated production of 
cytokines such as  TNF- [35, 89], CXCL10/IP-10 [91, 95] and CCL5/RANTES [87, 91] in the airways, 
deficient type I IFN responses, impaired virus clearance [35] and increased airway mucus production 
[35]. Additionally, the human experimental model has allowed comparison of inflammatory 
responses in RV-induced exacerbations of COPD compared to RV infection in healthy controls and 
showed increased airway neutrophil and lymphocyte recruitment, increased neutrophil chemokine 
CXCL8/IL-8 expression and increased levels of neutrophil elastase in sputum.[35] Positive 
correlations were also observed between virus loads and sputum levels of CXCL8/IL-8, IL-6 and TNF-
α in patients with COPD but not in healthy controls.[35] 
Modelling COPD in mice can be achieved by a number of approaches including cigarette smoke 
administration, instillation of tissue-degrading proteinases such as elastase, or genetic 
manipulation.[331] Models that employ elastase administration produce a rapid onset of 
emphysematous destruction of the lungs and may be considered the best short-term method for 
modelling severe disease. A number of studies have described elastase-induced models of stable 
COPD [365, 366] or exacerbation triggered by bacterial infection.[347, 348, 350] The only published 
mouse model of RV-induced exacerbation in COPD reported that weekly intranasal administration of 
porcine pancreatic elastase to induce histological emphysema combined with LPS for four weeks to 
mimic chronic bacterial colonisation, followed by RV1B infection, led to increased lung tissue mRNA 
expression of TNF-α, IL-13 and MUC5AC, increased AHR to MCH challenge, deficient type I IFN 
responses and delayed virus clearance from the airways.[344] Given that this model appeared to 
display many of the key features reported in human disease, we attempted to recreate the model 
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using the same dosing protocol so that it could subsequently be used to test the effects of ICS 
administration  in exacerbation of COPD induced by RV. 
3.2 Aim and hypotheses 
3.2.1 Aim 
To develop a clinically relevant mouse model of RV-induced exacerbation of COPD that mimics what 
is known of human disease including: histological emphysematous lung changes, deficient IFN 
responses and impaired virus control, increased cellular airways inflammation and inflammatory 
mediator production and mucus hypersecretion. 
3.2.2 Hypotheses 
1) Once weekly intranasal administration of elastase and LPS for four weeks to mice causes 
histological abnormalities consistent with emphysema and models other features of stable COPD 
including increased airway inflammation, mucus hypersecretion and increased AHR. 
2) Once weekly intranasal administration of elastase and LPS for four weeks to mice impairs RV 
induction of type I and III IFNs leading to increased virus loads in vivo. 
3) Once weekly intranasal administration of elastase and LPS for four weeks to mice leads to 
enhanced RV induction of inflammatory chemokines and cytokines, as previously reported and also 
increases other features of RV-induced inflammation reported in human studies of COPD such as 
cellular airways inflammation.  










3.3.1 RV1B infection in C57BL/6 mice 
The mouse model of RV1B infection was initially described in BALB/c mice [367] and relatively few 
studies from our group have been conducted in the C57BL/6 strain. Given that the RV-induced 
exacerbation of COPD mouse model that we were aiming to reproduce was reported in C57BL/6 
mice [344], we therefore initially carried out a time-course experiment assessing primary RV1B 
infection in C57BL/6 mice and measured a range of inflammatory parameters. Consistent with 
previous observations in BALB/c mice, C57BL/6 mice challenged with RV1B had increased lung tissue 
viral RNA copies at d1, 2 and 4 post-infection compared to mice challenged with UV-RV1B (fig 3.1a). 
Additionally,  IFN-λ BAL protein at d1 post-infection, CXCL1/KC BAL protein at d1 and 2 post-infection 
and CXCL10/IP-10 BAL protein at d1, 2 and 4 post-infection were increased in mice challenged with 
RV1B vs. UV-RV1B (fig 3.1b–d). Assessment of cellular airways inflammation showed increased BAL 
neutrophils at d1 and 2 and increased BAL lymphocytes at d2, 4 and 7 post-infection in mice 
challenged with RV1B vs. UV-RV1B (fig 3.1e&f). 
 
 




Figure 3.1 Virus loads and inflammatory responses to RV1B infection in C57BL/6 mice. 
C57BL/6 mice were challenged intranasally with RV1B or UV inactivated RV1B (UV-RV1B). (a) Lung tissue was 
harvested at the indicated timepoints post-infection, RNA was extracted from tissue and cDNA generated as 
described. RV RNA copies were assessed by Taqman quantitative PCR. (b-d) BAL was performed at the 
indicated timepoints post-infection and (b) IFN-λ (c) CXCL1/KC and (d) CXCL10/IP10 proteins in lavage 
supernatants were measured by ELISA. BAL cell cytospin slides were prepared as described. (e) neutrophils and 
(f) lymphocytes were differentially counted blind to experimental conditions. Data represent mean (+/- SEM) 
of 5 mice per group from one representative experiment with findings reproduced in at least 2 independent 
experiments (*p<0.05, ***p<0.001). 
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3.3.2 Administration of four doses of elastase and LPS in combination with RV1B infection to 
model COPD exacerbation 
The only previously published model of COPD RV exacerbation reported that weekly administration 
of porcine pancreatic elastase (1.2 units) and LPS (7 endotoxin units) for four weeks followed 7d 
later by infection with RV1B in C57BL/6 mice led to inflammatory features consistent with human 
COPD RV exacerbation.[344] We therefore attempted to recreate this model using the same dosing 
protocol and evaluated similar parameters to those reported, along with additional features that we 
deemed to be indicative of human COPD exacerbation based on what has been previously reported 
in experimental and naturally occurring infection studies. 
3.3.2.1 Lung histology 
Emphysematous lung changes are characteristic of COPD in humans and in the reported four dose 
elastase/LPS mouse model, histological changes consistent with severe COPD were observed.[344] 
Using this protocol, exactly as reported [344], we treated mice with four weekly doses of intranasal 
elastase and LPS and harvested lung tissue at 7d post final LPS or PBS challenge (fig 3.2a). 
Emphysematous changes were apparent in lung sections from mice treated with elastase regardless 
of LPS  treatment (elastase + LPS and elastase + PBS groups) and to a lesser extent with PBS + LPS 
treatment compared to PBS + PBS treatment, both visually (fig 3.2c-f) in H&E stained sections and 
when quantified by measuring mean linear intercept (fig 3.2b). The highest alveolar chord lengths 
were observed in lung sections from mice treated with combined elastase and LPS with significant 
increases compared to elastase + PBS, PBS + LPS or PBS + PBS treatment (fig 3.2b). Mice treated with 
elastase + PBS or PBS + LPS had increased mean linear intercept values compared to control mice 
dosed with PBS alone (fig 3.2b). Despite the histological changes induced by intranasal elastase and 
LPS administration, none of the animals studied showed any outward signs of illness or respiratory 
compromise. 
 




Figure 3.2 Histological changes in four dose elastase/LPS model.      
(a) C57BL/6 mice were challenged intranasally with elastase on d1 and LPS on d4 of each week, or with PBS as 
control, for four weeks. At d7 following final LPS or PBS challenge, lungs were harvested, formalin fixed, 
paraffin embedded and stained with haematoxylin and eosin (H&E). (b) The diameter of air spaces were 
measured in at least 10 random fields per slide and averaged to determine alveolar chord length. Data 
represent mean (+/- SEM) of 4 mice per group from one representative experiment with findings reproduced 
in at least 2 independent experiments (*p<0.05, **p<0.01, ***p<0.001). (c-f) Representative images are 
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3.3.2.2 Anti-viral immune responses and virus loads 
Having established that combined elastase and LPS administration led to histological airway changes 
consistent with COPD, we next added RV1B infection to this baseline model (fig 3.3a), exactly as 
reported.[344] Experimental infection studies in patients with COPD have reported deficient IFN 
responses to RV infection [35] and this was also shown in the previously reported four dose 
elastase/LPS COPD exacerbation model where elastase/LPS + RV treated mice had suppressed type I 
IFN mRNA expression and delayed RV clearance [344]. We found that IFN-β and IFN-λ mRNAs were 
increased at 8h post-infection in mice treated with PBS and infected with RV (PBS+RV treatment; 
modelling RV infected healthy subjects) vs. treatment with PBS and UV-RV1B (PBS + UV; modelling 
uninfected healthy subjects). Induction of IFNs-β and -λ mRNAs in lung tissue by RV was reduced in 
mice treated with four doses of elastase/LPS (elastase/LPS + RV treatment; modelling RV infected 
patients with COPD) compared to treatment with PBS + RV (fig 3.3b&c) at 8h post-infection. 
However, elastase/LPS + RV treatment led to reduced rather than increased lung virus loads 















Figure 3.3 Virus loads and interferon responses in four dose elastase/LPS + RV1B model.                      
(a) C57BL/6 mice were challenged intranasally with elastase on d1 and LPS on d4 of each week, or with PBS 
control, for four weeks. At d7 following final LPS or PBS challenge, mice were additionally challenged with 
RV1B or UV-inactivated RV1B. Lung tissue was harvested at the indicated timepoints post-infection. RNA was 
extracted from tissue and cDNA generated as described. (b) IFN-β, (c) IFN-λ mRNA and (d) RV RNA copies were 
assessed by Taqman quantitative PCR. Data represent mean (+/- SEM) of 5 mice per group from one 
representative experiment with findings reproduced in at least 2 independent experiments (***p<0.001). 
 
3.3.2.3 BAL cellular inflammation 
In the previously reported model, the effect of four dose elastase/LPS administration as a baseline 
model of the inflammatory changes of stable COPD was assessed and shown to increase numbers of 
macrophages, neutrophils and lymphocytes in BAL compared to PBS dosed controls [344], which are 
all features characteristic of stable COPD in humans. In contrast to the reported model, we observed 
no increases in BAL neutrophil and a non-significant trend towards increased lymphocyte numbers 
associated with four dose elastase/LPS administration (comparison between elastase/LPS + UV and 
PBS + UV groups)(fig 3.4a&b). However, in keeping with the reported model, we observed increased 
macrophages at d1 and d4 post administration in elastase/LPS + UV vs. PBS + UV treated mice (fig 
3.4c). Therefore, in our hands, the four-dose elastase/LPS model was only partially representative of 
the inflammatory changes of stable COPD reported in human studies. 
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Acute exacerbation of COPD is associated with a further enhancement of airway inflammation with 
increases in airway neutrophil and lymphocyte recruitment above stable state, as reported by 
several human naturally occurring exacerbation studies [31, 87, 96] and the human experimental RV 
infection model in COPD also reported increased inflammatory responses in patients with COPD 
compared to healthy controls [35]. This feature was not reported in the previously published four 
dose elastase/LPS model [344] but would be considered to be an important characteristic of a 
clinically relevant mouse model and we therefore considered these features in our assessment of 
the model. As previously observed, mice treated with PBS + RV had increased BAL neutrophils at d1 
and increased lymphocytes at d4 post-infection vs. PBS + UV treatment (fig 3.4a&b). Elastase/LPS 
administration suppressed RV induced neutrophilia (~60% reduction) at d1 post-infection (fig 3.4a) 
but neutrophil number was greater in elastase/LPS + RV vs. elastase/LPS + UV treated mice 
(modelling exacerbated COPD vs. stable COPD) at d1 post-infection (fig 3.4a). Elastase/LPS + RV 
treated mice had increased BAL lymphocyte numbers (~6 fold) vs. PBS + RV treatment at d1 post-
infection but there were no significant differences in BAL lymphocyte numbers between 
elastase/LPS + RV and elastase/LPS + UV treated mice (fig 3.4b). Macrophage numbers were no 
different in elastase/LPS + RV treated mice vs. PBS + RV or elastase/LPS + UV treated mice at either 
d1 or d4 post-infection (fig 3.4c).  
Therefore, as a model of enhanced inflammation associated with RV infection in COPD vs. RV 
infection in healthy controls, 4 dose elastase/LPS mimicked the increased lymphocyte but not 
neutrophil component. When considering this dosing strategy as a model for exacerbated vs. stable 
COPD, the opposite was observed with enhanced neutrophilic but not lymphocytic inflammation 
observed. Therefore, four dose elastase/LPS was only partially representative of airway 
inflammatory changes in RV-induced exacerbation of COPD. 
 




Figure 3.4 BAL cellular inflammation in four dose elastase/LPS + RV1B model.                                                                                       
C57BL/6 mice were challenged intranasally with elastase on d1 and LPS on d4 of each week or PBS as control 
for four weeks. At d7 following final LPS or PBS challenge, mice were additionally challenged with RV1B or UV-
inactivated RV1B. BAL was performed at the indicated timepoints. BAL cell cytospin slides were prepared as 
described. (a) neutrophils, (b) lymphocytes and (c) macrophages were differentially counted blind to 
experimental conditions. Data represent mean (+/- SEM) of 5 mice per group from one representative 
experiment with findings reproduced in at least 2 independent experiments (*p<0.05, **p<0.01, ***p<0.001). 
 
3.3.2.4 Chemokine and cytokine expression 
In addition to cellular inflammation, we also evaluated chemokine and cytokine production in the 
four dose elastase/LPS model.  The previous report of this model showed increased CXCL2/MIP-2, IL-
6, TNF-α and IL-1β in the baseline model of elastase/LPS vs. PBS administration [344], consistent 
with observations in human studies. We therefore assessed these features and, in contrast to that 
reported, found no significant differences in BAL protein levels of CXCL2/MIP-2 or IL-6 with 
elastase/LPS + UV vs. PBS + UV treatment (fig 3.5a&b). We were unable to detect TNF-α or IL-1β 
protein in BAL in the model but availability of a Taqman qPCR  assay for TNF-α allowed measurement 
of lung tissue mRNA expression of this cytokine with no difference also observed between 
elastase/LPS + UV and PBS + UV treated mice (fig 3.5e). Additionally, BAL protein levels of CXCL10/IP-
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contrast to data reported by Sajjan et al [344], we failed to observed increased chemokine and 
cytokine expression representative of stable COPD in the baseline four dose/elastase LPS model. 
In the previously reported model, four dose elastase/LPS administration also led to increases in RV 
induction of TNF-α and IL-13 mRNAs in lung tissue.[344] We therefore measured these parameters 
and also extended our analyses to include other chemokines and cytokines that have previously 
been shown to be upregulated in human COPD exacerbations. RV infection increased BAL protein 
levels of CXCL2/MIP-2, IL-6 and CCL5/RANTES (all at d1 post-infection) and CXCL10/IP-10 (at d1 and 
d4 post-infection) compared to PBS + UV treatment (fig 3.5a-d). RV infection also increased lung 
tissue mRNA expression of TNF-α at d1 post-infection (fig 3.5e). However, lung tissue IL-13 mRNA 
was not increased by RV infection at either d1 or d4 post-infection (fig 3.5f).  
In contrast to the previous report of the four dose elastase/LPS model, we observed suppressed 
(~90% inhibition) rather than increased RV induction of TNF-α mRNA in lung tissue of elastase/LPS 
treated mice at d1 post-infection with no difference observed at d4 (fig 3.5e). There was, however, 
increased TNF-α mRNA in elastase/LPS + RV vs. elastase/LPS + UV treated mice (~7 fold) at d1 post-
infection (fig 3.5e). Similar to the reported model, increased IL-13 mRNA expression was observed in 
elastase/LPS + RV vs. PBS+ RV treatment groups at d1 (~3 fold) and d4 (~4 fold) post-infection and 
vs. elastase/LPS + UV (~2 fold) at d1 post-infection (fig 3.5f).  
Assessment of a number of additional disease-relevant chemokines/cytokines in the four dose 
model showed that elastase/LPS suppressed RV induction of CXCL2/MIP-2 (~25% inhibition) and IL-6 
(~75% inhibition) proteins in BAL at d1 post-infection and completely inhibited induction of 
CXCL10/IP-10 protein in BAL at d4 post-infection (fig 3.5a-c). There was no difference in 
CCL5/RANTES BAL protein levels between elastase/LPS + RV and PBS + RV treated mice at d1 or 4 
post-infection (fig 3.5d). However increases were observed in protein levels of CXCL2/MIP-2, IL-6, 
CXCL10/IP-10 and CCL5/RANTES in BAL of elastase/LPS + RV vs. elastase/LPS + UV treated mice (fig 
3.5a-d). Therefore, four doses of elastase/LPS was a poor model of enhanced inflammatory 
cytokines and chemokine expression associated with RV infection in COPD vs. healthy controls but 
appeared to be a better model of exacerbated vs. stable COPD. 
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Figure 3.5 Chemokine and cytokine induction in four dose elastase/LPS + RV1B model. 
C57BL/6 mice were challenged intranasally with elastase on d1 and LPS on d4 of each week or PBS as control 
for four weeks. At d7 following final LPS or PBS challenge, mice were additionally challenged with RV1B or UV-
inactivated RV1B. (a-d) BAL was performed at the indicated time-points post-infection and (a) CXCL2/MIP-2, 
(b) IL-6, (c) CXCL10/IP-10 and (d) CCL5/RANTES proteins in lavage supernatants were measured by ELISA. (e-f) 
Lung tissue was harvested at the indicated timepoints post-infection. RNA was extracted from tissue and cDNA 
generated as described. (e) TNF-α and (f) IL-13 mRNA copies were assessed by Taqman quantitative PCR. Data 
represent mean (+/- SEM) of 5 mice per group from one representative experiment with findings reproduced 
in at least 2 independent experiments (*p<0.05, **p<0.01, ***p<0.001). 
 
3.3.2.5 Airway mucins 
Mucus hypersecretion is a prominent feature of stable COPD and has been shown to be increased by 
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mRNA expression in lung tissue with four dose elastase/LPS administration, thus demonstrating the 
mucus hypersecretion indicative of stable COPD.[344]  In contrast, we observed no difference in lung 
tissue mRNA expression of MUC5AC or the other major airway mucin MUC5B between elastase/LPS 
+ UV and PBS + UV treated mice and, therefore, in our hands the four dose elastase/LPS model did 
not appear to be representative of mucus hypersecretion, as reported in human studies of stable 
COPD. 
In the previous report of this model, addition of RV infection to four doses of elastase/LPS led to 
increases in MUC5AC mRNA expression over elastase/LPS or RV challenge alone.[344] We therefore 
assessed MUC5AC and additionally MUC5B mRNA in the four dose model. RV infection increased 
lung tissue MUC5AC mRNA expression at d4 post-infection but had no effect on MUC5B mRNA at d1 
or 4 post-infection (PBS + RV vs. PBS + UV treatment) (fig 3.6a&b). There were no significant 
differences in MUC5AC or MUC5B expression between elastase/LPS + RV and PBS + RV treated mice 
or between elastase/LPS + RV and elastase/LPS + UV treated mice (fig 3.6a&b). Therefore, four dose 
elastase/LPS administration did not appear to accurately model the mucus hyper-secretion that is 
indicative of RV-induced COPD exacerbation. 
 
Figure 3.6 Airway mucins in four dose elastase/LPS + RV1B model. 
C57BL/6 mice were challenged intranasally with elastase on d1 and LPS on d4 of each week or PBS as control 
for four weeks. At d7 following final LPS or PBS challenge, mice were additionally challenged with RV1B or UV-
inactivated RV1B. Lung tissue was harvested at the indicated timepoints post-infection. RNA was extracted 
from tissue and cDNA generated as described. (a) MUC5AC and (b) MUC5B mRNA copies were assessed by 
Taqman quantitative PCR.  Data represent mean (+/- SEM) of 5 mice per group from one representative 
































































































Chapter 3: Results  
99 
 
3.3.2.6 Airway hyper-responsiveness 
In the published four dose elastase/LPS model, invasive techniques were used to measure lung 
function in mice. Since these techniques were not available to us, we used whole body 
plethysmography to assess AHR to nebulised MCH at d1 and d7 in the model. As reported in BALB/c 
mice [367], RV infection alone did not lead to increased AHR measured by whole body 
plethysmography at d1, or at d7 post-infection (fig 3.7 a&b). We observed that elastase/LPS + UV 
treatment led to increased PenH average values at d1 (30mg/mL and 100mg/mL doses of MCH) and 
d7 post-infection (100mg/mL MCH dose) and lower PC20 values at d1 post-infection compared to 
treatment with PBS + UV. This contrasts with data reported by Sajjan et al using invasive 
measurement techniques where elastase/LPS treatment had no effect on baseline airway resistance 
or AHR in response to MCH.[344] 
Increased AHR to MCH challenge following RV infection was reported in the published four dose 
elastase/LPS model at d7 and d14 post-infection when measured in anesthetized mice by invasive 
techniques with increases seen in comparison to elastase or RV challenge alone.[344] We observed 
that elastase/LPS + RV treated mice had increased AHR compared to PBS + RV treatment at d1 (30 
and 100 mg/mL MCH doses) and d7 (100mg/mL) and a trend towards lower PC20 values at d1 post-
infection (figure 3.7 a-c). However, AHR was reduced in mice treated with elastase/LPS + RV 
compared to elastase/LPS + UV treatment at d1 with no difference at d7 post-infection and no 
differences in PC20 values at either timepoint (fig 3.7a-d). 




Figure 3.7 Airway hyper-responsiveness in four dose elastase/LPS + RV1B model. 
C57BL/6 mice were challenged intranasally with elastase on d1 and LPS on d4 of each week or PBS as control 
for four weeks. At d7 following final LPS or PBS challenge, mice were additionally challenged with RV1B or UV-
inactivated RV1B. Airway hyper-responsiveness expressed as (a & b) average PenH over a 5 minute period 
following MCH challenge and (c &d ) expressed as PC20, the provocative concentration of MCH that produces a 
20% increase in PenH was measured by whole body plethysmography at (a&c) d1 and (a&d) d7 post-infection. 
Airway hyperresponsiveness to MCH was measured by whole body plethysmography at (a) d1 and (b) d7 post-
challenge. Data represent mean (+/- SEM) of 5 mice per group from one representative experiment with 
findings reproduced in at least 2 independent experiments.(* denotes statistical comparison between 
elastase/LPS + RV vs. PBS + RV groups, Ɨ denotes comparison between elastase/LPS + UV vs. PBS + UV groups, 
ψ denotes comparison between elastase/LPS + RV vs. elastase/LPS + UV groups). 
 
3.3.3 Comparison of single vs. multiple dose elastase and LPS in combination with RV1B infection 
to model COPD exacerbation 
As shown above, in our hands, the four dose elastase/LPS plus RV model failed to produce an 
exacerbation of a number of features of disease that the existing literature suggests are indicative of 
human COPD exacerbation and we also failed to produce many of the reported features from the 
previously published study [344]. Some authors have previously speculated that inducing very severe 
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agents [347] perhaps explaining our observations with the published four dose elastase/LPS 
protocol. We therefore determined whether reducing the number of doses of elastase/LPS, to 
reduce lung damage, would more accurately model human COPD exacerbation. 
3.3.3.1 Lung histology 
Comparison of one, two, three and four weekly doses of elastase and LPS indicated a dose 
dependent increase in emphysematous lung changes apparent both visually in H&E stained lung 
sections (fig 3.8a–e) and when quantified by measuring mean linear intercept (fig 3.8f). A single dose 
of elastase and LPS was, however, sufficient to induce emphysematous lung changes with 
significantly increased mean linear intercept compared to control PBS treated mice (fig 3.8f).  
 
Figure 3.8 Effect of differing elastase and LPS dosing regimes on histological lung changes.                                                       
C57BL/6 mice were challenged intranasally with elastase on d1 and LPS on d4 of each week for 1, 2, 3 or 4 
weeks or PBS control. At d7 following final LPS or PBS challenge, lungs were harvested, formalin fixed, paraffin 
embedded and stained with haematoxylin and eosin (H&E). Representative images of mice treated with (a) 
PBS or (b) one dose (c) two doses (d) three doses or (e) four doses of elastase and LPS. (f) The diameter of air 
spaces were measured in at least 10 random fields per slide and averaged to determine alveolar chord length. 
Data represent mean (+/- SEM) of 4 mice per group from one representative experiment with findings 
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3.3.3.2 Virus loads and airway inflammation 
Having observed that only a single administration of elastase and LPS is required to induce 
emphysematous changes, we next assessed inflammatory and virological parameters following 
single or multiple doses of elastase/LPS plus RV infection. Regardless of the number of doses 
administered, elastase/LPS + RV treated mice had reduced RV RNA levels in lung tissue at d1 (fig 
3.9a), reduced or no difference in BAL neutrophilia (fig 3.9b) at d1 post-infection and no difference 
or increased BAL lymphocytosis at d4 post-infection (fig 3.9c) vs. PBS + RV treated mice. We also 
observed reduced or similar BAL protein levels of inflammatory chemokines CXCL10/IP10, 
CCL5/RANTES and cytokine IL-6 in BAL at d1 vs. PBS + RV treated mice (fig 3.9d-f). The number of 
doses of elastase and LPS therefore had little effect on the efficacy of this approach for modelling RV 
enhanced airway inflammation in COPD when comparing elastase/LPS + RV treatment to RV 
infection alone. However, a number of inflammatory endpoints including BAL neutrophilia (1 and 4 
dose protocols) , BAL lymphocytosis, BAL protein levels of CCL5/RANTES and IL-6 (1 and 2 dose 
protocols) and BAL protein levels of CXCL10/IP-10 (1,2, and 3 dose protocols) were increased in 
elastase/LPS + RV treated mice compared to elastase/LPS + UV treated mice (fig 3.9b-f). Therefore, 
although combined elastase/LPS appeared to be a poor model of RV infection in COPD vs. infection 
in healthy controls (elastase/LPS + RV vs. PBS + RV), it was a more representative model of 









Figure 3.9 Effect of differing elastase and LPS dosing regimes on virus loads and virus-induced airway 
inflammation.  
C57BL/6 mice were challenged intranasally with elastase on d1 and LPS on d4 of each week for 1, 2, 3 or 4 
weeks or PBS control. At d7 following final LPS or PBS challenge, mice were additionally challenged with RV1B 
or UV-inactivated RV1B. (a) Lung tissue was harvested at d1 post-infection, RNA was extracted from tissue, 
cDNA generated as described and RV RNA copies were measured in lung tissue by Taqman quantitative PCR. 
(b-f) BAL was performed at d1 and d4 post-infection. BAL cell cytospin slides were prepared as described and 
(b) neutrophils at d1 and (c) lymphocytes at d4 were differentially counted blind to experimental condition. (d) 
CXCL10/IP-10, (e) CCL5/RANTES and (f) IL-6 proteins in lavage supernatants at d1 were measured by ELISA. 
Data represent mean (+/- SEM) of 5 mice per group from one representative experiment with findings 
reproduced in at least 2 independent experiments (*p<0.05, **p<0.01, ***p<0.001). 
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3.3.4 Evaluation of single dose elastase without LPS administration in combination with RV1B 
infection to model COPD exacerbation  
Since the combination of elastase and LPS with RV did not produce a phenotype that was consistent 
with human COPD exacerbation, regardless of the number of doses administered, we next 
determined if the removal of LPS from the model would provide any benefit. Models of COPD 
exacerbation induced by bacterial challenge in mice have successfully used single dose elastase 
administration protocols with enhanced inflammatory responses reported following infection with 
H. influenzae or S. pneumoniae challenge.[348, 349]  
3.3.4.1 Anti-viral immune responses and virus clearance 
We assessed innate anti-viral immune responses and virus loads in the single dose elastase model 
(fig 3.11a). As previously observed with the four dose elastase/LPS model, lung tissue IFN-λ mRNA 
levels were reduced (~70% inhibition) in elastase + RV compared to PBS + RV treated mice on d1 
post-infection (fig 3.11b). However, there was no significant difference between these treatments in 
lung IFN-β mRNA levels (fig 3.11c) and no effect of elastase treatment on lung tissue RV RNA levels 
on either d1 or d4 post-infection (fig 3.11d). Therefore, similar to single or multiple dose 
elastase/LPS administration, single dose elastase alone did not accurately model the impaired virus 
clearance that is believed to be indicative of human disease. 
 




Figure 3.10 Effect of single dose elastase administration on virus loads and anti-viral immune responses.                                                                                                                                                                     
(a) C57BL/6 mice were challenged intranasally with elastase and additionally with RV1B or UV-inactivated 
RV1B, 10d later. Lung tissue was harvested at the indicated timepoints post-infection. RNA was extracted from 
tissue and cDNA generated as described. (b) IFN-λ (c) IFN-β mRNA and (d) RV RNA copies were measured in 
lung tissue by Taqman quantitative PCR. Data represent mean (+/- SEM) of 4 mice per group from one 
representative experiment with findings reproduced in at least 2 independent experiments (***p<0.001). 
 
3.3.4.2 BAL cellular inflammation 
We also assessed cellular airways inflammation in the single dose elastase model. In contrast to four 
dose elastase/LPS administration, single dose elastase led to increases in BAL lymphocytes at d1, 
macrophages at d1 and d4 and a trend towards increased BAL neutrophils at d1 compared to PBS + 
UV treatment (fig 3.11a-c). Therefore, single dose elastase was a more representative model of the 
increased cellular airway inflammation of stable COPD than four doses of elastase + LPS. 
Also in contrast to combined elastase/LPS models, single dose elastase plus RV administration led to 
significant increases in BAL neutrophilia vs. PBS + RV treatment (~ 2 fold at d1 and ~5 fold at d4) and 
also vs. elastase + UV treatment (~ 5 fold at d1 and ~12 fold at d4) (fig 3.11a). BAL lymphocytes were 
also increased with elastase + RV treatment vs. PBS + RV treatment at d1 (~4 fold) and vs. elastase + 
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more accurate model of RV-induced airways inflammation in COPD vs. healthy controls and in 
exacerbated vs. stable disease than combined elastase/LPS models. 
 
 
Figure 3.11 Effect of single dose elastase administration on RV1B-induced cellular airways inflammation 
C57BL/6 mice were challenged intranasally with elastase and additionally with RV1B or UV-inactivated RV1B, 
10d later. BAL was performed at the indicated timepoints post-infection. BAL cell cytospin slides were 
prepared as described and (a) neutrophils, (b) lymphocytes and (c) macrophages were differentially counted 
blind to experimental conditions.  Data represent mean (+/- SEM) of 4 mice per group from one representative 
experiment with findings reproduced in at least 2 independent experiments (*p<0.05, **p<0.01, ***p<0.001). 
 
3.3.4.3 Chemokine and cytokine expression 
We also measured inflammatory chemokine and cytokines in the single dose elastase + RV model. As 
with the four dose elastase/LPS model, no increases in inflammatory chemokines or cytokines were 
observed with elastase + UV vs. PBS + UV treatment and therefore the single dose elastase model 
also failed to mimic the enhanced airway cytokine levels associated with stable COPD. 
Elastase administration increased RV induction of CXCL10/IP-10 (~80% increase), CCL5/RANTES 
protein (~80% increase) in BAL at d1 (fig 3.12a&b) but had no effect on CXCL2/MIP-2 BAL protein (fig 
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dose elastase/LPS model, we were able to measure the mRNA expression of these cytokines in lung 
tissue by Taqman qPCR. Elastase administration suppressed RV induction of IL-13 mRNA (~50% 
reduction) at d1 post-infection (fig 3.12e). Additionally, TNF-α mRNA in lung tissue was significantly 
increased in elastase + RV treated mice vs. PBS + RV at d1 (~5 fold) and d4 (~2 fold) post-infection 
(fig 3.12d). Increases in  CXCL10/IP-10, CCL5/RANTES and CXCL2/MIP-2 BAL protein at d1 and TNF-α 
mRNA in lung tissue at d4 were also observed in elastase + RV vs. elastase + UV treated mice (fig 
3.12a-d). Therefore, in addition to being a more accurate model of enhanced cellular airways 
inflammation in COPD RV exacerbation, single dose elastase also more accurately modelled the 
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Figure 3.12 Effect of single dose elastase administration on RV1B-induced chemokine and cytokine 
production.  
C57BL/6 mice were challenged intranasally with elastase and additionally with RV1B or UV-inactivated RV1B, 
10d later. (a-c) BAL was performed at the indicated timepoints post-infection. (a) CXCL10/IP-10, (b) 
CCL5/RANTES and (c) CXCL2/MIP-2 proteins in lavage supernatants were measured by ELISA. (d–e) Lung tissue 
was harvested at the indicated timepoints post-infection. RNA was extracted from tissue and cDNA generated 
as described. (d) IL-13 and (e) TNF-α mRNA copies were measured in lung tissue by Taqman quantitative PCR.  
Data represent mean (+/- SEM) of 4 mice per group from one representative experiment with findings 
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3.3.4.4 Airway mucins 
We next assessed airway mucins in the single dose elastase model to determine whether single dose 
elastase +/- RV1B would model the mucus hypersecretion that is characteristically observed in stable 
and exacerbated COPD. In contrast to four dose elastase/LPS, single dose elastase administration 
increased MUC5AC mRNA expression in lung tissue at d1 post administration (comparison of 
elastase + UV and PBS + UV groups) (fig 3.13a). Similar expression levels of MUC5B mRNA in lung 
tissue were observed between elastase + UV and PBS + UV treated mice (fig3.13b). We also assessed 
mucin proteins in BAL and observed increases in MUC5AC at d4 and MUC5B at d1 and 4 post-
administration with elastase + UV vs. PBS + UV treatment (fig 3.13c&d). Therefore, in addition to 
more accurately modelling enhanced airway inflammation of stable COPD, single dose elastase 
administration was also more representative of mucus hypersecretion associated with stable disease 
than the four dose elastase/LPS model. 
Increases in MUC5AC mRNA in lung tissue and MUC5AC protein in BAL at d1 and d4 were observed 
in mice treated with elastase + RV vs. PBS + RV (fig 3.13a&c). MUC5AC mRNA at d4 and BAL protein 
at d1 were also increased in elastase + RV vs. elastase + UV treated mice (fig 3.13a&c). Increased 
MUC5B mRNA in lung tissue and protein in BAL were observed in mice treated with elastase + RV vs. 
PBS + RV at d4 post-infection but no significant differences were observed between elastase + RV 
and elastase + UV treatments (fig 3.13b&d). Therefore, single dose elastase also more accurately 
modelled increased mucin expression following RV infection in COPD. 




Figure 3.13 Effect of single dose elastase administration on RV1B-induced mucins. 
 C57BL/6 mice were challenged intranasally with elastase and additionally with RV1B or UV-inactivated RV1B, 
10d later. (a-b) Lung tissue was harvested at the indicated timepoints post-infection. RNA was extracted from 
tissue and cDNA generated as described. (a) MUC5AC and (b) MUC5B mRNA copies were measured in lung 
tissue by Taqman quantitative PCR. (c-d) BAL was performed at the indicated timepoints post-infection. (c) 
MUC5AC and (d) MUC5B protein in lavage supernatants were measured by ELISA. Data represent mean (+/- 
SEM) of 4 mice per group from one representative experiment with findings reproduced in at least 2 
independent experiments (*p<0.05, **p<0.01, ***p<0.001). 
 
 3.3.4.5 Lung periodic acid schiff staining  
Having observed that the single dose elastase model more accurately modelled mucus 
hypersecretion, we proceeded to further assess this characteristic of the model by staining lung 
sections with PAS to identify mucin-producing goblet cells. Abundant PAS-positive mucus producing 
cells were present in the airways of elastase + RV treated mice at d4 following RV challenge and, to a 
lesser extent, in the airways of elastase + UV treated mice (fig 3.14a&b). No PAS positive cells were 
visible in the airways of mice receiving PBS + RV or PBS+ UV treatments (fig 3.14c&d). PAS staining 
scores were increased in elastase + UV vs. PBS + UV treated mice and also in elastase + RV treated 











































































































































































Figure 3.14 Effect of single dose elastase administration and RV1B infection on PAS staining. 
C57BL/6 mice were challenged intranasally with elastase and additionally with RV1B or UV-inactivated RV1B, 
10d later.  At d4 post RV challenge, lungs were formalin fixed, paraffin embedded and stained with periodic 
acid Schiff (PAS). Representative images of mice treated with (a) elastase + RV1B (b) elastase + UV-RV1B (c) 
PBS + RV1B (d) PBS + UV-RV1B. (e) Scoring for PAS positive mucus producing cells, using a system described 
previously.[358] Data represent mean (+/- SEM) of 4 mice per group from one representative experiment with 
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3.3.4.6 Airway hyper-responsiveness 
Whole body plethysmography was used to assess AHR to nebulised MCH at d1 post-infection in the 
single dose elastase + RV model. Neither RV infection (PBS + RV) nor elastase treatment (elastase + 
UV) in isolation caused increased AHR compared to PBS + UV treated double negative controls. 
However, mice exposed to single dose elastase followed by RV infection had significantly increased 
PenH average values at MCH dose of 100mg/mL compared to PBS + RV and elastase + UV treated 
mice (fig 3.15a).  Mice treated with elastase + RV or elastase + UV showed a trend towards lower 
PC20 values than mice treated with PBS + RV or PBS + UV (figure 3.15b). Therefore single dose 
elastase administration did not demonstrate any lung function abnormalities consistent with stable 
COPD when assessed by whole body plethysmography. However, it modelled the increased AHR 
associated with RV infection in COPD vs. RV infection in healthy controls or vs. stable disease.  
 
Figure 3.15 Airway hyper-responsiveness in single dose elastase and RV1B infection model. 
 C57BL/6 mice were challenged intranasally with elastase and additionally with RV1B or UV-inactivated RV1B, 
10d later. Airway hyper-responsiveness expressed as (a) average PenH over a 5 minute period following MCH 
challenge and (b) expressed as PC20, the provocative concentration of MCH that produces a 20% increase in 
PenH was measured by whole body plethysmography at d1 post-infection.  Data represent mean (+/- SEM) of 
5 mice per group from one representative experiment with findings reproduced in at least 2 independent 
experiments (*** denotes statistical comparison between elastase + RV vs. PBS + RV groups (p<0.001), ψψ 



















































































In contrast to the previously published description of the model, we found that administration of 
four doses of elastase and LPS in combination with RV1B led to unchanged or impaired rather than 
enhanced inflammatory responses compared to PBS + RV treatment. Therefore, in our hands, this 
model was not a representative model of RV infection in patients with COPD compared to infection 
in healthy controls. However, we did observe exacerbation of some inflammatory parameters 
compared to elastase + UV treatment, modelling some aspects of exacerbated vs. stable disease. We 
also failed to demonstrate the previously reported impaired virus control associated with four dose 
elastase/LPS administration [344] and therefore this model also did not recreate this key feature 
that has been reported in the human experimental model.[35] Reducing the number of elastase/LPS 
doses led to less severe histological emphysematous changes but also did not improve the accuracy 
of the model for mimicking the key features of exacerbation.  
In contrast to combined elastase/LPS models, we found that single dose elastase without LPS  
administration in combination with RV infection modelled many of the key pathological features 
reported in human experimental and naturally occurring disease, including enhanced neutrophilic 
and lymphocytic airways inflammation, exaggerated inflammatory cytokine production and 
increased airways mucin production compared to PBS + RV and elastase + UV treatments. Therefore, 
this model was a more representative model of the enhanced inflammation and exaggerated mucus 
secretion following RV infection in COPD vs. either RV infection in healthy controls or stable COPD. 
Despite this, single dose elastase also failed to recreate the impaired virus control that has been 
reported in human experimental infection disease models. Since impaired virus control was a key 
component of our hypothesis that COPD and ICS administration would synergistically suppress IFN 
responses to RV and increase virus replication, none of the models we evaluated were deemed to be 
suitable for further testing of this hypothesis.  
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Chapter 4: Results – Effects of inhaled corticosteroids on rhinovirus infection 
4.1 Introduction 
ICS are prescribed as maintenance therapy in up to 70% of patients with COPD, either alone or in 
combination with long acting β2-adrenoreceptor agonists.[370] Their use is supported by clinical 
guidelines which recommend prescription in patients with forced expiratory volume in the first 
second (FEV1)<50% predicted and history of frequent disease exacerbations.[9] Randomised 
controlled trials have reported that inhaled corticosteroid use in COPD reduces exacerbation 
frequency by only a modest 20-25%.[217, 239] There has been speculation that ICS may have a 
relative lack of benefit in the context of acute respiratory virus infections in particular.[57]  
Emerging evidence suggests that this lack of efficacy of ICS in respiratory virus-induced 
exacerbations could be due to suppression of innate anti-viral immune responses. In vitro studies 
have reported suppression of RV-induced IFN-α by budesonide in peripheral blood mononuclear 
cells (PBMCs) and suppression of IFN-stimulated genes by dexamethasone in fibroblasts and by 
budesonide in bronchial epithelial cells.[246-248] In vivo, Gustafson et al reported that oral 
prednisolone administration prior to experimental RV challenge in healthy subjects led to increased 
viral titres in nasal lavage [249] and Puhakka et al showed prolonged virus shedding with intranasal 
FP administration during naturally occurring colds.[250] Other studies assessing ICS in experimental 
RV-induced asthma exacerbations have shown only minimal effects on cellular airways 
inflammation, further reinforcing the belief that these drugs may be ineffective at reducing virus-
induced airway inflammation.[67] As discussed in chapter 3, COPD is believed to be associated with 
an inherent deficiency in IFN responses to RV infection [35] and given that ICS are frequently used in 
patients with COPD, they may interact with the disease to synergistically inhibit IFN responses and 
thus potentially lead to impaired virus clearance and increased exacerbation severity. 
To date, however, no study has provided a thorough analysis of the in vivo effects of ICS on anti-viral 
immunity and virus clearance. The mouse model of RV1B infection allows us to investigate effects of 
ICS administration on innate and adaptive immune responses to RV in vivo and to assess disease-
relevant features including airway inflammation and mucin production 
 
Chapter 4: Results  
115 
 
4.2 Aims and Hypotheses 
4.2.1 Aims 
To characterise the effects of FP on anti-viral immune responses to minor group RV infection: 
i) To determine the effects of inhaled FP on innate immune responses to RV infection in a 
mouse model including type I and III IFNs, ISG induction and virus replication. 
ii) To evaluate the effects of inhaled FP  on adaptive immunity, specifically pulmonary CD4+ 
and CD8+ T cell responses and RV-specific serum IgG and neutralising antibody levels.  
iii) To evaluate the effects of inhaled FP on human disease associated endpoints including 




1) FP suppresses RV induction of type I and III IFNs and ISGs, leading to increased virus loads in vivo. 
2) FP suppresses adaptive immunity to RV infection by inhibiting CD4+ and CD8+ T cell responses and 
impairs production of RV specific serum IgG and neutralising antibody. 
3) Increased virus loads associated with FP administration leads to increased airway inflammation 













In the initial data presented within this chapter, mice were treated as described in section 2.2.2.5. 
For clarity, the nomenclature used for the treatment groups in the FP plus RV model is summarised 




































Table 4.1: Treatment group nomenclature in FP and RV1B infection model 
 
4.3.1 Determination of FP dosing strategy 
The intranasal dosing route was chosen for administration of FP in our experimental model due to 
familiarity with this method and because it was reasoned that this would be a more efficient 
strategy for consistent dosing compared to nebulised drug administration. At the time of 
commencement of these experiments there were few published studies using intranasal 
administration of FP in mice and so advice was sought from an industrial collaborator who had 
expertise in mouse models of steroid administration in asthma. The dose of 1mg/kg FP used was 
chosen as a high dose that was expected to have effects on immune responses. Lower doses of FP 
were also assessed and are presented in section 4.3.8.  In preliminary experiments, vehicle DMSO 
and PBS administration were compared for a range of inflammatory parameters including BAL 
differential cell counts and BAL chemokine and cytokine levels and no differences between these 
treatments were observed (data not shown). Therefore vehicle was used as the negative control for 
FP in all subsequent experiments shown. 
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4.3.2 Effect of FP administration on nuclear transcription factor activation  
The pharmacological actions of ICS are mediated by binding of the drug to the GR in the cell 
cytoplasm, forming a complex that subsequently translocates to the nucleus to interact with GREs 
located in the promoter region of target genes.[223] To initially determine the efficacy and duration 
of action of intranasally administered FP, we assessed GR activation in lung tissue by measuring 
nuclear GR-DNA binding by ELISA. We found increased activated GR in the lung tissue of mice 
treated with FP compared to mice treated with vehicle DMSO at 8h post administration which 
returned to basal levels of vehicle treated mice by 24h post administration (fig 4.1a). For subsequent 
experiments, we therefore administered FP 1h prior to infection with RV1B since gene expression of 
a number of inflammatory mediators also peaks at 8h post-infection in the mouse model [367] and 
this dosing strategy would allow a direct assessment of the anti-inflammatory effects of FP at the 
most appropriate timepoint. 
The immune response to RV infection involves an innate anti-viral response mediated by type I and 
III IFNs and regulation of IFN synthesis requires participation of several transcription factors 
including IRF-1, -3 and -7, AP-1 and NFB, which are activated in response to virus–specific 
signals.[56, 57] Glucocorticoids are known to interact directly or indirectly with these transcription 
factors and thus alter the expression of pro-inflammatory genes.[371] We therefore used DNA 
binding ELISAs to study transcription factor activation in response to RV infection +/- FP 
administration. As previously reported [56], RV infection (vehicle + RV treatment) induced an 
increase in NFB p65 activation at 8 and 24h post-infection which was suppressed at 8h post-
infection in mice dosed with FP prior to infection with RV1B (FP + RV treatment) (fig 4.1b).  
Activation of IRF-3 was initially assessed at the same time-points as assessed for GR and NFB 
activation but we found no effect of RV infection on activation at 8 or 24h post-infection. We 
reasoned that IRF-3 activation may occur earlier and therefore subsequently evaluated activation at 
2h post-infection. RV infection increased IRF-3 activation vs. UV-RV administration at 2h post-
infection and FP administration suppressed this effect (fig 4.1 c).   
 




Figure 4.1 Effect of FP administration on RV1B-induced nuclear transcription factor activation. 
(a) C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO control intranasally and glucocorticoid 
receptor nuclear DNA binding in lung tissue was measured by ELISA. (b&c) 1h after FP or vehicle 
administration, mice were additionally challenged with RV1B or UV-inactivated RV1B and (b) NFB p65 and (c) 
IRF-3 activation in lung tissue was assessed by measuring nuclear DNA binding by ELISA. Data represent mean 
(+/- SEM) of 5 mice per group from one representative experiment with findings reproduced in at least 2 
independent experiments (**p<0.01, ***p<0.001). 
 
 
4.3.3 Effect of FP administration on RV1B-induced inflammation                                                
4.3.3.1 BAL cellular inflammation 
A key effect of ICS is their ability to reduce the number of inflammatory cells in the airways [372] but 
effects on virus-induced inflammation have not been extensively studied. We therefore evaluated 
the effect of FP on RV-induced cellular airways inflammation in BAL by assessment of cell counts on 
cytospins. RV infection led to increases in neutrophils at 8 and 24h, lymphocytes at d2 and 7 and 
macrophages at d2 post-challenge compared to UV-inactivated RV challenge. Administration of FP 
prior to RV infection led to suppressed numbers of BAL neutrophils (complete inhibition at 8h and 
~60% reduction at 24h post-infection), lymphocytes (~80% reduction at d2 and ~65% reduction at d7 
post-infection) and macrophages (~80%  reduction at d2 post-infection) in comparison to mice 


























































































































































































Figure 4.2 Effect of FP administration on cellular airways inflammation. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. BAL was performed at the indicated timepoints. BAL cell 
cytospin slides were prepared as described and (a) neutrophils, (b) lymphocytes and (c) macrophages were 
differentially counted blind to experimental conditions. Data represent mean (+/- SEM) of 5 mice per group 
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4.3.3.2 BAL chemokines  
To investigate whether the effects of FP on cellular airways inflammation were associated with 
suppression of RV-induced chemokine expression, we measured BAL protein levels of neutrophil and 
lymphocyte chemokines by ELISA. RV1B infection led to increases in neutrophil chemokines 
CXCL2/MIP-2 at 8h and CXCL1/KC at 8 and 24h (fig4.3a&b). RV infection also increased Th1 
lymphocyte chemokines CXCL9/MIG (24h post-infection) and CCL5/RANTES (8 and 24h post-
infection) and Th2 lymphocyte chemokines CCL22/MDC and CCL17/TARC (8 and 24h post-infection). 
Mice treated with FP + RV infection had suppressed levels of neutrophil chemokines CXCL2/MIP2 
(~70% reduction) and CXCL1/KC proteins (~60% reduction) in BAL at 8h post-infection (fig 4.3a&b) 
and suppressed levels of Th1 lymphocyte chemokines CXCL9/MIG (~65% reduction) and RANTES 
(~55% reduction) proteins in BAL at 24h post-infection (fig 4.3c&d) compared to treatment with 
vehicle + RV. Conversely, BAL protein levels of Th2 lymphocyte chemokine CCL17/TARC were no 
different at 8h and significantly increased in FP + RV vs. vehicle + RV treated mice at 24h post-
infection with similar trends observed for CCL22/MDC (fig 4.3e&f).   




Figure 4.3 Effect of FP administration on RV1B-induced BAL chemokine production. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. BAL was performed at the indicated timepoints post-
infection. Chemokines (a) CXCL2/MIP2 (b) CXCL1/KC (c) CXCL9/MIG (d) CCL5/RANTES (e) CCL22/MDC and (f) 
CCL17/TARC in lavage supernatants were measured by ELISA. Data represent mean (+/- SEM) of 5 mice per 
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4.3.3.3 BAL proinflammatory cytokines 
We also assessed the effect of FP administration on RV induction of proinflammatory cytokines by 
ELISA. RV infection led to increased BAL protein levels of IL-6 at 8 and 24h post-infection and TNF-α 
at 8h post-infection (fig 4.4a&b). FP suppressed RV induction of IL-6 (~70% inhibition) and TNF-α 
(~85%) at 8h post-infection (fig 4.4a&b). 
 
Figure 4.4 Effect of FP administration on RV1B-induced BAL proinflammatory cytokine production. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. BAL was performed at the indicated timepoints post-
infection. Cytokines (a) IL-6 and (b) TNF-α in lavage supernatants were measured by ELISA. Data represent 
mean (+/- SEM) of 5 mice per group from one representative experiment with findings reproduced in at least 2 
independent experiments (***p<0.001). 
 
 
4.3.4 Effect of FP administration on innate anti-viral immune responses to RV1B infection 
4.3.4.1 Type I and III interferons  
In vitro studies have recently reported that ICS pre-treatment of fibroblasts and PBMCs can suppress 
the induction of types I and III IFNs by RV [246, 248] but these effects have not been demonstrated 
in vivo. We therefore assessed the effect of FP on innate anti-viral immune responses to RV infection 
in the mouse model.  RV infection induced IFN -β and -λ mRNAs in lung tissue (8h post-infection), 
IFN-α and β protein in BAL (24h post-infection) and IFN-λ protein in BAL (8 and 24h post-infection) 
(fig 4.5a-e). FP suppressed RV induction of IFN-β (complete inhibition) and –λ (~40% reduction) 
mRNA expression in lung tissue at 8h post-infection (fig 4.5a&b). FP also almost completely inhibited 
RV-induced IFN-α and –β proteins in BAL at 24h post-infection and suppressed IFN–λ protein in BAL 






































































Figure 4.5 Effect of FP administration on type I and III IFN induction by RV1B infection. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. (a&b) Lung tissue was harvested at the indicated timepoints 
post-infection. RNA was extracted from tissue, cDNA generated as described and (a) IFN-β and (b) IFN-λ mRNA 
copies were assessed by Taqman quantitative PCR. (c-d) BAL was performed at the indicated timepoints post-
infection and (c) IFN-α, (d) IFN-β and (e) IFN-λ protein in lavage supernatants were measured by ELISA. Data 
represent mean (+/- SEM) of 5 mice per group from one representative experiment with findings reproduced 

























































































































































































4.3.4.2 Interferon-stimulated genes  
Interferons act by inducing expression of ISGs which encode a range of proteins that selectively 
interfere with virus replication, protein synthesis or protein trafficking.[57, 373]  RV infection 
increased lung tissue mRNA levels of the ISGs oligoadenylate synthetase (OAS), viperin, IL-15 and 
CXCL10/IP-10 protein in BAL at 8 and 24h post-infection (fig 4.6a-d). Consistent with the suppression 
of type I and III IFNs, FP also attenuated RV-induced lung tissue mRNA expression of OAS at 8h (near 
complete inhibition), viperin at 8h and 24h post-infection (~60 % and ~50% inhibition respectively) 
and IL-15 at 8h post-infection (~75% inhibition) (fig 4.6 a-c). FP also suppressed RV induction of 
CXCL10/IP10 protein in BAL at 8h post-infection (~90% inhibition) (fig 4.6d).  
 
Figure 4.6 Effect of FP administration on RV1B induction of interferon stimulated genes.  
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. (a-c) Lung tissue was harvested at the indicated timepoints 
post-infection. RNA was extracted from tissue, cDNA generated as described and (a) OAS, (b) viperin and (c) IL-
15 mRNA copies were assessed by Taqman quantitative PCR. (d) BAL was performed at the indicated 
timepoints post-infection. CXCL10/IP-10 protein in lavage supernatants was measured by ELISA. Data 
represent mean (+/- SEM) of 5 mice per group from one representative experiment with findings reproduced 
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4.3.4.3 Natural killer cells in lung tissue and BAL 
NK cells also play an important role in the innate immune response against respiratory virus 
infections by directly eliminating virally infected cells.[61, 69] Type I IFN signalling has previously 
been shown to be required for NK cell responses to RV.[56] We therefore assessed NK cell 
populations in the lung and BAL by flow cytometry staining for the cell surface markers NK.1.1 and 
CD69. RV infection had no effect on total numbers of NK cells in lung but increased numbers of 
activated NK cells in lung (d2 post-infection) and numbers of total and activated NK cells in BAL (d2 
and  d7 post-infection)(fig 4.7a–d). There was no difference in total NK cell numbers in lung tissue 
between mice treated with FP + RV vs. vehicle + RV (fig 4.7a). Mice treated with FP + RV had 
suppressed numbers of activated NK cells in lung tissue (~60% reduction) and suppressed numbers 
of total and activated NK cells in BAL (~60% reduction) at d2 post-infection compared to mice 
treated with vehicle + RV (fig 4.7b-d). 
Figure 4.7 Effect of FP on RV1B-induced natural killer cell response.     
 C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. Lung tissue was harvested and BAL was performed at the 
indicated timepoints post-infection. Lung and BAL cells were stained for CD3 and the NK cell marker NK1.1 and 
the early activation marker CD69 (as indicated) and analysed by flow cytometry. (a) Lung CD3- NK1.1+ cell 
number, (b) Lung activated (CD69+) CD3- NK1.1+ cell number (c) BAL CD3- NK1.1+ cell number and (d) BAL 
activated (CD69+) CD3- NK1.1+ cell number. Data represent mean (+/- SEM) of 5 mice per group from one 
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4.3.5 Effect of FP administration on adaptive immune responses to RV1B infection 
T cell and antibody responses may be important for both viral clearance and prevention of 
reinfection.[64, 71, 72]  In addition to evaluating the effect of FP administration on innate immune 
responses to RV infection, we therefore also determined if there were any effects on adaptive 
immunity including T cell responses, virus-specific serum IgG and serum neutralising antibodies. 
4.3.5.1 BAL and lung CD4+ T cells 
Harvested BAL and lung cells were stained for T cell markers CD3 and CD4 and the activation marker 
CD69 and analysed by flow cytometry. RV infection had no effect on lung CD3+CD4+ cell numbers 
but increased total CD3+CD4+ cells in BAL and activated CD3+CD4+ cell numbers in lung and BAL at 
d2 and d7 post-infection (fig 4.8a-d). Total CD3+CD4+ cell numbers in lung tissue were no different 
between FP+RV treated and vehicle+RV treated mice (fig 4.8a). Decreased numbers of CD3+CD4+ 
cells in BAL at d2 and d7 post-infection (~45% and ~75% reduction) and decreased numbers of 
activated CD3+CD4+ cells in lung tissue (~70% reduction at d2 and d7 post-infection) and BAL (~50% 
reduction at d2 and ~75% reduction at d7 post-infection) were observed in mice treated with FP + 


















Figure 4.8 Effect of FP on lung and BAL CD4+ T cell responses to RV1B infection. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. Lung tissue was harvested and BAL was performed at the 
indicated timepoints post-infection. Lung and BAL cells were stained with antibodies specific for CD3, CD4 and 
CD69. (a) Lung CD3+ CD4+ T cell number and (b) BAL CD3+ CD4+ T cell number. (c) Lung activated (CD69+)CD3+ 
CD4+ T cell number and (d) BAL activated (CD69+)CD3+ CD4+ T cell number.  Data represent mean (+/- SEM) of 
5 mice per group from one representative experiment with findings reproduced in at least 2 independent 
experiments (*p<0.05, **p<0.01, ***p<0.001). 
 
 
4.3.5.2 BAL and lung CD8+ T cells 
We also measured the effect of FP administration on RV-induced CD8+ T cell responses. Harvested 
BAL or lung cells were stained for T cell markers CD3, CD8 and the activation marker CD69 and 
analysed by flow cytometry. RV infection had no effect on lung CD3+CD8+ cell numbers but 
increased activated CD3+CD8+ cell numbers in lung (d2 post-infection) and  total and activated 
CD3+CD8 + cells in BAL (d2 and d7 post-infection) (fig 4.9 a-d). 
As with CD4+ T cells, total numbers of CD8+ cells in lung tissue were no different between FP + RV 
treated and vehicle + RV treated mice (fig 4.9a). Decreased numbers of total CD8+ cells in BAL (~60% 
reduction) and decreased numbers of activated CD8+ cells in lung tissue and BAL (~70 and ~60% 
reduction respectively) were observed in mice treated with FP + RV compared to mice treated with 


































































































































































































Figure 4.9 Effect of FP on lung and BAL CD8+ T cell responses to RV1B infection.                                            
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. Lung tissue was harvested and BAL was performed at the 
indicated timepoints post-infection. Lung and BAL cells were stained with antibodies specific for CD3, CD8 and 
CD69. (a) Lung CD3+CD8+ T cell number and (b) BAL CD3+CD8+ T cell number. (c) Lung activated (CD69+) 
CD3+CD8+ T cell number and (d) BAL activated (CD69+) CD3+CD8+ T cell number. Data represent mean (+/- 
SEM) of 5 mice per group from one representative experiment with findings reproduced in at least 2 
independent experiments (*p<0.05, **p<0.01, ***p<0.001). 
 
4.3.5.3 RV1B-specific serum IgG and neutralising antibodies 
Peripheral blood was collected on d14 post-infection and RV1B-specific IgG1 and IgG2a in serum 
were measured by ELISA. RV infection led to increased levels of RV1B- specific IgG1 and IgG2a 
compared to treatment with UV-RV1B. Sera from mice treated with FP + RV had reduced levels of 
RV1B-specific IgG1 and a non-significant trend towards reduced IgG2a compared to vehicle + RV 
treatment (fig 4.10a&b). We also assessed the effect of FP treatment on the ability of sera to 
neutralise RV infection of HeLa cells in vitro. Sera taken at d14 from mice infected with RV prevented 
any CPE to a dilution of at least 1 in 320 with no protection observed in sera from mice treated with 
UV-RV1B.  Neutralisation of RV1B CPE was reduced in sera from mice treated with FP + RV with loss 


























































































































































































Figure 4.10 Effect of FP on RV1B-specific serum IgG and neutralising antibody production. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. On d14 post-infection, peripheral blood was harvested and 
(a) RV-specific IgG1 and (b) RV-specific IgG2a in serum were quantified by ELISA. Data represent mean (+/- 
SEM) of 5 mice per group from one representative experiment with findings reproduced in at least 2 
independent experiments (**p<0.01, ***p<0.001; ns = non significant). (c) Sera were assayed for their ability 
to prevent cytopathic effect caused by the same RV serotype used for in vivo challenge. Cytopathic effect was 
quantified by crystal violet staining. Top dotted lines; serum only (uninfected) controls. Bottom dotted lines; 
virus infected (no serum) control. Data points represent sera pooled from 4 mice per treatment group from 
one representative experiment with findings reproduced in at least 2 independent experiments. 
 
4.3.6 Effect of FP administration on virus loads 
In our model, FP therefore suppressed IFN and ISG induction and adaptive cellular and humoral 
immune responses. Suppressed IFN has previously been shown to correlate with increased RV 
replication in asthma and COPD [35, 374] but the influence of ICS therapy has not been previously 
assessed in vivo. We therefore evaluated whether the effects of FP on suppression of anti-viral 
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Measurement of RV RNA in lung tissue  by Taqman quantitative PCR showed increased copy 
numbers in mice treated with FP + RV vs. vehicle + RV at 8h (~3 fold), 24h (~2 fold) and 48h (~3 fold) 
post-infection. There was no difference between RV RNA copies at 1h post-infection between FP+ RV 
and vehicle + RV groups, suggesting that initial binding of RV to lung epithelial cells in the mouse 
model is not affected by FP (fig 4.11a). To further interrogate this finding, we also quantified 
rhinovirus load in lung tissue by titration of lung homogenate supernatants in HeLa cells and found 
increased titres in FP + RV compared to vehicle + RV treated mice (~ 0.5 log) at 24h post-infection 
(fig 4.11b). 
Figure 4.11 Effect of FP on lung tissue virus loads. 
C57BL/6 mice were treated with intranasal FP (1mg/kg) or vehicle DMSO and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. Lung tissue was harvested at the indicated timepoints post-
infection. (a) RNA was extracted from tissue, cDNA generated as described and RV RNA copies were assessed 
by Taqman quantitative PCR. (b) Lungs were homogenised and infectious virus in lung tissue homogenate 
supernatant was measured by titration in HeLa cells. Data represent mean (+/- SEM) of 5 mice per group from 
one representative experiment with findings reproduced in at least 2 independent experiments. Statistical 
significance is indicated in (a) for FP + RV vs. vehicle + RV treatments only (*p<0.05, ***p<0.001, n.s not 
significant). 
 
4.3.7 Effect of FP administration on RV1B-induced airway mucins 
Mucus hypersecretion is a prominent feature of COPD and may contribute to airways 
obstruction.[18] Rhinoviruses have been shown to induce mucin expression in the mouse model of 
disease [367] and in vitro in epithelial cells in a replication dependent manner.[369] Studies 
evaluating the effect of glucocorticoids on mucin expression in vitro have reported conflicting results 
with some studies showing suppression of MUC5AC [306, 307], others showing no effect [309] and 
one study reporting increased IL-13 induced MUC5AC in response to dexamethasone administration 
in bronchial epithelial cells [311]. The effect of glucocorticoids on mucin expression in response to 
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RV infection has not been investigated previously. We therefore assessed lung tissue mRNA 
expression and BAL protein levels of the major airway mucins MUC5AC and MUC5B in the mouse 
model.  
RV infection had no effect on MUC5AC mRNA but significantly increased MUC5B mRNA in lung tissue 
at d4 post-infection (fig 4.12a&b). BAL protein levels of MUC5AC at d7 post-infection and MUC5B 
protein at d1, 2, 7 and 14 post-infection were increased by RV infection (fig 4.12c&d). Lung tissue 
mRNA and BAL protein levels of MUC5AC were increased (~3 fold and 1.5 fold respectively) in mice 
dosed with FP + RV compared to vehicle + RV administration at d7 post-infection (fig 4.12a&c). There 
was no difference in lung tissue MUC5B mRNA expression between FP + RV vs. vehicle + RV 
administration (fig 4.12b). MUC5B protein in BAL was reduced (~75% suppression) at d1 but 
increased (~1.5 fold) at d14 post-infection in FP + RV treated mice compared to vehicle + RV 
treatment (fig 4.12d). 
 
Figure 4.12 Effect of FP on RV1B-induced airway mucins. 
C57BL/6 mice were treated with intranasal FP (1mg/kg) or vehicle DMSO and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. (a&b) RNA was extracted from harvested lung tissue, cDNA 
was generated as described and (a) MUC5AC and (b) MUC5B mRNA copies were assessed by Taqman 
quantitative PCR. (c&d) BAL was performed and (c) MUC5AC and (d) MUC5B proteins in lavage supernatants 
were measured by ELISA. Data represent mean (+/- SEM) of 5 mice per group from one representative 
experiment with findings reproduced in at least 2 independent experiments. *denotes statistical comparison 
for FP + RV vs. vehicle + RV treatments and Ɨdenotes comparison for vehicle + RV vs. vehicle + UV treatments 
(*p<0.05, ***p<0.001; Ɨ p<0.05, Ɨ Ɨ p<0.01, Ɨ Ɨ Ɨ p<0.001). 
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4.3.8 Dose responsive effects of FP on innate anti-viral immune responses, virus loads and airway 
inflammation 
The dose of FP (1mg/kg) used in experiments described above was based on that defined as optimal 
in asthma models by an industry collaborator. Although it is difficult to compare intranasal dosing in 
mice with inhaled dosing in patients with COPD, this dose is likely to be considerably higher than FP 
doses used in clinical practice which are typically around 1000μg per day (~0.014mg/kg for a 70kg 
human). We therefore evaluated the effects of lower 0.5mg/kg and 0.1mg/kg doses of FP on anti-
viral immunity and airway inflammation to determine if similar effects are observed at these lower, 
perhaps more realistic, doses. Endpoint analysis was limited to 8h and d1 post-infection and 
therefore dose responsive effects of FP on parameters expressed later in the infection timecourse 
such as BAL lymphocytes and mucins were not assessed. 
Mice dosed with 1mg/kg FP + RV and 0.5mg/kg FP + RV had significantly reduced BAL neutrophils 
(~50% suppression) at 24h post-infection compared to vehicle + RV treatment (fig 4.13a). There was 
no difference in BAL neutrophil numbers between mice dosed with 0.1mg/kg FP + RV and vehicle + 
RV (fig 4.13a). RV RNA copy numbers in lung tissue measured by Taqman quantitative PCR were 
increased with FP 1mg/kg + RV (~5 fold) and 0.5mg/kg FP + RV (~3 fold) administration at d1 post-
infection in comparison with vehicle + RV administration but no difference was observed between 
0.1mg/kg FP + RV and vehicle + RV administration (fig 4.13b). IFN-λ mRNA in lung tissue was 
suppressed in mice administered 1mg/kg FP + RV (~75% inhibition) compared to vehicle + RV at 8h 
post-infection with non-significant trends towards suppression observed in mice receiving 0.5mg/kg 
or 0.1mg/kg FP + RV (fig 4.13c). We also observed trends towards reduced IL-6 and CXCL10/IP-10 
protein in mice treated with 1mg/kg or 0.5mg/kg FP + RV vs. vehicle + RV at 8h post-infection. These 
differences at 1mg/kg failed to reach statistical significance which contrasts the significant reduction 
observed with 1mg/kg FP + RV vs. vehicle + RV treatment shown in sections 4.3.3.2 and 4.3.4.2. This 
is likely to be due to the increased number of groups required for these experiments thus leading to 
multiple post-test comparisons, preventing significant differences from being observed. 
In summary, effects of FP on virus loads and virus-induced airway inflammation appeared to be dose 
responsive with a 50% dose reduction (0.5mg/kg) showing similar effects to the highest dose 
(1mg/kg) of FP assessed. At 90% dose reduction (0.1mg/kg), impairment of anti-viral responses and 
anti-inflammatory effects of FP are lost. We were unable to identify a dose of FP where anti-
inflammatory effects were retained but detrimental effects on anti-viral immune responses were 
absent. 




Figure 4.13 Effect of FP dose on airway inflammation, virus loads and innate anti-viral immunity. 
C57BL/6 mice were treated with FP at 1mg/kg, 0.5mg/kg. 0.1mg/kg or vehicle DMSO intranasally and 
challenged with RV1B or UV-inactivated RV1B, 1h following FP administration. Lung tissue was harvested and 
BAL was performed at 8 and 24h post-infection. RNA was extracted from tissue and cDNA generated as 
described. Cell cytospin slides were prepared as described and (a) neutrophil numbers in BAL at 24h post-
infection were differentially counted blind to experimental conditions. (b) RV RNA at 24h and (c) IFN-λ mRNA 
at 8h post-infection were measured in lung tissue by Taqman quantitative PCR. (d) IL-6 and (e) CXCL10/IP-10 
protein were measured in lavage supernatants at 8h post-infection. Data represent mean (+/- SEM) of 5 mice 
per group from one representative experiment with findings reproduced in at least 2 independent 
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4.3.9 Evaluation of the effects of recombinant IFN-β administration in the FP and RV1B infection 
model 
The effects on virus loads by FP could be explained at least in part by suppression of type I and III 
IFN. To evaluate whether the effects of FP in suppressing innate immune responses and enhancing 
virus loads were causally related to suppression of IFN, we therefore administered recombinant IFN-
β to FP treated mice. A dose of 104 units of recombinant IFN-β was administered 1h after RV1B 
infection as previous experiments had shown that this dosing strategy caused upregulation of ISGs 
comparable to RV1B infection at 8h post-challenge (N.Glanville, unpublished data). This model is 
summarised in table 4.2. 
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4.3.9.1 Interferons and interferon-stimulated genes 
We initially evaluated whether administration of recombinant IFN-β led to reconstitution of FP 
suppressed ISG expression. Administration of recombinant IFN-β alone (vehicle + UV + IFN-β 
treatment) significantly induced lung tissue OAS mRNA and IP-10 BAL protein vs. vehicle + UV 
treatment at 8h post-administration (fig 4.14a&b) and led to a non-significant trend towards 
increased viperin mRNA in lung tissue at 8h post-administration (fig 4.14c). There was no effect of 
IFN-β administration on lung tissue mRNA expression or BAL protein levels of IFN-λ (fig 4.14d&e). 
Lung tissue mRNA expression of OAS was increased in mice receiving FP + RV in combination with 
IFN-β (FP + RV + IFN-β treatment) vs. FP + RV treatment, back to levels similar to those observed 
with vehicle + RV treatment (fig 4.14a) at 8h post-infection. BAL protein levels of CXCL10/IP-10 and 
IFN-λ were also increased in mice dosed with FP + RV + IFN-β compared to treatment with FP + RV at 
8h post-infection with CXCL10/IP-10 levels restored to similar levels as those observed with vehicle + 
RV treatment but only partial restoration of IFN-λ was observed (fig 4.14b&e). Conversely, there 
were no significant differences in IFN-λ or viperin mRNA levels in lung tissue between FP + RV + IFN-β 
and FP + RV treated mice (fig 4.14c&d). 
 




Figure 4.14 Effect of recombinant IFN-β administration on FP suppressed innate immune responses to RV1B 
infection.                                                                     
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. Mice were additionally dosed intranasally with recombinant 
IFN-β 10
4 
units 1h after RV infection. Lung tissue was harvested and BAL was performed at 8h post-infection. 
RNA was extracted from lung tissue and cDNA generated as described. (a) OAS mRNA copies were assessed by 
Taqman quantitative PCR. (b) CXCL10/IP-10 protein in lavage supernatants were measured by ELISA. (c) viperin 
and (d) IFN-λ mRNA copies were assessed by Taqman quantitative PCR. (e) IFN-λ protein in lavage 
supernatants was measured by ELISA. Data represent mean (+/- SEM) of 4 mice per group from one 
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4.3.9.2 Airway inflammation 
We also assessed whether administration of recombinant IFN-β had any effect on the (perhaps 
desirable) suppression of RV-induced airway inflammation by FP. There was no difference between 
BAL neutrophil (fig 4.15a) and lymphocyte numbers (fig 4.15b) and BAL IL-6 protein levels (fig 4.15c) 
between mice treated with FP + RV + IFN-β vs. treatment with FP + RV. BAL CXCL2/MIP2 protein 
levels were also no different between FP + RV and FP + RV + IFN-β treated mice but CXCL1/KC 
protein in BAL was suppressed (~60% reduction) in FP + RV + IFN-β vs. FP + RV treated mice at 8h 
post-infection. Therefore, recombinant IFNβ had either no effect or enhanced (in the case of 
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Figure 4.15 Effect of recombinant IFN-β administration in combination with FP on RV1B-induced airway 
inflammation 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. Mice were additionally dosed intranasally with recombinant 
IFN-β 10
4
 units 1h after RV infection. BAL was performed and BAL cell cytospin slides were prepared as 
described and (a) neutrophils at 24h and (b) lymphocytes at 48h post-infection were differentially counted 
blind to experimental conditions. (c) IL-6 (d) CXCL2/MIP-2 and (e) CXCL1/KC protein in lavage supernatants 
were measured by ELISA at 8h post-infection. Data represent mean (+/- SEM) of 4 mice per group from one 
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4.3.9.3 Adaptive immune responses 
We also carried out an assessment of whether administration of recombinant IFN-β would have any 
effect on FP suppression of adaptive immunity including total numbers of CD4+ and CD8+ T cells in 
BAL and neutralising antibody production in serum. Numbers of CD8+ T cells at d2 post-infection and 
CD4+ T cells at d7 post-infection were no different between FP + RV + IFNβ treated mice compared 
to FP + RV treated mice (fig 4.16a&b). Neutralising antibodies were suppressed to the same extent in 
FP + RV and FP + RV + IFN-β treated mice compared to mice receiving vehicle + RV at d14 post-
infection (fig 4.16c). This suggests that suppression of IFN does not explain the observed effects of 
FP on impaired adaptive immune responses.  
Figure 4.16 Effect of recombinant IFN-β administration in combination with FP on adaptive immune 
responses to RV.                                                                                
C57BL/6 mice were treated with intranasal FP (1mg/kg) or vehicle DMSO and infected with RV1B or UV-
inactivated RV1B, 1h following FP administration. Mice were additionally dosed intranasally with recombinant 
IFN-β 10
4
 units 1h after RV infection. (a & b) BAL was performed at d2 and d7 post-infection. BAL cells were 
stained with antibodies specific for (a) CD3 and CD8 at d2 or (b) CD3 and CD4 at d7 post-infection. Data 
represent mean (+/- SEM) of 4 mice per group. (* p<0.05, **p<0.01, n.s non significant). (c) Peripheral blood 
was harvested at d14 post-infection. Sera were assayed for their ability to prevent cytopathic effect caused by 
the same RV serotype used for in vivo challenge Cytopathic effect was quantified by crystal violet staining. Top 
dotted lines; serum only (uninfected) controls. Bottom dotted lines; virus infected (no serum) control. Data 
points represent sera pooled from 4 mice per treatment group from one representative experiment with 
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4.3.9.4 Virus loads 
We next assessed whether reconstitution of FP suppressed innate responses by administration of 
recombinant IFN-β would reduce the increased virus loads previously observed with administration 
of FP + RV (as shown in section 4.3.6). Increased virus loads were again seen in mice treated with FP 
+ RV compared to vehicle + RV at 24h post-infection. Administration of recombinant IFN-β in 
combination with FP + RV (FP + RV + IFN-β) led to significantly reduced virus loads compared to FP + 
RV administration reducing loads down to similar levels as those observed with vehicle + RV 
treatment (fig 4.17). 
 
Figure 4.17 Effect of recombinant IFN-β administration in combination with FP on virus loads.       
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. Mice were additionally dosed intranasally with recombinant 
IFN-β 10
4
 units 1h after RV infection. Lung tissue was harvested at 24h post-infection. RNA was extracted from 
tissue and cDNA generated as described. RV RNA copies were assessed by Taqman quantitative PCR. Data 
represent mean (+/- SEM) of 4 mice per group from one representative experiment with findings reproduced 
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4.3.9.5 Airway mucins 
We next assessed whether recombinant IFN-β administration had any effect on the increase in RV 
induced BAL mucin proteins observed with FP administration at the time-points that increases had 
previously been observed. There was no difference between levels of BAL MUC5AC at d7 (fig 4.18a) 
and MUC5B at d14 post-infection (fig 4.18b) in mice treated with FP + RV + IFN-β compared to 
treatment with FP + RV. Therefore, administration of IFN-β did not reverse FP induced enhancement 
of mucin production. 
 
Figure 4.18 Effect of recombinant IFN-β administration in combination with FP on airway mucins. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. Mice were additionally dosed intranasally with recombinant 
IFN-β 10
4
 units 1h after RV infection. BAL was performed at d7 and d14 post-infection. (a) MUC5AC and (b) 
MUC5B protein at d7 and d14 respectively were measured in lavage supernatants by ELISA. Data represent 
mean (+/- SEM) of 4 mice per group from one representative experiment with findings reproduced in at least 2 
independent experiments (*p<0.05, ns = non-significant). 
 
4.3.10 Investigation into components of IFN signalling pathways affected by FP 
It is known that the type 1 IFN response is bimodal with an initial release of IFN in response to virus 
detection and a secondary response where type I IFN acts in an autocrine fashion via IFNAR to 
stimulate further production of IFN and induction of ISGs.[57] We therefore sought to assess which 
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4.3.10.1 Evaluation of effect of FP on virus sensing pathway mediated expression of IFN 
In order to determine whether ICS acted upon the intracellular cytosolic MDA5 virus sensing 
pathway or cell surface/endosomal TLR3 sensing pathway, we assessed IFN-β promoter activity 
using a luciferase (reporter) gene expression assay. Since primary airway epithelial cells were 
unavailable for these experiments, BEAS2B cells were chosen as a representative airway epithelial 
cell line that has been previously used in similar published studies from our group involving IFN 
pathway agonists [52]. Cells were transfected with IFN-β promoter reporter constructs and then 
treated with either 5µg/ml TLR3 agonist (Poly(I:C)) or 250ng/ml MDA-5 agonist (transfected 
Poly(I:C)) in the presence or absence of FP. FP led to suppressed TLR-3 induced IFN-β promoter 
activity (fig 4.19a) but had no effect on MDA-5 induced IFN-β promoter activity (fig 4.19b). 
 
Figure 4.19 Effect of FP on virus sensing pathway mediated IFN expression in vitro. 
BEAS-2B cells were transfected with interferon-β promoter reporter constructs and then treated with FP 1nM 
or 10nM or medium control 24h later. Cells were then stimulated with (a) 5µg/ml TLR3 agonist (Poly(I:C)) or 
medium control, (b) 250 ng/ml MDA-5 agonist (transfected Poly(I:C)) or medium control, harvested at 24h and 
relative light units (RLU) were determined. Data represent mean (+/- SEM) comprising 3 independent 
experiments. (**p<0.01,***p<0.001, n.s non significant). 
 
4.3.10.2 Evaluation of effect of FP on IFNAR signalling  
We also planned to use in vitro systems to assess whether FP acts on the secondary component of 
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However, evaluation of the relevant control groups from the in vivo recombinant IFN-β experiment 
allowed an analysis of effects of FP administration on exogenous IFN-β induced ISG expression. 
Recombinant IFN-β administration led to increased lung tissue mRNA expression of ISGs OAS, viperin 
and IFN-λ and CXCL10/IP-10 protein in BAL at 8h post administration (fig4.20a-d). Administration of 
FP suppressed IFN-β induced OAS (~25% reduction) and IFN-λ mRNAs (near complete inhibition) in 
lung tissue at 8h but had no effect on viperin mRNA expression (fig 4.20a–c). FP administration also 
reduced IFN-β induced CXCL10/IP-10 BAL protein (~50% reduction) at 8h post-infection (fig 4.20d). 
These results therefore suggest that ICS also impair the secondary component of IFN signalling via 
IFNAR. 
  
Figure 4.20 Effect of FP on recombinant IFN-β induced ISGs in mice.                                                          
C57BL/6 mice were treated with intranasal FP (1mg/kg) or vehicle DMSO and additionally with intranasal 
recombinant IFN-β 10
4
 units, 2h following FP administration. (a-c) Lung tissue was harvested at the timepoints 
indicated post IFN-β administration. RNA was extracted from lung tissue and cDNA generated, as described. (a) 
OAS, (b) IFN-λ and (c) viperin mRNA copies were assessed by Taqman quantitative PCR. (d) BAL was performed 
at the indicated timepoints post-infection. CXCL10/IP-10 protein was measured in lavage supernatants by 
ELISA. Data represent mean (+/- SEM) of 4 mice per group from one representative experiment with findings 






































































































































































Consistent with previous observations from in vitro studies, administration of FP to the airways prior 
to infection with RV1B in mice led to suppressed induction of innate anti-viral responses including 
type I and III IFNs and ISGs. This was associated with increased virus loads in vivo. Despite these 
potentially adverse effects on innate anti-viral immunity, virus-induced airway inflammation 
including BAL neutrophil and lymphocyte numbers were suppressed by FP. However, the expression 
of airway mucins was conversely increased at later timepoints in mice treated with FP + RV 
compared to treatment with vehicle + RV. Further adverse immune effects of FP were demonstrated 
by an impairment of adaptive immunity including reduced CD4+ and CD8+ T lymphocyte recruitment 
to the airways and reduced RV-specific IgG1, IgG2a and neutralising antibody production in serum.  
Administration of recombinant IFN-β in combination with FP led to reconstitution of suppressed 
innate responses, upregulation of ISGs and reduced virus loads without having any effect on FP 
suppression of inflammation, thereby confirming a direct causal role for suppression of IFN-β by FP 
for the observed effect on virus loads. Mechanistic studies in airway epithelial cells and in vivo show 
that suppression of IFN by FP occurs through inhibition of both the initial virus sensing release of IFN 
via TLR-3 mediated pathways and the secondary component of IFN signalling via IFNAR. 
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Chapter 5: Results – Effect of inhaled corticosteroids on respiratory bacterial infection 
5.1 Introduction 
Patients with COPD are known to be at increased risk of developing pneumonia [125, 375] and a 
large body of clinical evidence now demonstrates that this risk may be further increased by the use 
of ICS. Randomised controlled trials have reported an increased incidence of pneumonia in patients 
treated with FP, either alone or in combination with LABAs.[217, 256-258] This association has been 
further demonstrated in case-control studies that have additionally suggested that the risk of 
pneumonia may be dose dependent.[222, 266, 267]  
Culture based studies have indicated that patients with COPD are frequently colonised with 
potentially pathogenic microrganisms (PPM) including Streptococcus pneumoniae, Haemophilus 
influenzae and Moraxhella catarrhalis.[376-380] Acquisition of new bacterial strains increases risk of 
exacerbation [40] but the pathobiology underlying development of bacterial pneumonia in COPD is 
unclear. New culture independent molecular techniques have recently revealed the presence of 
complex bacterial communities in the lower airways of healthy individuals, with evidence of 
alterations in COPD.[114-116, 381]  Studies have also begun to characterise the upper and lower 
respiratory microbiome in specific pathogen free mice and have shown similar communities to those 
present in humans.[199, 355, 356] 
 COPD has been shown to be associated with a number of specific impairments of innate anti-
bacterial host defence in the lungs including reduced expression of PRRs [161-163], impaired 
macrophage function [169, 170], impaired mucociliary clearance [180, 181] and deficiencies in some 
AMPs [183, 185, 186, 188]. Additionally, there is a large body of evidence demonstrating that 
respiratory virus infection can impair anti-bacterial immune responses via a number of mechanisms, 
thus predisposing to secondary bacterial infection.[191, 192, 208] In a human experimental model of 
COPD exacerbation, RV infection was shown to directly precipitate secondary bacterial respiratory 
infection when assessed by either microbiological culture or culture-independent techniques.[122, 
190]   
 The precise molecular mechanisms underlying the increased risk of pneumonia associated with ICS 
use in COPD are unclear. Some in vitro and in vivo studies have reported that corticosteroids can 
alter a number of components of anti-bacterial host defence including downregulation of TLR4 
[163], impairment of macrophage phagocytosis [280-282], suppression of anti-bacterial cytokines 
including IL-6[283, 287-289], TNF-α [288-291] and CXCL8/IL-8 [287, 288] and suppression of AMPs 
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such as LL37/cathelicidin [303], β-defensins [301, 302] and lactoferrin.[231, 293] Whether all or any 
of these effects contribute to the increased risk of pneumonia associated with ICS use is unclear. 
Studies that have previously evaluated the effects of ICS in mouse models of pneumonia have 
yielded conflicting results with some studies showing improved bacterial clearance [312, 313] and 
others showing impairment.[283, 303]  Studies have also focussed on whether ICS have any effects 
on colonising bacteria in the lungs during clinical stability. Increased sputum bacterial loads have 
also been shown to correlate with ICS use in COPD during stable state.[315] Pragman et al observed 
segregation of communities according to use or non-use of ICS, thereby suggesting that ICS may lead 
to alterations in the airway microbiome.[120] Similarly, Huang et al reported a trend towards 
increased richness and diversity of microbial communities associated with ICS use in COPD.[316]  
These studies all provide intriguing evidence that ICS use and respiratory virus infection could 
potentially combine to synergistically impair anti-bacterial host defence. This may lead to alteration 
of the respiratory microbiome in COPD, promoting the proliferation of existing PPMs and 
subsequent increased risk of bacterial pneumonia. 
5.2 Aims and Hypotheses 
5.2.1 Aims 
i) To evaluate anti-bacterial innate responses in the mouse model of RV-induced COPD 
exacerbation. 
ii) To characterise the lower respiratory microbiota in naïve mice. 
iii) To evaluate the effects of RV1B infection on the lower respiratory microbiota in mice in 
order to determine whether RV1B infection leads to proliferation of existing PPMs 
and/or acquisition of new bacterial species. 
iv) To evaluate the effects of inhaled FP on anti-bacterial host defence responses following 
RV infection and to assess the effect of FP on the lower respiratory microbiota, when 









1) Administration of a single dose of elastase to model COPD in mice suppresses RV induction of 
innate anti-bacterial host responses, including PRR expression and production of AMPs. 
2) The lower respiratory microbiome in naïve mice consists of PPMs that are relevant to human 
COPD disease including Streptococcus pneumoniae  and Haemophilus influenzae. 
3) RV1B infection in mice results in disturbance of the respiratory microbiome leading to 
proliferation of colonising PPMs in the airways.  
4) FP administration prior to RV1B infection suppresses production of anti-bacterial host defence 
mediators. This further exaggerates disturbances of the respiratory microbiome leading to increased 



















5.3.1 Evaluation of innate anti-bacterial immune responses in the RV-induced COPD exacerbation 
model 
Although we were unable to define a model of COPD RV exacerbation that accurately represented 
the impaired virus control reported in human disease, we showed in chapter 3 that single dose 
elastase administration was the most representative model of enhanced inflammation tested. We 
therefore evaluated whether this model displayed any of the features of impaired anti-bacterial 
host-defence that have been reported in human studies. We have already shown that mucins were 
increased in the model (chapter 3, section 3.3.4.4) and this would represent one feature that could 
be associated with impaired anti-bacterial function. We also evaluated a number of other features in 
the model including expression of PRRs and AMPs.  
Elastase administration alone (elastase + UV vs. PBS + UV groups) was not associated with any 
changes in TLR2 or TLR4 mRNA expression in lung tissue (fig 5.1a-b) and therefore did not mimic 
findings from human studies which have reported reduced expression in patients with stable 
COPD.[161, 163] RV infection alone increased TLR2 but not TLR4 mRNA expression in lung tissue at 
d1 post challenge (fig 5.1a&b). The combination of elastase and RV infection suppressed RV-induced 
TLR2 mRNA (~75% inhibition) but increased lung tissue TLR4 mRNA at d1 post challenge compared 
to either treatment alone. Elastase + RV treated mice had increased TLR4 mRNA vs. elastase + UV 
treated mice (~60%) but there was no difference in TLR2 mRNA between these groups (fig 5.1a-b). 
A commercially available ELISA duoset for pentraxin-3 enabled measurement of protein levels of this 
AMP in BAL. Although similar assays were not available for surfactant protein-A, SLPI or β-defensin 2, 
we were able to measure mRNA expression of these AMPs in lung tissue by Taqman quantitative 
PCR. Elastase administration did not lead to any changes in pentraxin-3 protein in BAL or lung tissue 
mRNA expression of surfactant protein-A, SLPI or β-defensin-2 (comparison of elastase + UV vs. PBS + 
UV groups) (fig 5.1c-f) and therefore the baseline model of COPD did not show any deficiencies in 
expression of any of the AMPs measured. RV infection increased pentraxin-3 BAL protein at d1 and 4 
post-challenge but had no effect on surfactant protein-A, SLPI or β-defensin 2 mRNAs in lung tissue. 
Elastase administration led to increased (~65%) RV induction of pentraxin-3 BAL and lung tissue 
mRNA expression of surfactant protein-A (~2.5 fold increase)  and β-defensin 2 (~3 fold increase) at 
d1 post challenge but had no effect on RV induction of SLPI mRNA (fig 5.1c-f). Pentraxin-3 BAL 
protein and surfactant protein-A lung tissue mRNA were also increased in elastase + RV vs. elastase + 
UV treated mice at d1 post challenge (fig 5.1c&e). Therefore, with the exception of RV induced TLR2 
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expression, the single dose elastase was a model of enhanced or unchanged rather than impaired 
anti-bacterial host defence. 
 
Figure 5.1 Effect of single dose elastase administration on RV1B induction of anti-bacterial host-defence 
responses. 
C57BL/6 mice were challenged with elastase and additionally with RV1B or UV-inactivated RV1B, 10d later.     
(a-b & d-f)  Lung tissue was harvested at the indicated timepoints post-infection. RNA was extracted from 
tissue and cDNA generated, as described. (c) BAL was performed at the indicated timepoints post-infection.  
(a) TLR2 and (b)TLR4 mRNA expression was measured in lung tissue by Taqman quantitative PCR. (c) pentraxin-
3 protein in lavage supernatants were measured by ELISA.  (d) SLPI (e) surfactant protein-A and (f) β-defensin 2 
mRNA copies were measured in lung tissue by Taqman quantitative PCR.  Data represent mean (+/- SEM) of 4 
mice per group from one representative experiment with findings reproduced in at least 2 independent 
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5.3.2 Evaluation of effect of FP administration on RV induction of anti-bacterial immune responses 
Previously, in chapter 4, we showed that FP suppresses RV1B induction of IL-6, TNF-α, type I IFNs 
and neutrophil recruitment to the airways, which are all components of anti-bacterial host defence 
that may theorectically alter the course of secondary bacterial infection following initial virus 
exacerbation.  
We also measured similar additional components of anti-bacterial host defence in the FP and RV1B 
infection model as those measured in the single dose elastase model of COPD. RV infection induced 
mRNA expression of TLR2 and SLPI in lung tissue and increased pentraxin-3 protein in BAL (fig 
5.2a,c&d). Treatment with FP completely inhibited RV-induced TLR2 mRNA expression at d1 post-
infection but had no effect on TLR4 expression in lung tissue (fig 5.2a-b). FP administration also 
suppressed RV induction of pentraxin 3 protein at d1 (~70% inhibition) and d4 (~80% inhibition) 
post-infection but increased surfactant protein-A mRNA expression in lung tissue (~2.5 fold) at d4 
post-infection (fig5.2c&e). FP administration had no significant effect on RV induction of SLPI, or β-








Figure 5.2 Effect of FP administration on RV1B induction of anti-bacterial host-defence responses.                                                                                                                                                                
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO intranasally and challenged with RV1B or UV-
inactivated RV1B, 1h following FP administration. (a-b & d-f) Lung tissue was harvested at the indicated 
timepoints post-infection. RNA was extracted from tissue and cDNA generated as described. (c) BAL was 
performed at the indicated timepoints post-infection.  (a) TLR2 and (b) TLR4 mRNA expression was measured 
in lung tissue by Taqman quantitative PCR. (c) pentraxin-3 protein in lavage supernatants were measured by 
ELISA.  (d) SLPI (e) surfactant protein-A and (f) β-defensin 2 mRNA copies were measured in lung tissue by 
Taqman quantitative PCR.  Data represent mean (+/- SEM) of 5 mice per group from one representative 
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5.3.3 Evaluation of the naïve mouse airway microbiota by 16S pyrosequencing  
Previous studies have assessed the airway microbiome in upper and lower respiratory tract samples 
taken from human subjects by 16S rRNA pyrosequencing using the Roche 454 platform.[115, 116, 
122] We therefore initially used this technique to evaluate whether the microbiome of the mouse 
airway could be measured in BAL from naïve wild-type mice.  
Total DNA was extracted and the V3-V5 portion (550 base pairs (bp)) of the bacterial 16S rRNA gene 
was amplified, as previously described.[122] PCR products were separated on a 1% agarose gel in 
order to confirm successful amplification and presence of a measurable microbiome in these 
samples (fig 5.3). Although not quantitative, the presence of bands of reasonable intensity, and 
based on prior experience of the group, suggested that the bacterial DNA content would be 
sufficient to allow progression to amplicon sequencing for some of the samples.  
 
Figure 5.3 Gel electrophoresis of 16S PCR products from naïve mouse BAL samples using standard sampling 
technique.  
BAL was performed in naïve, wild type C57BL/6 mice. Total DNA was extracted from BAL samples, as 
described.  Bacterial 16S rRNA gene was amplified by PCR using primers specific to the V3–V5 region. PCR 
products of DNA from individual BAL samples were separated on a 1% agarose gel. Arrows 1 and 2 denote 
representative experimental samples. Arrow 3 denotes positive control. Arrow 4 denotes negative no template 
control.  
 
Quadruplicate 25µL PCRs were then set up, amplified and combined, purified and prepared for 
sequencing (as described in chapter 2, section 2.2.8). Pyrosequencing was carried out and 16S rRNA 
sequences were assigned a taxonomic identity with the ribosomal database project classifier (as 
described in chapter 2, section 2.2.8.6). A phylogenetic tree of the OTU sequences was constructed 
and a representative heat map of bacterial 16S rRNA sequences derived from mouse BAL samples is 
shown in fig 5.4. At the genus level, the microbiota in all samples was dominated by Herbaspirillum. 
This bacterial genus is a nitrogen-fixing Proteobacteria that is typically found in plants [382] and has 
not been described in previous studies that have evaluated the airway microbiome in either human 
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or mouse airway samples.[116, 122, 355, 356] It is therefore extremely unlikely to be a normal 
dominant component of the resident mammalian airway microbiome. We reasoned that presence of 
this bacterial genus represented an environmental contaminant that had been introduced most 
likely during the BAL sampling process or possibly at a later stage during DNA extraction or 
amplification. 
 
Figure 5.4 Heat map of 16S bacterial rRNA sequences from naïve mouse BAL samples. 
BAL was performed in untreated C57BL/6 mice. DNA was extracted and V3-V5 component of bacterial 16S 
gene was amplified by PCR. Quadruplicate 25µL PCR products were combined, purified and sequenced using 
the Roche 454 Junior pyrosequencer. A representative group of individual samples taken from naïve mice is 
shown, organized by taxonomy with abundance indicated by colour (see figure key). Columns represent 
individual samples with numerical sequence reads for each particular genus shown.  
 
Given that BAL taken by standard sampling techniques was likely to have been the source of the 
environmental contaminant, we next proceeded to perform BAL by a more sterile technique. To 
minimize the risk of contamination, autoclaved BAL tubing and sterile instruments were used (as 
described in chapter 2, section 2.2.3.1). A similar technique was described in a recent study that 
reported successful characterization of the mouse airway microbiota in BAL samples.[355] Total DNA 
was extracted from these more optimally collected samples and PCR of the 16S rRNA gene was again 
carried out. As before, the obtained PCR product was separated on a 1% agarose gel, but only faint 
bands at ~550bp size were visible, suggesting a very low yield of 16S rRNA (data not shown). Formal 
quantification of PCR product using a Quant-iT PicoGreen dsDNA assay kit (as described in chapter 2, 
section 2.2.8.4) further confirmed a very low bacterial DNA yield with all samples containing levels 
below the threshold of 2.5ng/µL that is the minimal requirement for successful 16S pyrosequencing. 
Most abundant genus within sample
Second most abundant genus within sample
Third most abundant genus within sample
Fourth most abundant genus within sample
Least abundant genus within sample
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5.3.4 Quantitative PCR to evaluate 16S bacterial load in the lower respiratory tract of naïve mice 
5.3.4.1 Bronchoalveolar lavage 
Subsequent establishment of a 16S quantitative PCR assay (as described in chapter 2, section 
2.2.7.4) enabled evaluation and comparison of overall bacterial loads in BAL samples taken from 
naïve mice via the modified sterile BAL sampling and normal BAL sampling methods. The mean 16S 
copy numbers in samples from sterile BAL technique was ~2 logs lower than samples that had been 
obtained with standard BAL sampling (mean 6.36 x 103 copies vs. 3.49 x 105 copies) and ~3 logs 
lower than a positive control of human sputum samples that had been previously successfully 
sequenced using the Roche 454 pyrosequencing platform (mean 5.02 x 106 copies) (fig 5.5). Although 
the minimum threshold of qPCR copy numbers that is sufficient to allow sequencing is currently 
unclear, these data further suggested that BAL samples obtained by sterile sampling techniques 
would not have a high enough 16S bacterial DNA content to enable sequencing.  
Previous studies have reported that pooling BAL samples from multiple mice may increase the 
bacterial yield and allow 16S rRNA sequencing.[383] We therefore evaluated whether pooled BAL 
samples taken from four separate naïve mice would give higher 16S copy numbers but found 
similarly low levels of 16S rRNA copies in a single BAL sample compared to four pooled BAL samples 
(mean 6.36 x 103 copies for single BAL sample vs. 4.90 x 103 copies for four pooled BAL samples) (fig 
5.5). 
5.3.4.2 Nasal lavage 
A recent study has reported successful characterisation of the microbiome in nasal lavage samples 
taken from mice.[356] We therefore assessed bacterial 16S copy numbers in nasal lavage taken from 
untreated mice using a sterile sampling technique. Once more, we found low yields of a similar level 
to BAL performed by sterile technique (mean 3.34 x 103 copies)(fig 5.5). 
 
 




Figure 5.5 Evaluation of 16S rRNA gene copy number in mouse BAL and nasal lavage.  
 BAL or nasal lavage was performed in untreated C57BL/6 mice. DNA was extracted, as described and 16S rRNA 
gene copy numbers in 1µL of extracted DNA were measured by SYBR green quantitative PCR. 16S rRNA copy 
numbers were evaluated in BAL taken by normal sampling method, sterile sampling method (single sample or 
four pooled samples assessed) and nasal lavage by a sterile sampling method. Positive control of human 
sputum sample with known high bacterial DNA content and negative control of extracted DNA from fluid 
which had been passed through sampling tube but not been used to lavage lungs are also shown. Individual 
data points for single samples, or pooled samples where indicated and mean for group shown. 
 
5.3.4.3 Lung tissue 
Given the relatively low 16S qPCR copy numbers observed in BAL and nasal lavage samples, we next 
proceeded to measure bacterial loads in lung tissue taken from untreated mice, again using a sterile 
sampling technique to minimize contamination risk. We evaluated 16S rRNA copy numbers in 
different quantities of tissue including single lobe (right upper), single lung (left) and both lungs 
combined. 16S rRNA copy numbers were similar whether DNA was extracted from a single lobe, 
single whole lung or two whole lungs (mean 2.31 x 105, 1.64 x 105 and 1.20 x 105 copies for single 
lobe, single whole lung and two whole lungs respectively) (fig 5.6).  This suggested that a single lung 
lobe provided sufficient DNA to reach the maximum amount that could be extracted via the 



























































































   Chapter 5: Results  
156 
 
were around 2 logs higher than copy numbers in BAL samples obtained by sterile sampling 
techniques. This suggested that use of lung tissue samples to characterize the respiratory 
microbiome by 16S pyrosequencing may be more feasible than use of BAL samples.  
 
Figure 5.6: Evaluation of 16S rRNA gene copy number in mouse lung tissue samples.  
16S rRNA copy numbers in lung tissue harvested from untreated wild-type C57BL/6 mice were measured in 
1µL of extracted DNA by SYBR green quantitative PCR in varying quantities of lung tissue including single apical 
lung lobe, single whole lung and two whole lungs. Positive control of human sputum sample with known 
presence of high bacterial DNA content and negative control of extracted DNA from fluid which had been 
passed through sampling tube but not been used to lavage lungs are also shown. Individual data point for each 
sample and mean for group shown. 
  
5.3.5 Evaluation of quantitative 16S rRNA copy numbers in mice treated with FP and/or RV1B 
Given that quantitative PCR of extracted DNA samples from lung tissue of naïve mice showed 
relatively high copy numbers of 16S rRNA gene, we next used this technique to evaluate whether FP 
administration and/or RV1B infection in mice had any effects on total bacterial loads in the lungs. 
Time course analysis showed no effect of RV infection and/or FP administration on 16S rRNA copies 
in lung tissue at d1, 4 or 7 post-infection when compared to vehicle + UV treatment (fig 5.7). 
However, at 8h post-infection increased 16S rRNA copies (~4 fold)  were observed in mice treated 
with FP + RV or FP + UV vs. vehicle + RV and increased 16S rRNA copies (~2 fold) were also observed 
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bacterial loads in the lung, regardless of RV infection. Furthermore, 16S rRNA copy numbers were ~2 
fold lower in mice treated with vehicle + RV compared to treatment with vehicle + UV (fig 5.7) 
suggesting that RV infection may transiently reduce bacterial loads in the lung.  
  
Figure 5.7 Effect of FP and RV1B infection on 16S rRNA bacterial copy number in lung tissue. 
C57BL/6 mice were treated with FP 1mg/kg or vehicle DMSO control intranasally and challenged with RV1B or 
UV-inactivated RV1B, 1h after FP administration. Lung tissue was harvested at the indicated timepoints post-
infection and DNA was extracted, as described. 16S rRNA copy numbers were assessed by SYBR green 
quantitative PCR. Data represent mean (+/- SEM) of 4 mice per group from one representative experiment 
with findings reproduced in at least 2 independent experiments (*p<0.05, **p<0.01, ***p<0.001). 
 
 
5.3.6 Exogenous administration of S.pneumoniae in mice to model bacterial colonisation in COPD 
Since difficulties were experienced with attempts to undertake 16S pyrosequencing in lower 
respiratory tract samples from mice and following further delays due to a requirement for a change 
to use of the Illumina MiSeq sequencer at the Brompton Molecular Genetics and Genomics 
laboratory because of an unexpected discontinuation of the the Roche Junior 454 sequencing 
platform, the decision was made to establish a mouse model of low dose bacterial infection in order 
to directly model lower respiratory tract colonisation in COPD. Streptococcus pneumoniae, a PPM 
that is frequently cultured from sputum of patients with COPD in stable state [376, 378] and the 
most commonly implicated pathogen causing pneumonia in patients with COPD was the bacteria 
chosen for the model.[132] We aimed to use this model to assess the effects of FP on anti-bacterial 
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host defence and thus test the hypothesis that ICS use promotes proliferation of potentially 
pathogenic colonising bacteria and increases pneumonia risk in COPD. 
 Streptococcus pneumoniae capsular serotype 2 strain (D39) was used for all studies as frozen stocks 
of known concentration were available from previous in vitro work carried out the St Mary’s Airway 
Disease Infection group. This strain has previously been used in published mouse models of 
pneumococcal pneumonia.[384, 385]  
5.3.6.1 Evaluation of varying infecting doses of S.pneumoniae on bacterial loads in lung tissue, 
systemic dissemination and survival 
Colonisation is defined as presence of a pathogen in the airways without acute symptoms of 
infection.[98] We therefore sought to define a model of bacterial infection in which bacteria could 
be cultured from harvested lung tissue samples but only a mild inflammatory response was elicited 
in vivo.  
We initially conducted a series of optimization experiments with the aim of defining a suitable 
infecting dose of S.pneumoniae to be used. Previous mouse models of acute pneumonia induced by 
S.pneumoniae D39 administration have used doses up to 2 x 108 CFU.[386] We therefore assessed a 
range of reducing doses from 1 x 106 CFU to define the optimum lowest dose for modelling bacterial 
colonisation. A dose dependent increase in bacterial CFU recovered from lung tissue harvested at 
24h post-infection was observed up to 5 x 105 CFU infecting dose with no increase in recovery 
observed above this dose (fig 5.8). Very low bacteria loads were cultured from tissue of mice 
infected with the lowest dose evaluated 1 x 105 CFU (mean 176.7 CFU /mL recovered), thereby 
suggesting that this infecting dose was too low for reliable recovery of bacteria in lung tissue (fig 
5.8). 




Figure 5.8 Assessment of lung tissue bacterial loads following infection with varying doses of S.pneumoniae.  
C57BL/6 mice were challenged with S.pneumoniae D39 at doses of 1 x 10
6
, 7.5 x 10
5
, 5 x 10
5
 2.5 x 10
5
, 1 x 10
5
 
CFU or PBS control. Lung tissue was harvested at 24h post-infection, homogenized, serially diluted, plated on 
columbia horse blood agar plates and incubated at 37
0
C for 18h. Counts were performed on plates containing 
50-300 colonies and CFU/mL calculated. Individual data points for each animal within group and mean for 
group shown. n= 5-6 mice per treatment group. Single experiment only. 
 
Previous studies using S.pneumoniae D39 in mouse models of pneumonia have shown varying 
survival with one study reporting that administration of 2 x106 CFU led to 50% mortality at d4 post-
infection [384] and another which used the same dose reporting 0% mortality at the same timepoint 
[386]. In the mouse model of S.pneumoniae, mortality is caused by systemic dissemination of 
bacteria into the bloodstream leading to septicaemia.[352] We therefore assessed bacterial loads in 
the bloodstream and survival for a range of S.pneumoniae infecting doses. Systemic bacterial 
dissemination, defined by the presence of culturable S.pneumoniae from blood samples was present 
at 24 and 48h in at least some animals within the group at all infecting doses of S.pneumoniae 
assessed, with the exception of the lowest dose of 1 x 105 CFU. By 48h post-infection, bloodstream 
dissemination was present in 37.5% of mice infected with 2.5 x 105 CFU and 100% of mice infected 
with 1 x 106, thereby suggesting a dose dependent increase in the proportion of mice within a group 
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post-infection for all doses of S.pneumoniae tested. The highest mortality rates were actually 
observed with 7.5 x 105 CFU (50% at d2), the second highest evaluated dose, followed by 1 x 106 CFU 
(25% at d2), 5 x 105 CFU (12.5% at d2) and 2.5 x 105 CFU (6.25% at d2). One hundred percent of mice 
treated with 1 x 105 CFU dose survived to d3 (fig 5.9b). Weight loss at d2 post infection was greatest 
in mice infected with 7.5 x 105 CFU  (9.0% reduction from baseline weight), followed by 5 x 105 CFU 
(3.4% reduction) and 1 x 106 CFU (2.4% reduction) with no weight loss observed in mice infected 
with 2.5 x 105 CFU, 1 x 105 CFU or PBS control (fig 5.9c). 
 
Figure 5.9 Assessment of bacterial loads in bloodstream, survival and weight loss following infection with 
varying doses of S.pneumoniae.  
C57BL/6 mice were challenged with S.pneumoniae D39 at doses of 1 x 10
6
 CFU, 7.5 x 10
5 
CFU, 5 x 10
5
 CFU, 2.5 x 
10
5
 CFU and 1 x 10
5
 or PBS control. (a) Blood samples were harvested by cardiac puncture at 24 and 48h post-
infection, serially diluted, plated onto columbia horse blood agar plates and incubated at 37
0
C for 18h. Counts 
were performed on plates containing 50-300 colonies and CFU/mL calculated. Individual data points for each 
animal within group and mean for group shown.(b) Survival curves according to infecting dose of 
S.pneumoniae. Mice were killed when they exhibited signs of severe disease from which recovery was unlikely, 
as previously described.[387] (c) Mice were weighed daily and % change from pre-infection weight calculated. 
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5.3.6.2 Evaluation of effect of S.pneumoniae dose on airway inflammation  
Assessment of cellular airways inflammation at 24h post-infection showed no neutrophilia 
associated with administration of 1 x 105 CFU infecting dose but a dose dependent increase in 
neutrophilia with increasing doses up to 1x 106 CFU (fig 5.10a). Measurement of BAL levels of the 
anti-bacterial pro-inflammatory cytokine IL-6 showed significantly increased levels in mice treated 
with 1x 106 CFU S.pneumoniae compared to PBS dosed controls and a non-significant trends towards 
increases with lower infecting doses vs. PBS treatment (fig 5.10b). 
 
Figure 5.10 Assessment of airway inflammation following infection with varying doses of S. pneumoniae.  
C57BL/6 mice were challenged with S.pneumoniae D39 at doses of 1 x 10
6
 CFU, 7.5 x 10
5 
CFU, 5 x 10
5
 CFU, 2.5 x 
10
5
 CFU and 1 x 10
5
 or PBS control. BAL was performed at 24h post-infection. Cytospin slides were prepared as 
described. (a) Neutrophils were differentially counted blind to experimental conditions. (b) IL-6 protein was 
measured in lavage supernatants by ELISA. Data represent mean (+/- SEM) of 5-6 mice per treatment group 
(*p<0.05, **p<0.01, ***p<0.001). Single experiment only. 
 
The dose optimisation experiments described above highlighted the difficulty of modelling bacterial 
colonisation in mouse models using S.pneumoniae D39. We observed a narrow threshold between 
rapid bacterial clearance and minimal inflammation associated with use of low doses such as 1 x 105 
CFU, but evidence of increasing systemic dissemination resulting in mortality observed with doses of 
2.5 x 105 CFU and higher. We considered 1 x 105 CFU to be too low a dose to be used as the lack of a 
measurable inflammatory response to instilled bacteria observed would prevent assessment of the 
hypothesised suppressive effects of steroids on anti-bacterial host defence. Consequently, we chose 
2.5 x 105 CFU as the infecting dose of S.pneumoniae to be used in further experiments assessing the 
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numbers of culturable bacteria in lung tissue at 24h post-infection as well as inducing a mild 
inflammatory response that could potentially be modulated by ICS administration. We also decided 
to limit assessment of endpoints to 24h post-infection as the latest timepoint evaluated, since 
beyond this timepoint a proportion of mice, at all doses assessed (except 1 x 105 CFU), developed 
systemic dissemination leading to mortality. We therefore reasoned that administration of FP may 
impair anti-bacterial immunity and therefore potentially lead to even higher mortality.   
5.3.7 Effect of FP on low dose S.pneumoniae infection  
5.3.7.1 Bacterial loads in lung tissue 
The effects of intranasal FP (1mg/kg) administration prior to infection with S.pneumoniae 2.5 x 105 
CFU on lung bacterial loads were assessed by culture of homogenized lung tissue. Mice treated with 
FP prior to S.pneumoniae infection (FP + SP treatment) had increased bacterial loads in lung tissue 
(~1 log difference) at 8h post-infection compared to treatment with vehicle DMSO prior to 
S.pneumoniae (vehicle + SP). No significant differences in lung tissue bacterial loads were observed 
between FP + SP and vehicle + SP treatment at 4h or 24h post-infection, although there was a trend 
towards increased bacterial loads in FP + SP treated mice observed at both time-points (fig 5.11). 
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Figure 5.11 Effect of FP on lung tissue bacterial loads following S. pneumoniae infection. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO control intranasally and additionally challenged 
with S.pneumoniae D39 2.5 x 10
5 
CFU or PBS control, 1h following FP administration. Lung tissue was harvested 
at the indicated timepoints, homogenized, serially diluted, plated on columbia horse blood agar plates and 
incubated at 37
0
C for 18h. Counts were performed on plates containing 50-300 colonies and CFU/mL 
calculated. Individual data points for each animal within group and mean for group shown. n= 12 mice per 
treatment group, comprising 2 independent experiments (*** p<0.001, n.s non significant). 
 
5.3.7.2 Bacterial dissemination  
To assess whether the increased lung tissue bacterial loads associated with FP treatment led to 
increased systemic bacterial dissemination of S.pneumoniae, we measured bacterial loads in blood 
samples taken by cardiac puncture. There were no significant differences in numbers of CFUs in 
blood taken from mice treated with FP + SP compared to vehicle + SP at any time-point post-
infection, although FP + SP treatment was associated with a trend towards increased bacterial loads 
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Figure 5.12 Effect of FP on blood bacterial loads following S. pneumoniae infection.                       
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO control intranasally and additionally challenged 
with S.pneumoniae D39 2.5 x 10
5
 CFU or PBS control, 1h following FP administration. Blood was harvested by 
cardiac puncture at the indicated timepoints, serially diluted, plated on columbia horse blood agar plates and 
incubated at 37
0
C for 18h. Counts were performed on plates containing 50-300 colonies and CFU/mL 
calculated. Individual data points for each animal within group and mean for group shown. n= 12 mice per 
treatment group, comprising 2 independent experiments (n.s non significant). 
 
5.3.7.3 Pattern recognition receptor expression 
To identify a mechanism for the increased total bacterial loads measured by 16S qPCR and increased 
S.pneumoniae loads associated with FP administration, we next assessed effects of FP on 
components of anti-bacterial innate immunity following S.pneumoniae infection. The initial 
recognition of invading pathogens by the host is mediated by PRRs that are activated by PAMPs. 
Activation of PRRs triggers a signalling cascade that culminates in production of inflammatory 
mediators.[138] We therefore assessed lung tissue mRNA expression of PRRs TLR2 and TLR4 (which 
recognise pneumococcal wall component lipoteichoic acid and virulence factor pneumolysin 
respectively) that have previously been shown to be important in pneumococcal infection.[140, 388, 
389] Previous studies in human patients with COPD have shown reduced lung epithelial expression 
of TLR4 associated with FP treatment and in vitro studies have shown that lung epithelial cell 
expression of TLR2 is upregulated by dexamethasone administration.[163, 278] In our model, vehicle 
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vehicle + PBS (~3 fold increase). This effect was almost completely inhibited in mice treated with FP 
+ SP (fig 5.13a). There was no effect of either S.pneumoniae or FP, alone or in combination, on TLR4 
mRNA in lung tissue (fig 5.13b).  
Figure 5.13 Effect of FP on pattern recognition receptor expression following S.pneumoniae infection. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO control intranasally and additionally challenged 
with S.pneumoniae D39 2.5 x 10
5 
CFU or PBS control, 1h following FP administration. Lung tissue was harvested 
at the indicated timepoints. RNA was extracted from tissue and cDNA generated as described. (a) TLR2 and (b) 
TLR4 mRNA expression was assessed by Taqman quantitative PCR. Data represent mean (+/- SEM) of 6 mice 
per group from one representative experiment with findings reproduced in at least 2 independent 
experiments (*p<0.05, **p<0.01). 
 
 
5.3.7.4 Cellular airway inflammation 
Previously, in chapter 4, we showed that FP suppresses induction of several chemokines and 
proinflammatory cytokines following rhinovirus infection. We therefore assessed the effect of FP on 
induction of inflammatory parameters by S.pneumoniae to determine whether inflammatory 
responses to bacteria were also impaired by FP.  
SP infection led to significantly increased BAL neutrophils compared to vehicle + PBS from 8h and 
peaking at 24h post challenge. FP treatment suppressed BAL neutrophil number at 8h (complete 
inhibition) and 24h (~65% suppression) post SP infection (fig 5.14a). SP infection also increased BAL 
macrophages compared to vehicle + PBS at 4h, 8h and 24h post challenge. FP treatment completely 
suppressed BAL macrophage numbers at 8h post challenge (fig 5.14b). SP infection did not increase 





















































































Figure 5.14 Effect of FP on cellular airways inflammation following S. pneumoniae infection. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO control intranasally and challenged with 
S.pneumoniae D39 2.5 x 10
5 
CFU or PBS control, 1h following FP administration. BAL was performed at the 
indicated timepoints post-infection. BAL cytospin slides were prepared as described. (a) neutrophils and (b) 
macrophages were differentially counted blind to experimental conditions. Data represent mean (+/- SEM) of 
6 mice per group from one representative experiment with findings reproduced in at least 2 independent 
experiments (*p<0.05, ***p<0.001). 
 
 
5.3.7.5 Anti-bacterial chemokines and cytokines 
Investigation of antibacterial pro-inflammatory cytokines IL-6 and TNF-α (fig 5.15a&b) and 
neutrophil chemokines CXCL2/MIP-2 and CXCL1/KC (fig 5.15c&d) revealed them all to be increased 
in mice treated with vehicle + SP vs. vehicle + PBS at 4h post-challenge. FP suppressed IL-6 (~90% 
inhibition), TNF-α (~90% inhibition), CXCL2/MIP-2 (~85% inhibition) and CXCL1/KC (~80% inhibition) 















































































Figure 5.15 Effect of FP on chemokine and cytokine production following S. pneumoniae infection. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO control intranasally and challenged with 
S.pneumoniae D39 2.5 x 10
5 
CFU or PBS control, 1h following FP administration. BAL was performed at the 
indicated timepoints post-infection.  Cytokines (a)  IL-6 and (b) TNF-α and chemokines (c) MIP-2/CXCL2 and (d) 
KC/CXCL1 in lavage supernatants were measured by ELISA. Data represent mean (+/- SEM) of 5 mice per group 




5.3.7.6 Anti-microbial peptides 
AMPs are a further important component of the innate host response to respiratory bacterial 
infection.[182] Corticosteroids appear to have variable effects on the expression of different AMPs in 
vitro and in vivo.[294, 296, 298, 301-303] We assessed the effect of FP on induction of a range of 
AMPs following S.pneumoniae infection. CRAMP protein in BAL was significantly increased by vehicle 
+ SP treatment vs. vehicle + PBS at 8 and 24h post-infection. Suppressed CRAMP protein in BAL 
(~90% inhibition)  was observed in mice treated with FP + SP vs. vehicle + SP at 8h but not 24h post-
infection (fig 5.16a), matching the temporal kinetic of increased bacterial loads observed at 8h post-
challenge. SLPI mRNA in lung tissue was significantly increased (~3 fold) in vehicle + SP treated mice 
vs. vehicle + PBS at 4h post-infection. There were no significant differences in lung tissue SLPI mRNA 
in FP + SP and vehicle + SP treated mice (fig 5.16b). Surfactant protein-A mRNA in lung tissue was not 
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significantly induced by SP and FP had no effects on it’s expression (fig 5.16c). Other AMPs that were 
assessed including pentraxin-3 protein in BAL and β-defensin-2 mRNA in lung tissue were not 
detectable at 4, 8 or 24h post-infection (data not shown). 
 
Figure 5.16: Effect of FP on anti-microbial peptides following S. pneumoniae infection. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO control intranasally and challenged with 
S.pneumoniae D39 2.5 x 10
5 
CFU or PBS control, 1h following FP administration. (a) BAL was performed at the 
indicated timepoints post-infection and CRAMP protein was measured in lavage supernatants by ELISA. (b&c) 
Lung tissue was harvested at the indicated timepoints post-infection. RNA was extracted from tissue and cDNA 
generated as described. (b) SLPI and (c) surfactant protein-A mRNA copies were assessed by Taqman 
quantitative PCR. Data represent mean (+/- SEM) of 6 mice per group from one representative experiment 




Previously, in chapter 4, we showed suppression of RV-induced type I and III IFN induction by FP 
which was causally related to impaired virus control. In addition to anti-viral roles, emerging 
evidence suggests that IFNs are also an important component of the host response to bacteria 
including S. pneumoniae.[138] A previous study has shown that mice deficient in IFNα/β receptor 
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signalling or mice treated with type I IFN neutralising antibody exhibit enhanced development of 
bacteraemia following primary infection with S. pneumoniae.[154] IFN-γ deficient mice have also 
been shown to display increased bacterial loads in lung tissue following infection with S. 
pneumoniae.[155] We therefore assessed whether IFNs were induced by S. pneumoniae infection in 
mice and evaluated the effects of FP administration. S. pneumoniae infection increased lung tissue 
IFN-β and IFN-γ mRNAs at 4 and 8h (vehicle + SP vs. vehicle + PBS). FP suppressed SP induction of 
IFNs-β and -γ at 4h post-infection down to similar levels as those observed with vehicle + PBS 
treatment (fig 5.17a&b). IFN-β and -γ proteins were undetectable in BAL at 4, 8 and 24h post-
infection (data not shown). Additionally, SP infection did not increase lung tissue mRNA expression 
or BAL protein levels of IFN-λ (data not shown). 
Figure 5.17: Effect of FP on interferons following S. pneumoniae infection. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO control intranasally and challenged with 
S.pneumoniae D39 2.5 x 10
5
 CFU or PBS control, 1h following FP administration. Lung tissue was harvested at 
the indicated timepoints post-infection. (a) IFN-β and (b) IFN-γ mRNA copies were assessed by Taqman 
quantitative PCR. Data represent mean (+/- SEM) of 5 mice per group from one representative experiment 




































































































Mucus hypersecretion in COPD leads to impairment of mucociliary clearance, potentially facilitating 
increased bacterial growth.[26] We assessed the effect of S.pneumoniae +/- FP administration on 
airway mucin expression. SP infection increased lung tissue MUC5AC mRNA at 24h post-infection ~5 
fold over vehicle + PBS treatment, an effect that was completely suppressed by FP (fig 5.18a). FP had 
no impact on expression levels of MUC5B mRNA in lung tissue (fig 5.18b).  
Figure 5.18: Effect of FP on mucin expression following S. pneumoniae infection. 
C57BL/6 mice were treated with FP (1mg/kg) or vehicle DMSO control intranasally and challenged with 
S.pneumoniae D39 2.5 x 10
5 
CFU or PBS control, 1h following FP administration. Lung tissue was harvested at 
the indicated timepoints post-infection. RNA was extracted from tissue and cDNA generated as described. (a) 
MUC5AC and (b) MUC5B mRNA copies were assessed by Taqman quantitative PCR. Data represent mean (+/- 
SEM) of 5 mice per group from one representative experiment with findings reproduced in at least 2 







































































































Resident alveolar macrophages in the airways play a key early role in the innate immune response to 
bacterial infection with direct phagocytic functions contributing to early clearance of 
pathogens.[144] There is evidence that macrophage phagocytosis may be impaired in COPD [170, 
390] but the effect of corticosteroids on phagocytosis is unclear with some studies showing an 
impairment of function [280-282] and others reporting no effect [170, 283]. We therefore assessed 
phagocytosis of FITC-labelled S.pneumoniae ex vivo by BAL alveolar macrophages (which represent 
>99% of cells in BAL of naïve mice).  
To confirm macrophage phagocytosis, we initially incubated alveolar macrophages from naïve mice 
with FITC-labelled S.pneumoniae D39 and confirmed internalisation of bacteria by mixing with 
ethidium bromide (to counterstain extracellular bacteria) followed by visualisation by fluorescence 
microscopy (see methods, section 2.2.10.3). Macrophages that had been incubated with FITC-
labelled S.pneumoniae with addition of ethidium bromide showed presence of internalised 
S.pneumoniae which fluoresced green (while extracellular bacteria fluoresced red) (fig 5.19a). The 
relevant controls including macrophages incubated with FITC-labelled S.pneumoniae without 
addition of ethidium bromide and macrophages incubated with unlabelled S.pneumoniae with and 
without ethidium bromide were also assessed (fig 5.19b-d). We concluded that the protocol adopted 
led to successful ex vivo phagocytosis of bacteria by macrophages and we could thus proceed to 
quantify this effect. 
To quantify the effect of FP on macrophage phagocytosis, we incubated BAL alveolar macrophages 
harvested at 4h post-administration from mice treated with FP 1mg/kg or vehicle control with FITC-
labelled S.pneumoniae D39 and used flow cytometry to measure the proportion of phagocytosing 
cells and mean fluorescence intensity, indicating the amount of bacteria taken up by each cell. There 
was no difference observed in proportion of phagocytosing cells or mean fluorescence intensity 
between BAL macrophages harvested from mice treated with FP vs. treatment with vehicle DMSO 
(fig 5.19 e&f) suggesting that FP administration had no effect on the ability of BAL macrophages to 
phagocytose S.pneumoniae. 
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Figure 5.19 Effect of FP on ex vivo phagocytosis of S. pneumoniae by alveolar macrophages.  
(a–d) BAL was performed in naïve C57BL/6 mice and processed as described. Obtained macrophages were 
opsonised with mouse serum and incubated with FITC-labelled heat killed S.pneumoniae D39 at 37
o
C for 30 
mins. Ethidium bromide was added to the macrophage/bacteria mixture and the suspension was 
cytocentrifuged onto a slide and immediately visualised by fluorescence microscopy to confirm phagocytosis. 
Representative images shown for (a) macrophages + FITC-S.pneumoniae with ethidium bromide (b) 
macrophages + FITC-S.pneumoniae without ethidium bromide, (c) macrophages + unlabelled S.pneumoniae 
with ethidium bromide and (d) macrophages + unlabelled S.pneumoniae without ethidium bromide. n= 5 mice 
pooled/group.  (e&f) C57BL/6 mice were dosed intranasally with FP 1mg/kg or vehicle DMSO control and BAL 
was performed at 4h post administration. Macrophages were again opsonised with mouse serum and 
incubated with FITC-labelled heat killed S.pneumoniae D39, as described. (e) the proportion of phagocytosing 
cells and (f) mean fluorescence intensity was assessed by flow cytometry. n= 5 mice pooled/group. Single 
experiment only. 
 
5.3.8 Dose responsive effects of FP on innate anti-bacterial responses, bacterial loads and airway 
inflammation 
Previously, in chapter 4, the effect of lower FP doses on inflammatory parameters following RV1B 
infection was assessed. Prior clinical studies have suggested that effects of ICS on pneumonia risk 
may be dose dependent [266, 267], raising speculation that use of lower doses may be safer in 
COPD. Furthermore, a previous study that assessed ICS effects on S.pneumoniae in a mouse model 
showed the opposite effect to our experiments with improved rather than impaired bacterial 
clearance. However, it should be noted that in this study, doses lower than 1mg/kg were used.[313] 
We therefore reasoned that lower doses of FP may have different effects on S.pneumoniae infection 
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in our model and decided to assess the effects of 0.5mg/kg and 0.1mg/kg doses of FP with the 
1mg/kg dose used previously.    
5.3.8.1 Effect of FP dose on bacterial loads in lung tissue and systemic dissemination  
In contrast to the effects of high dose (1mg/kg) FP which increased bacterial loads in lung tissue at 
8h post-infection, administration of 0.1mg/kg FP led to significantly lower CFUs (~7 fold reduction) 
compared to treatment with vehicle + SP. There was also a non-significant trend towards reduced 
lung tissue bacterial loads in mice treated with 0.5mg/kg FP + SP vs. vehicle + SP (fig 5.20).  
Figure 5.20 Effect of FP dose on lung tissue bacterial loads following S. pneumoniae infection. 
C57BL/6 mice were treated with FP at doses of 1mg/kg, 0.5 mg/kg, 0.1mg/kg or vehicle DMSO control 
intranasally and challenged with S.pneumoniae D39 2.5 x 10
5
 CFU or PBS control, 1h following FP 
administration. Lung tissue was harvested at 8h post-infection, homogenized, serially diluted, plated on 
columbia horse blood agar plates and incubated at 37
0
C for 18h. Counts were performed on plates containing 
50-300 colonies and CFU/mL calculated. Individual data points for each animal within group and mean for 
group shown. n=7-9  mice per treatment group, comprising 2 independent experiments (*p<0.05; ** p<0.001, 
n.s non significant). 
 
There were no significant differences in blood bacterial CFU counts between mice dosed with vehicle 
+ SP compared to FP 1mg/kg + SP, FP 0.5mg/kg + SP or FP 0.1 mg/kg + SP treatment at 24h post-
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Figure 5.21 Effect of FP dose on blood bacterial loads following S. pneumoniae infection.  
C57BL/6 mice were treated with FP at doses of 1mg/kg, 0.5 mg/kg, 0.1mg/kg or vehicle DMSO control 
intranasally and challenged with S. pneumoniae D39 2.5 x 105 CFU or PBS control, 1h following FP 
administration. Blood was harvested by cardiac puncture at 24h post-infection, serially diluted, plated on 
horse blood agar plates and incubated at 37
0
C for 18h. Counts were performed on plates containing 50-300 
colonies and CFU/mL calculated. Individual data points for each animal within group and mean for group 
shown. n= 4-5 mice per treatment group. Single experiment only. 
 
5.3.8.2 Effect of FP dose on innate anti-bacterial responses 
Next, we assessed the effect of different doses of FP on components of innate anti-bacterial innate 
immunity. As previously shown, 1mg/kg FP reduced BAL neutrophilia and BAL protein levels of IL-6 
and TNF-α at 8h post-infection compared to vehicle + SP treatment. Lower doses of FP (0.5mg/kg 
and 0.1mg/kg) also significantly reduced BAL neutrophils, IL-6 and TNF-α protein levels down to 
similar levels as those observed with 1mg/kg FP (fig 5.22a-c). Therefore, although the lower dose of 
0.1 mg/kg FP appeared to have opposite effects on lung tissue bacterial loads compared to 1mg/kg 
FP, inflammatory suppressive effects were nonetheless retained. This suggested that components of 
anti-bacterial host defence other than neutrophil recruitment or production of anti-bacterial 
cytokines IL-6 and TNF-α were differentially affected by lower FP doses.  
A previous in vitro study has suggested that corticosteroids may increase expression of TLR2 induced 
by H. influenzae.[391] We therefore assessed whether lower doses of FP had similar augmenting 
effects in our model of S.pneumoniae infection. We observed a similar trend towards suppressed 
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post-infection, as observed previously (fig 5.22d). However, lower doses of FP (0.5mg/kg or 
0.1mg/kg) did not significantly alter TLR2 expression (fig 5.22c) and thus increased PRR expression 
does not appear to be the mechanism by which lower doses of FP improve bacterial clearance in our 
model. We also observed trends towards suppressed MUC5AC mRNA expression in lung tissue in 
mice treated with either 1mg/kg, 0.5mg/kg or 0.1mg/kg FP + SP compared to vehicle + SP (fig 5.22e) 
and therefore differential effects on mucin expression also did not appear to be an underlying 
mechanism for our observations of opposite effects on bacterial clearance with high versus lower 
doses of FP. 
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Figure 5.22 Effect of FP dose on innate anti-bacterial responses following S. pneumoniae infection.  
 C57BL/6 mice were treated with FP at doses of 1mg/kg, 0.5 mg/kg, 0.1mg/kg or vehicle DMSO control 
intranasally and challenged with S. pneumoniae D39 2.5 x 10
5
 CFU or PBS control, 1h following FP 
administration. (a-c) BAL was performed at 8h post-infection. BAL cytospin slides were prepared as described 
(d&e) Lung tissue was harvested at 4 and 24h post-infection, RNA was extracted and cDNA generated, as 
described. (a) neutrophils were differentially counted blind to experimental conditions. (b) IL-6 and (c) TNF-α 
proteins in lavage supernatants were measured by ELISA. (d) TLR2 mRNA expression at 4h post-infection and 
(e) MUC5AC mRNA copies at 24h post-infection were assessed by Taqman quantitative PCR. Data represent 






























































































































































































































































































































































































The single dose elastase mouse model did not accurately reproduce features of impaired anti-
bacterial host-defence believed to be characteristic of human disease. FP administration suppressed 
RV induction of some components of anti-bacterial host-defence including expression of TLR2 and 
pentraxin-3. Using 16S qPCR, we also showed a transient early increase in bacterial loads in lung 
tissue associated with FP administration but a transient early reduction in lung tissue bacterial loads 
associated with RV infection in mice.  
Attempts to evaluate the composition of lower respiratory microbiota in mice by 16S 
pyrosequencing were unsuccessful initially due to likely environmental contamination when BAL was 
obtained by normal sampling methods. However, a more sterile sampling protocol was optimised 
and showed that BAL samples from mice contain a very low bacterial yield which is likely to be below 
the threshold required for pyrosequencing. 16S qPCR showed that lung tissue samples have a higher 
bacterial content and pyrosequencing may thus be more feasible in these samples.  
Since we were unable to proceed with evaluation of the lower respiratory microbiome in mice, we 
adopted a direct approach to modelling lower airways colonisation using S.pneumoniae 
administration. Administration of FP at high doses (1mg/kg) prior to S.pneumoniae infection 
impaired a number of components of anti-bacterial host defence including attenuated expression of 
TLR2 mRNA, suppressed neutrophil recruitment and reduced expression of anti-bacterial mediators 
including IL-6, TNF-α, IFN-β and –γ, and CRAMP. Consistent with the observed impairment in 
multiple components of anti-bacterial host defence, lung tissue bacterial loads were also increased 
by high dose FP treatment, an effect that supports the increased risk of pneumonia associated with 
ICS in clinical practice. Conversely, administration of FP at lower doses (0.1mg/kg) retained similar 
anti-inflammatory effects to higher dose FP but had the opposite effect on bacterial clearance, 
causing reduced bacterial loads in lung tissue.  
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Chapter 6: Discussion and future work 
Using mouse models, we have evaluated the effect of inhaled corticosteroids on viral and bacterial 
respiratory infection. We were unable to define a model of COPD exacerbation that recreated the 
deficient anti-viral and anti-bacterial immune responses indicative of human disease and therefore, 
we subsequently used separate virus and bacterial challenge alone as surrogates for viral 
exacerbation and bacterial colonisation in COPD and assessed the effects of inhaled FP on a number 
of parameters. 
6.1 Mouse model of COPD 
Prior to commencement of the project, the only existing model of RV exacerbation in COPD available 
in the literature was a protocol comprising of four dose elastase/LPS challenge in mice reported by 
Sajjan et al.[344] We chose to recreate this model for a number of reasons. Firstly, in terms of 
maximizing time for the project, this was a relatively short-term model when compared to cigarette 
smoke exposure and, as discussed in chapter 1, it perhaps represented a more accurate model of 
patients with severe disease, the sub-population who are most at risk of exacerbations in clinical 
practice.[25] Secondly, based on the data presented by Sajjan et al [344], four dose elastase + LPS 
administration in mice appeared to be an accurate model of both stable COPD and, when combined 
with RV infection, of virus-induced COPD exacerbation.[344] Finally, the reported model also 
showed deficient IFN and impaired virus clearance that has been reported in human models of 
experimental RV infection [35] and this feature was critical to our hypothesis that inhaled FP would 
synergistically combine with COPD and lead to further impairment in IFN responses. 
6.1.1 Stable COPD 
As discussed in chapter 1, stable COPD is associated with a number of characteristic features 
including histological emphysema, enhanced airway inflammation, mucus hypersecretion and lung 
function impairment.[9, 11, 12] Therefore, a representative mouse model of COPD would be 
expected to mimic these features. We hypothesised that four dose elastase/LPS administration 
would model representative features of stable COPD, as reported by Sajjan et al. In our hands, 
administration of four doses of elastase/LPS led to replication of some but not all of the previously 
reported features, namely histological emphysema, increased BAL macrophages and exaggerated 
AHR to MCH challenge. However, in contrast to the model reported by Sajjan et al, we failed to 
observe several features of stable COPD including increased inflammatory cytokine and chemokine 
expression, increased airway neutrophilia and lymphocytosis and mucus hypersecretion. Therefore, 
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in our hands, the four-dose elastase/LPS model was only partially representative of stable COPD in 
humans.   
We additionally, assessed single dose elastase administration without LPS as an alternative model of 
stable COPD and found this dosing protocol to be more representative of human disease with 
increased BAL lymphocytes and macrophages and increased mucin expression compared to PBS 
dosed controls. Our findings are in keeping with a study by Inoue et al which assessed airway 
inflammation in response to varying doses of elastase administration in mice. Administration of a 
similar dose of elastase to the dose used in our study led to increases in BAL macrophages and 
lymphocytes and a trend towards increased neutrophils [337], which mirrors our findings.  
In contrast to combined four dose elastase/LPS, the single dose elastase model did not show any 
increased AHR, which is presumably due to the reduced level of lung destruction associated with 
administration of fewer doses of elastase. However, non-invasive measurements of lung function 
such as whole body plethysmography used in our study may be less relevant to obstructive airway 
disorders such as COPD and it is possible that invasive lung function techniques may have revealed 
more subtle abnormalities associated with a single dose elastase challenge, as suggested by a recent 
study which directly compared invasive and non-invasive techniques in an elastase-induced model 
mouse of COPD.[335] In summary, none of the dosing protocols that we assessed accurately 
mimicked all the key features of stable COPD in humans but single dose elastase was the best model 
of enhanced cellular airways inflammation and mucus hypersecretion.   
6.1.2 RV-induced exacerbation of COPD 
6.1.2.1 Airway inflammation and mucus hypersecretion 
Respiratory virus infection in COPD is associated with a further amplification of airways inflammation 
and mucus production above stable state and is also associated with increased inflammation when 
compared to RV infection in healthy subjects.[31, 35, 91, 392] Therefore, if deemed to be clinically 
relevant, a model of COPD RV exacerbation should be expected to show increases in these 
parameters compared to either the baseline COPD model (elastase + UV administration, analogous 
to stable COPD) or RV infection alone (PBS + RV administration, analogous to RV infection in healthy 
subjects).  
We hypothesised that four dose elastase/LPS administration in combination with RV1B infection 
would also model features of human RV-induced exacerbation of COPD, as reported by Sajjan et 
al.[344]  However, we found that the four-dose elastase/LPS model mimicked some but not all of the 
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relevant inflammatory and disease-specific parameters. Similar to the data reported by Sajjan et al 
[344], we observed that four-dose elastase/LPS led to increased RV induction of IL-13 mRNA in lung 
tissue. However, in contrast to the published study, we observed reduced, rather than increased 
expression of TNF-α and no change in MUC5AC mRNA in lung tissue. To further evaluate the model, 
we also assessed a number of other inflammatory endpoints that were not reported by Sajjan et al 
but had been reported in previous human studies of COPD exacerbation. For most of the parameters 
we assessed (except lymphocytic inflammation) including BAL neutrophilia and expression of 
inflammatory cytokines and airway mucins, four dose elastase/LPS administration failed to enhance 
responses to RV when compared to PBS + RV treatment. Therefore, as a model of the increased 
airway inflammation observed in RV infection in COPD vs. RV infection in healthy controls, the four 
dose elastase/LPS model failed to demonstrate exacerbation of many of the key inflammatory 
parameters. However, we found this model to be a better representation of exacerbated vs. stable 
COPD with enhanced neutrophilic inflammation and increased inflammatory cytokine levels 
observed in elastase/LPS+RV vs. elastase/LPS+UV treated mice. 
Some investigators have previously speculated that inducing severe lung damage with very high 
doses of elastase may lead to impaired inflammatory responses to infectious agents, perhaps 
explaining our observations with the published four dose elastase/LPS protocol. Inoue et al showed 
that administration of a very high dose of elastase (12 units, 10 fold higher than doses used in our 
study) led to severe lung damage and impairment of early BAL neutrophilia and BAL protein levels of 
TNF-α and CXCL2/MIP-2 induction in response to subsequent challenge with S. pneumoniae.[347] 
However, we found that RV-induced airway inflammation was not enhanced by reducing the 
number of doses of elastase/LPS and, therefore, this strategy did not produce a more representative 
model of COPD exacerbation.  
Some reported mouse models of bacterial exacerbation have also successfully used single dose 
elastase administration alone to induce COPD and have shown enhanced inflammatory responses to 
challenge with S. pneumoniae and H. influenzae.[348, 349] Repeated LPS exposure may attenuate 
neutrophil recruitment by inducing a tolerogenic state [338] and additionally, a recent in vitro study 
demonstrated that LPS administration attenuates RV-induced chemokine production.[393] We 
therefore reasoned that removal of LPS from the dosing protocol so that only elastase was 
administered to induce COPD would potentially lead to enhancement of inflammatory responses to 
RV and therefore produce a more representative model of COPD exacerbation. In contrast to 
combined elastase/LPS models, single dose elastase administration led to increased RV induction of 
inflammatory cytokines, mucins and increased cellular airways inflammation and therefore more 
Chapter 6: Discussion and Future work  
181 
 
accurately modelled the enhanced airway inflammation observed in RV infection in COPD vs. RV 
infection in healthy controls. Single dose elastase was also a representative model of the enhanced 
inflammation observed in exacerbated vs. stable disease with increases in several key parameters 
including BAL neutrophil and lymphocyte numbers, and inflammatory cytokine production observed 
in elastase + RV vs. elastase + UV treated mice. 
6.1.2.2 Airway hyper-responsiveness 
Data from the human experimental model of COPD exacerbation showed that RV infection was 
associated with reduced peak expiratory flow rate following onset of exacerbation compared to 
stable state with similar reductions not observed in RV infected healthy controls.[35] This would 
therefore, be expected to be another important feature of a clinically relevant mouse model of 
COPD exacerbation and we hypothesised that increases in AHR would be observed with four dose 
elastase/LPS in combination with RV infection when compared to elastase/LPS or RV administration 
alone. Using invasive measurements of lung function Sajjan et al reported increased AHR at d7 post-
infection in elastase/LPS + RV vs. PBS + RV or elastase + sham treated mice. We used an alternative 
non-invasive technique of whole body plethysmography and observed increased PenH values 
following MCH challenge with four doses of elastase/LPS + RV vs. PBS + RV treatment but reduced 
values compared to elastase/LPS + UV treatment. Therefore, in our hands, the four dose 
elastase/LPS model appeared to be a good model of increased AHR in RV infection in COPD vs. RV 
infection in healthy controls but a poor model of increased AHR in exacerbated vs. stable COPD. The 
differences between our findings and those reported by Sajjan et al may be due to the mode of lung 
function measurement used with invasive techniques more likely to pick up the subtle changes 
induced when RV1B infection is combined with elastase/LPS while whole body plethysmography 
perhaps unable to distinguish additional impairment above the severe phenotype induced by 
multiple elastase/LPS challenges. 
Assessment of AHR in our alternative single dose elastase model of RV-induced COPD exacerbation 
demonstrated increased PenH values following MCH challenge compared to either elastase or RV 
administration alone. Therefore, although single dose elastase did not increase AHR above 
treatment with PBS and thus did not accurately model this particular component of stable COPD, 
single dose elastase in combination with RV infection was a good model of increased AHR in 
response to RV infection in COPD vs. RV infection in healthy controls (PBS + RV). In contrast to four 
dose elastase/LPS, single dose elastase + RV infection also accurately modelled increased AHR of 
exacerbated vs. stable COPD. This may have been due to the fact that less severe lung destruction is 
induced with single dose elastase compared to four doses of elastase and LPS and, therefore, 
Chapter 6: Discussion and Future work  
182 
 
additive effects of RV1B infection may be more readily observed, even with use of less sensitive non-
invasive lung function techniques. 
6.1.2.3 Anti-viral immune responses and virus control 
Deficient anti-viral immune responses and impaired virus clearance are also features of human 
COPD and these were both reported in the four dose elastase/LPS mouse model [344] and also the 
human experimental RV infection in COPD model [35]. We considered deficient IFN associated with 
increased virus loads to be an essential feature of a mouse model of COPD exacerbation and we 
required this feature to be present to enable us to proceed with testing the hypothesis that ICS use 
in COPD would synergistically impair IFN induction and lead to impaired virus control in vivo. We 
hypothesised that four dose elastase/LPS administration would suppress IFN responses to RV and 
impair virus control, as previously reported.[344]  
Similar to data reported by Sajjan et al, we observed suppressed RV induction of IFN-β and -λ mRNAs 
in lung tissue in mice treated with four doses of elastase/LPS. However, this effect was associated 
with reduced rather than increased virus loads and therefore, rather than being a model of primary 
IFN deficiency leading to impaired virus control and increased replication, in our hands, four dose 
elastase/LPS administration produced a model where RV replication was actually reduced and 
consequently less induction of IFNs occurred. Reducing the number of doses of elastase and LPS had 
no effect on virus loads with reduced lung tissue RV RNA copies observed in elastase/LPS treated 
mice regardless of whether 1, 2, 3 or 4 doses were administered. Although single dose elastase 
combined with RV infection more accurately modelled enhanced airway inflammation and mucus 
hypersecretion than elastase/LPS, this model also failed to show enhanced virus replication. 
 Therefore, despite assessing a number of different dosing strategies, we were unable to define a 
mouse model of COPD exacerbation that displayed increased virus replication. The precise reasons 
for differences between our findings in the combined elastase/LPS or single dose elastase + RV 
mouse models and those of the human experimental RV infection in COPD study with respect to 
virus control are unclear. One possible explanation may be that the elastase-induced mouse model 
of COPD is one of severe lung damage representing advanced disease, whereas the human 
experimental model was carried out in patients with relatively mild airflow obstruction (mean FEV1 
% predicted 69.7%). To date, there are no human models of experimental RV infection in severe 
COPD to draw reference from. We can speculate that, with severe emphysematous lung tissue 
destruction, as displayed in our mouse model, there may be a reduction in viable airway epithelium 
required for RV replication to occur. Furthermore, virus replication kinetics differ between human 
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and mouse experimental RV infection models. In the human model, increased virus levels were only 
apparent by d3 post-infection, by which time replication has ceased in the mouse.[35, 367] It must 
be also noted that evidence for increased RV replication and impaired IFN induction in COPD is 
based on only one human and one mouse study to date and in vitro, air liquid interface cultured 
bronchial cells from patients with moderate to severe COPD have demonstrated enhanced virus 
replication but increased rather than decreased interferon induction [83].  
6.1.3 Limitations of elastase-induced mouse model of COPD 
There are a number of limitations of the elastase model of COPD that may limit the validity and 
relevance of findings to human disease. Unlike models involving cigarette smoke exposure, elastase 
models do not use the primary disease-causing agent in humans. Although smoke exposure models 
are acknowledged to require prolonged administration and do not induce severe emphysematous 
changes consistent with advanced disease [325], such approaches may be considered to more 
closely related to human disease. It could be argued that elastase administration is more consistent 
with a model of acute lung injury rather than the chronic repetitive tissue injury associated with 
prolonged cigarette smoking in humans. Alternative models of COPD in mice including ozone 
exposure [394] and transgenic strains such as IL-13 over-expression [322] have been used previously 
but can also be criticised for their lack of relevance to human disease.  
Another potential limitation of the elastase model is with the use of the intranasal dosing route. This 
approach was chosen because it was the method employed in the four dose elastase/LPS model 
previously reported by Sajjan et al. [344] Although intranasal dosing is a recognised method of 
administration to lung tissue in mice, a proportion of the elastase dose may theoretically have been 
absorbed by the nasal mucosa, potentially leading to some degradation of the nasal epithelium.  
Histological evaluation of nasal tissue following elastase administration was not carried out in this 
model but would have allowed a direct evaluation. It is possible that the reduced rhinovirus loads 
observed with elastase models may have been directly related to destruction of nasal epithelium 
preventing subsequent effective infection with rhinovirus. Notably, some previously reported 
elastase administration models have used the intra-tracheal exposure route [337, 349] which would 
avoid the potential issue of degradation of nasal epithelium and thus may represent a better 
approach. 
6.1.4 Summary  
In summary, as a model of RV exacerbation in COPD compared to either RV infection in healthy 
controls or stable COPD, four dose elastase/LPS + RV administration failed, in our hands, to produce 
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an exacerbation of a number of features of human disease and impaired virus control that the 
existing literature suggests are indicative of human COPD exacerbation. The precise reasons for our 
failure to replicate the findings from the study by Sajjan et al [344] are unclear. We contacted the 
authors to enquire whether there were any additional methodological factors that we had not 
considered and also to clarify reagents and techniques used. However, we could not identify any 
potential areas of inconsistency. We therefore made the decision to try to optimize the model and 
assessed a number of alternative dosing protocols, as discussed. Single dose elastase administration, 
in combination with RV infection, as an alternative model, more accurately modelled the enhanced 
airway inflammation and mucus hypersecretion that have been reported in human studies. This 
strategy was also a better model of increased AHR in exacerbated vs. stable disease. However, 
similar to combined elastase/LPS, the model also failed to show impaired virus control. 
 
6.2 Effect of FP on RV1B infection 
Since we were unable to define a representative model of RV infection in COPD that displayed the 
key feature increased virus replication, we did not proceed to assess the effects of ICS administration 
in this model, as set out in our aims. Instead, primary RV1B infection in mice was used as a surrogate 
for virus-induced exacerbation of COPD. Previous studies have used the mouse RV infection model 
as a surrogate for studying disease mechanisms relevant to exacerbations of asthma and COPD [56, 
69] and therefore this represents a valid approach but it should be emphasised that the relevance of 
any findings from the mouse model must be interpreted with caution and require validation in 
human models of  disease. 
6.2.1 Anti-viral innate immune responses  
We hypothesized that ICS would suppress anti-viral innate immune responses in vivo and this was 
confirmed by our finding that high dose FP (1mg/kg) administered intranasally prior to RV1B 
infection led to impaired lung tissue mRNA expression of IFN-β and -λ and BAL protein levels of IFNs 
–α, -β and -λ. These findings are in keeping with in vitro studies that have used a range of different 
corticosteroid compounds in a number of different cell types and shown suppressed IFN 
responses.[246-248] However, our data provides the first in vivo confirmation of these potentially 
detrimental effects of ICS. Consistent with these effects, we also showed that RV induction of a 
number of ISGs, which encode proteins with specific anti-viral roles, was significantly suppressed by 
FP.  NK cells also play an important role in the innate immune response to virus infections by directly 
eliminating virally infected cells [61] and have been shown to be dependent on type I IFN responses 
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during RV infections [56]. In keeping with the effect of FP on IFN induction by RV, we also observed 
suppressed numbers of NK cells in BAL and activated NK cells in lung and BAL and this represents a 
further impairment of innate anti-viral immune responses. 
6.2.2 Adaptive immune responses 
In addition to impairment of innate anti-viral immune responses, we also observed impairment of 
adaptive immune responses to RV infection by FP including reduced numbers of total CD4+ and 
CD8+ cells in BAL and reduced numbers of activated CD4+ and CD8+ T cells in lung and BAL. T cells 
possess cytotoxic effector functions and may therefore contribute directly to virus control and 
effective clearance from the airways and, additionally, CD4+ cells provide assistance to B cells and 
are thus indirectly involved in the production of antibody responses.[64, 395, 396]. A number of 
studies have shown previously that ICS can suppress numbers of CD4+ and CD8+ cells in the lungs of 
patients with stable COPD.[233, 235, 236] Although no existing studies have assessed the effects of 
ICS on T cell responses during COPD exacerbations, one study examined ICS administration in a 
human model of experimental RV infection in asthma.[67] This study reported no effect of 4 weeks 
inhaled budesonide therapy on CD4+ or CD8+ T cell numbers in the lamina propria or epithelium 
from bronchial biopsies following experimental infection with RV16.[67] Our findings are in contrast 
to the minimal effects on T cell responses observed in this human study. The reasons for this are not 
entirely clear but may relate to the underlying asthmatic status of patients and/or potentially the 
likely lower doses used in the human study. 
In addition to suppression of T cell responses, FP administration in our model also led to reduced 
production of RV-specific IgG and neutralizing antibodies in blood. Neutralising antibody responses 
to RVs provide protection against infection and symptoms in humans and, as well as accelerating 
virus clearance during the first naturally acquired infection with a given serotype, also protect 
against reinfection with the same serotype.[71, 72, 397] RV infection in the mouse is a poor model of 
the protective antibody responses observed in man, since sequential infection with the same RV 
serotype does not detectably improve virus control during the second RV infection (G.McLean, 
unpublished observations). However, our observation that FP impairs production of antibody 
responses following RV infection in the mouse model suggests that use of these drugs during acute 
RV exacerbations in patients with COPD may potentially impair protective responses against future 
RV infections, an effect that would further limit their efficacy in reducing disease exacerbations. 
Yerkovich et al followed a group of 60 patients with COPD for 1 year and showed that those who had 
at least one exacerbation had lower serum RV-specific IgG1 levels in stable state than those who 
were exacerbation free. They also showed a trend towards increased ICS use in the exacerbation-
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prone group and this indirectly suggests that ICS use may be associated with reduced antibody 
responses in humans.[85] However, there are a number of other potential confounding factors such 
as disease severity and comorbidities that may be contributing and were not accounted for in the 
study. 
6.2.3 Virus control 
Whether FP suppression of innate and adaptive immune responses to RV is associated with 
impairment of virus control and increased virus replication has previously been unclear. Studies have 
reported that administration of systemic corticosteroids prior to experimental RV infection in 
healthy subjects or use of intranasal FP during naturally occurring colds can increase virus 
loads.[249, 250] Farr et al also reported a non-significant trend towards prolonged virus shedding in 
healthy subjects treated with combined inhaled beclomethasone and oral prednisolone during 
experimental infection with RV39.[398] These studies have raised speculation that corticosteroids 
may interfere with virus control in the airways and thus potentially worsen exacerbation severity. 
In our study we provided further support for this hypothesis by showing that FP administration 
significantly increases RV loads in the lungs, measured by either Taqman quantitative PCR or 
titration assay. This effect is in contrast to a study by Singam et al where intranasal FP administration 
(alone and in combination with salmeterol) following RSV infection in a mouse model of ovalbumin-
induced allergic asthma led to reduced rather than increased virus loads.[399] A number of factors 
may explain the differences observed between this study and ours, including the different viruses 
used and different mouse strains used (RSV in BALB/c mice vs. RV in C57BL/6 mice in our study) and 
differences in the ICS dosing strategy used (multiple administrations of low dose FP compared to a 
single higher dose of FP used in our study). Other studies have assessed systemic corticosteroid 
administration in mouse models of respiratory virus infection with one study showing increased 
virus replication when hydrocortisone was administered during pneumovirus infection [251], and 
another showing that dexamethasone had no effect on virus loads following influenza 
infection.[253] However, it is difficult to directly compare these models of systemic corticosteroid 
therapy with our model of direct administration of FP into the airways. 
In a clinical context, our finding that FP administration increases virus loads in vivo imply that ICS use 
may render patients with COPD more prone to RV-induced exacerbations and potentially question 
the uncritical use of these medications during acute exacerbations. As discussed, COPD is believed to 
be associated with an inherent deficiency of IFN responses [35] and therefore, use of ICS may further 
suppress innate anti-viral responses and synergistically impair virus control and increase virus loads. 
Chapter 6: Discussion and Future work  
187 
 
Whether strategies such as cessation of ICS at the onset of exacerbation or targeting of therapy to 
sub-groups based on underlying immune profile could be beneficial in limiting these potentially 
adverse effects requires further investigation in human models of disease. The increased virus loads 
associated with FP administration may also potentially have adverse effects on other clinical disease 
parameters in COPD such as airway remodelling and FEV1 decline that could not be measured in our 
mouse model. 
6.2.4 Airway inflammation 
To assess whether increased virus replication had any disease-relevant effects in the context of 
acute exacerbations of COPD, we assessed the effect of FP administration on virus-induced airway 
inflammation in our model. Although corticosteroids have extensively been shown to be potent anti-
inflammatory agents in the context of stable airways disease [233-236], there has been speculation 
that their effects may be limited in the context of acute exacerbations.[57] This hypothesis is based 
on the relatively poor effect of ICS on reducing COPD exacerbation frequency in clinical trials [217, 
239, 240] and also experimental virus infection studies in human and animal models that have 
shown limited effect of ICS on inflammation.[67, 254] 
We therefore hypothesised that the increased virus loads observed with FP administration in our 
model would outweigh the anti-inflammatory effects of ICS on inflammatory chemokine and 
cytokine expression and thus lead to enhanced rather than reduced airway inflammation. However, 
our findings disproved this hypothesis as we observed that FP led to near complete inhibition of 
protein levels of neutrophil and lymphocyte chemokines (including CXCL1/KC, CXCL2/MIP-2, 
CCL5/RANTES and CXCL9/MIG) and proinflammatory cytokines IL-6 and TNF-α in BAL. We also 
observed that FP administration led to a profound impairment in numbers of neutrophils and 
lymphocytes recruited to the airways in response to RV infection. Therefore, the adverse effects of 
FP on virus control did not appear to impact upon the ability of the drug to suppress inflammatory 
responses to RV. These findings have important clinical implications as suppression of inflammation 
may be one mechanism of potential benefit of ICS on exacerbations. Although clinical trials report 
only a modest effect of these drugs on exacerbations, their use is still associated with a ~20-25% 
reduction [217, 239] and this may be due to the fact that anti-inflammatory effects are preserved 
despite adverse effects on virus control. It is possible that suppressed inflammation associated with 
ICS use leads to a greater frequency of unnoticed exacerbations in which virus infection occurs but 
absence of an airway inflammatory response leads to failure of the patient to report symptoms. The 
long term sequelae of the occurrence of such events are unclear but studies that have employed 
diary cards to longitudinally follow patients with COPD have revealed that around 50% of 
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exacerbations are unreported but still associated with similar falls in peak flow to reported 
events.[24] 
Although RV induction of many inflammatory chemokines was suppressed by FP, interestingly, 
opposite effects were observed with regards to the Th2 lymphocyte chemokines CCL22/MDC and 
CCL17/TARC which were enhanced rather than suppressed. Primary RV infection in the mouse model 
is dominated by a Th1 mediated response with limited Th2-mediated inflammation (no eosinophilia 
and limited expression of Th2 cytokines IL-4, -5 and -13). Th2-mediated inflammation is classically 
associated with asthmatic airways disease, although some studies have also implicated these 
processes in COPD.[400-402] Whether the effects of FP on increasing Th2 lymphocyte chemokine 
induction would lead to enhanced Th2 mediated inflammation in mouse models of asthma and/or in 
patients with asthma or COPD during acute RV exacerbations would be of interest.  
6.2.5 Airway mucins 
To assess whether FP had any other adverse effects on disease-relevant features, we also measured 
major airway mucins MUC5AC and MUC5B in the model. In contrast to the potentially beneficial 
effects on reduced RV-induced airway inflammation, we observed that administration of FP led to 
increased MUC5AC lung tissue mRNA and BAL protein at d7 post-infection and increased MUC5B 
BAL protein at d14 post-infection. Impaired mucociliary clearance with mucus hypersecretion is a 
recognised feature of stable COPD [11] and RV can further stimulate mucus production from the 
airway epithelium and thus potentiate sputum production during acute exacerbations [368, 369]. 
Our finding that FP administration increases RV-induced mucin expression further suggests that use 
of these therapies in the context of acute RV exacerbations may have potentially detrimental effects 
in COPD, if similar effects were applicable in human disease.  
Previous studies that assessed the effect of corticosteroids on mucin expression have reported 
variable findings. In vitro studies in a range of cell types have reported suppression [306, 403, 404] or 
no effect [309, 405] of corticosteroids on constitutive mucin expression. Other in vitro studies have 
shown that corticosteroids suppress mucin expression in response to LPS [406], H. influenzae [308] 
or P.aeruginosa in airway epithelial cells [307]. In vivo studies in animal models have reported 
reduced MUC5AC expression in response to nebulised budesonide in an ovalbumin model of asthma 
in guinea pigs [407] and in response to intraperitoneal dexamethasone in a mouse model of H. 
influenzae challenge [308]. In humans, ICS treatment had no effect on the expression of MUC5AC or 
MUC5B in airway biopsy samples from asthmatic patients.[310] Therefore, the majority of existing 
studies report that corticosteroids have either no effect or cause a reduction in mucin expression. 
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This is in contrast to our finding that FP increases mucins in the context of RV infection. The only 
existing study that is supportive of our findings reported that dexamethasone administration 
increased MUC5AC mRNA and protein expression in response to recombinant IL-13 administration in 
bronchial epithelial cells.[311] Ours is the first study to specifically assess the effect of ICS on virus-
induced mucins. The signalling pathways involved in the induction of mucins are poorly understood 
but the differences between our study and the majority of studies discussed above may be due to 
the fact that different signalling pathways are likely to be involved in virus-induced mucin expression 
compared to constitutive expression or in response to bacterial stimuli. A previous in vitro study 
demonstrated that RV induction of MUC5AC occurs through a distinct epidermal growth factor 
receptor (EGFR) pathway mediated through TLR3 [369], a pathway that would therefore be specific 
to double stranded RNA viruses and may be directly affected by ICS.  
 As discussed, FP also increased RV induction of Th2 lymphocyte chemokines CCL22/MDC and 
CCL17/TARC. Th2 cytokines, particularly IL-13 play a key role in pathways leading to MUC5AC 
expression, particularly in animal models of allergic airway inflammation.[408] However, as 
discussed previously, the mouse model of RV1B infection induces a predominantly Th1 mediated 
inflammatory response. We were unable to measure any increases in IL-13 mRNA expression in lung 
tissue or protein levels in BAL with either FP treatment and/or RV1B infection in the model and 
therefore, increased IL-13 does not appear to be playing a mechanistic role in the increased 
expression of mucins observed in our model. 
6.2.6 Dose responsive effects of FP  
The dose selected for use in our model of 1mg/kg was based on advice from an industry collaborator 
who had prior experience of the use of ICS in mouse asthma models. It is important to note that the 
dose that was used represents one that is higher than those used in clinical practice, which are 
typically around 1000μg per day (which equates to ~0.014 mg/kilogram for a 70kg human, ~70-fold 
lower than the 1mg/kg dose used in our model). Comparison of intranasal dosing in mice with 
inhaled dosing in humans is difficult because it is unclear exactly how much effective drug is 
delivered to lung tissue via either method. Intranasal delivery in the mouse is likely to lead to 
relatively higher tissue drug concentrations than delivery via inhaler devices in humans, which have 
been shown to be around 1-10nM for a 1000μg FP dose administered via volumatic spacer.[409] Use 
of mass spectrometric techniques would allow a similar characterisation of lung tissue 
concentrations in the mouse model of intranasal FP administration and enable direct comparisons to 
be made. Nonetheless, we evaluated the effects of 0.5mg/kg and 0.1mg/kg doses of FP on similar 
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inflammatory and immune parameters to assess whether similar effects were observed with lower, 
perhaps more clinically realistic, doses.  
We found that a 50% dose reduction (0.5mg/kg) had similar effects on anti-viral innate responses 
and virus control to the 1mg/kg dose with a trend towards suppression of RV-induction of IFN-λ and 
significantly increased virus loads. We also observed a similar suppression of virus-induced airway 
inflammation. By contrast, at 90% dose reduction (0.1mg/kg) many of the effects of FP on RV 
infection were lost with no significant changes in RV-induced inflammation, a non-significant trend 
towards lower IFN-λ mRNA in lung tissue and minimal effect on virus loads.  
We were unable to identify a dose of FP which retained potentially beneficial anti-inflammatory 
effects but did not display the adverse effects on virus control. However, at 50% dose reduction, a 
similar level of anti-inflammatory effect was observed to the higher 1mg/kg dose but the effect on 
increased virus loads was less pronounced with ~6 fold increase in RV loads observed with 1mg/kg 
FP administration and only ~3 fold increase observed with 0.5mg/kg. A 90% dose reduction 
(0.1mg/kg) led to loss of both anti-inflammatory effects and adverse effects on virus control. 
Therefore, it is theoretically possible that a dose between 0.1mg/kg and 0.5mg/kg may potentially 
have beneficial anti-inflammatory effects without having detrimental effects on anti-viral immune 
responses, although time constraints prevented a more extensive dose response from being 
assessed. 
Although the doses at which we observed detrimental effects on virus control in the mouse model 
are likely to be higher than those used in humans, it is also worth noting that we observed increased 
virus loads in a model where minimal replication (no more than 24h) occurs.[367] In human RV 
infection, where replication is much more robust and of longer duration [35], it may be possible that 
daily administration of lower doses of ICS may still exert similar adverse effects. This is supported by 
studies of naturally occurring colds where increased RV culture positivity was observed at d7 post 
onset in patients treated with intranasal FP vs. placebo.[250] These human studies suggest that 
detrimental effects of ICS on anti-viral responses may occur at lower doses. Additionally, since COPD 
is associated with an inherent deficiency in IFN responses [35], effects of ICS may be even more 
pronounced in disease states than in healthy subjects. 
6.2.7 Effect of recombinant IFN-β on FP suppressed responses 
To further confirm the importance of FP suppressed IFN responses and assess whether this effect 
was causally related to the enhanced virus loads observed, we evaluated whether recombinant IFN-
β administration could reconstitute suppressed responses and improve virus control. IFN-β 
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administration in combination with FP led to reconstitution of suppressed innate responses to RV 
infection with increased expression of ISGs. Addition of IFN-β also improved the impaired virus 
control associated with FP. These data suggest that FP suppression of IFN responses does play a 
major mechanistic role in the adverse effects observed on virus control. We also demonstrated that 
recombinant IFN-β did not alter the effect of FP on suppression of RV-induced airway inflammation. 
Therefore, recombinant IFN-β was able to improve virus control without reducing the beneficial 
effect of FP in suppressing inflammation.  
However, IFN-β administration had no impact on the increased mucin expression and suppressed 
adaptive immune responses associated with FP administration and therefore could not directly 
improve these other potentially detrimental effects. The fact that recombinant IFN improved virus 
control but could not improve other adverse disease-relevant effects questions the potential benefit 
of using recombinant IFN-β as a therapeutic agent during virus-induced exacerbations of airways 
disease in ICS-users. In a recently published study assessing the effect of inhaled IFN-β therapy in 
asthmatic patients taking ICS who developed an exacerbation, a similar enhancement of ISG 
expression and a trend towards reduced virus loads was observed [410] as seen in our mouse model. 
These effects did not correlate with any improvements in the primary endpoint of asthma symptom 
scores [410] which mirrors our finding that recombinant IFN-β in the mouse model had no impact on 
airway inflammation or mucin expression. However a sub-analysis did reveal some benefit in 
patients with more severe disease in this study.[410] IFN-β therapy also improved morning PEF 
recovery, thereby suggesting that reduced virus loads may have beneficial effects other than 
symptomatic improvements [410] but such parameters cannot be easily measured in our mouse 
model.  
6.2.8 Components of interferon signalling pathways affected by FP 
To further characterise the effect of FP on suppression of IFN, we attempted to define which 
components of IFN signalling were disrupted. The type I IFN response is biphasic with initial release 
of IFN related to virus detection by endosomal receptors TLR3, 7 and 8 or cytosolic receptors MDA5 
and RIG-I.[50-52] Secreted type I IFN then binds to IFNAR and stimulates further release and 
induction of ISGs.[55] Using a luciferase reporter assay in BEAS2B cells, we observed that FP 
suppressed TLR3-agonist (Poly(I:C)) induced IFN-β promoter activity but conversely had no effect on 
MDA-5-agonist (transfected Poly(I:C)) induced IFN-β promoter activity, thereby suggesting that FP 
acts on the TLR3 but not MDA5 mediated virus detection pathway. Matsukura et al similarly 
reported that FP administration suppressed Poly(I:C) induced mRNA and protein expression of ISG 
CXCL10/IP-10 in BEAS2B cells.[411] Conversely, in a mouse model of intranasal Poly(I:C) 
Chapter 6: Discussion and Future work  
192 
 
administration, FP treatment had no effect on IFN-β or CXCL10/IP-10 protein in BAL.[412] However a 
dose of 0.125 mg/kg FP was used in this study which is similar to the 0.1mg/kg dose used in our in 
vivo model that also had no effects on innate responses to RV infection. With use of higher doses, 
suppressive effects on Poly(I:C) induced IFN responses, in keeping with our in vitro experiments, may 
have been observed.  
Time constraints prevented us from assessing the effect of FP on other virus sensing pathways 
including TLR 7/8 and RIG-I signalling and the secondary component of IFN signalling via IFNAR using 
specific agonists within a similar in vitro system. However, evaluation of the relevant control groups 
from the in vivo recombinant IFN-β administration experiment allowed analysis of the IFNAR 
pathway component. We observed that FP suppressed IFN-β induction of the ISGs OAS and IFN-λ 
mRNA in lung tissue and CXCL10/IP-10 protein in BAL, thereby suggesting that ICS may also impair 
the secondary component of IFN signalling via IFNAR. 
6.2.9 Limitations of FP and RV1B infection mouse model 
A limitation of the FP mouse model was that it involved a single dose of intranasal FP administration 
immediately prior to infection. This contrasts with the typical daily inhaled dosing that occurs in 
humans and it could be argued that a more representative model of disease would involve daily 
administration of FP prior to and/or during infection, as employed in a previous mouse model.[399]  
The validity of the mouse model of RV1B infection may also be questioned as it involves use of a 
human pathogen rather than a mouse adapted strain and therefore relatively high infecting doses 
are required to produce inflammatory responses that are representative of human disease. 
Therefore, separate rhinovirus batches were required for each individual experiment and, despite 
use of similar virus TCID50 in each experiment, variations in inflammatory responses between 
experiments were frequently observed. Use of a mouse adapted strain may have improved inter-
experimental variability. Additionally, there is an obligate requirement for use of minor group RV1B 
in the mouse model due to lack of the cellular receptor ICAM-1 in mouse lung preventing use of 
major group serotypes. This makes it difficult to make direct comparisons between findings from this 
study and those of human experimental models of disease, which commonly use major group RV 
serotypes [35, 67]. Whether inflammatory responses associated with minor group serotypes are 
comparable with those of major group RVs in humans is unclear. 




We have shown that FP can suppress innate and adaptive immune responses to RV infection and 
also impair virus control in vivo. Although the hypothesised increase in RV-induced inflammation 
with FP was not evident, we did observe an increase in mucin expression associated with FP 
administration in this model. In a clinical context, our results suggest potentially beneficial and 
detrimental effects of ICS in the context of RV-induced exacerbations of COPD with the desirable 
effect of reduced inflammation but the potentially adverse effect of increased mucus production 
which may theoretically lead to protracted symptoms.  
Additionally, the reduced adaptive immune responses associated with FP administration may also 
impair protective responses to reinfection with the same RV strain and thus limit the efficacy of FP in 
reducing exacerbation frequency. We have also shown that administration of recombinant IFN-β 
reconstituted FP suppressed immune responses, improved virus control but did not have any 
beneficial effects on adaptive immune responses or mucin expression.  We must be cautious in 
directly extrapolating effects observed in an otherwise healthy mouse to exacerbations of complex 
chronic lung disorders. Therefore, confirmation of the applicability of our findings to COPD through 
translation into human models of disease is warranted.  
 
6.3 Effect of FP on bacterial infection 
Having evaluated the effects of FP on anti-viral immune responses following RV infection, we next 
sought to investigate our hypothesis that ICS administration would suppress RV induction of anti-
bacterial mediators and thus alter the lower respiratory microbiota leading to proliferation of 
colonising PPMs and increased risk of secondary bacterial pneumonia. 
6.3.1 Anti-bacterial host defence mechanisms in the single dose elastase COPD model 
COPD is associated with a deficiency in certain anti-bacterial host responses to respiratory virus 
infection and, in the human model of experimental infection in COPD, RV was shown to directly 
precipitate secondary bacterial infection defined by sputum culture or culture-independent methods 
in a significantly greater proportion of patients with COPD than healthy controls.[122, 190] Given 
that single dose elastase administration was the most representative model of RV-induced COPD 
exacerbation that we assessed, we measured a number of anti-bacterial factors in this model. 
Similar to observations in human studies, single dose elastase administration was associated with 
increased numbers of BAL macrophages and addition of RV infection also led to further increases in 
BAL neutrophils and pro-inflammatory cytokine TNF-α compared to RV infection in PBS dosed 
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controls. Since these components all have recognised anti-bacterial effector functions, the observed 
increase would be expected to be associated with enhancement rather than impairment of host 
defence against bacteria. Whether the function of macrophage and neutrophils in our model is 
associated with similar impairments as those reported in human disease [170, 172-174] is unknown. 
Ganesan et al reported that macrophage phagocytosis of H .influenzae was impaired in the four dose 
elastase/LPS COPD mouse model [350] but it is unclear whether similar abnormalities are induced 
with single dose elastase administration. 
Mucus hypersecretion was one feature that was observed in the single dose elastase model that 
could be associated with impaired anti-bacterial host-defence. Increased mucus production in COPD 
is believed to contribute to impaired mucociliary clearance with increased particle and pathogen 
retention in the airways precipitating defective bacterial clearance and potentially contributing to 
lower airways colonisation and development of bacterial exacerbations.[98] We observed increased 
mucins and PAS staining scores in the baseline elastase model with further increases observed when 
elastase was combined with RV compared to elastase or RV administration alone.  
We also assessed a number of other factors that have been reported to be impaired in human 
studies, including expression of PRRs TLR2 and 4. We found no difference in expression of either 
TLR2 or TLR4 in elastase + UV vs. PBS + UV treated mice. Although this contradicts findings from 
some human studies which have reported reduced TLR2 and TLR4 expression in stable COPD [162, 
163] others have conversely shown increased expression [164, 165]. Therefore the precise 
expression pattern in human lung tissue is unclear and thus modelling these features accurately in 
mice is difficult.  We found that elastase administration suppressed TLR-2 induction by RV but 
increased TLR4 expression. The dynamics of bacterial PRR expression during RV-induced 
exacerbations of COPD have not been studied in human models and therefore, the relevance of 
these observations to secondary bacterial infection in COPD is difficult to evaluate. 
We also measured AMPs SLPI, surfactant protein A, β-defensin 2 and pentraxin-3 and also found no 
difference in expression between elastase + UV vs. PBS + UV treated mice and expression of 
surfactant protein-A and β-defensin 2 was increased rather than reduced following RV infection in 
elastase treated mice compared to mice treated with PBS + RV. Very few human studies have 
characterised the dynamic changes of AMP expression from stable state to RV-induced exacerbation 
and, as with PRRs, it is therefore difficult to determine whether the observed effects are 
representative of human disease. Regardless of this, our model failed to demonstrate deficiencies in 
these particular components of anti-bacterial host defence. 
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Due to time constraints and methodological problems (discussed in section 6.3.3) we were unable to 
assess whether any of the measured anti-bacterial deficiencies in the single dose elastase model 
affected the lower respiratory microbiota. Therefore, whether this model accurately recreates the 
chronic bacterial colonisation associated with stable COPD and whether RV infection in the model 
leads to dysregulation of the microbiota with increased proliferation of PPMs, as described in human 
models [122], could not be characterised.  
6.3.2 Anti-bacterial host defence mechanisms in the FP and RV1B infection model 
In the INSPIRE study, pneumonia was shown to occur more frequently following an unresolved 
exacerbation in COPD patients taking ICS.[317] This has raised speculation that ICS may increase the 
risk of virus-induced secondary bacterial infection and thus increase pneumonia frequency. Although 
time constraints prevented evaluation of the effect of FP administration on combined RV1B and S. 
pneumoniae challenges, we assessed whether ICS administration led to impairment of RV induction 
of anti-bacterial mediators. We assessed a number of parameters in the high dose (1mg/kg) FP + 
RV1B mouse model and observed a number of features that were suppressed by FP that may 
theoretically increase risk of development of and/or worsen the course of secondary bacterial 
infection.  
In our model, FP suppressed RV-induction of IL-6, TNF-α, neutrophil chemokines and BAL 
neutrophils, effects that have also been reported in a number of previous in vitro studies in response 
to viral stimuli.[246, 247, 413] This effect might be expected to increase the risk of acquisition of 
secondary bacterial infection, particularly in patients with COPD who are chronically colonised with 
bacteria in the lower airways since all these factors have been shown to have roles in anti-bacterial 
host defence.[147-149]  Studies that have assessed sequential infection with RV and H. influenzae 
have shown impaired neutrophil responses and delayed bacterial clearance associated with RV 
infection prior to bacterial infection [209] and therefore an initial robust inflammatory response to 
one infection may dampen responses to a second pathogen and impair clearance. Suppression of 
inflammatory responses to RV by FP may interfere with this dynamic and thus theoretically improve 
the immune response to a secondary bacterial infection.  Therefore it may be possible that ICS 
increase the risk of development of pneumonia through suppression of anti-bacterial mediators and 
proliferation of PPMs in the lungs of patients with COPD but paradoxically improve the course of a 
secondary bacterial infection by limiting the initial immune response to virus infection and thus 
increasing the response to the secondary infection. This hypothesis is supported by existing clinical 
data which reveal an increase in risk of development of pneumonia [217, 256, 257] but an 
improvement in pneumonia-related adverse outcome associated with ICS use in COPD [274, 275].  
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Another effect of FP in the RV1B infection model that may impact upon secondary bacterial infection 
is the observed alteration in mucin expression. We found that FP suppressed BAL MUC5B protein at 
early timepoints but led to increases in MUC5AC and MUC5B proteins at later timepoints post-
infection. Interestingly, although the quantity of mucus produced in the airways of patients with 
COPD is increased overall, expression of MUC5B has been shown to actually be impaired in the 
airway epithelial surfaces of smokers.[414] Roy et al showed that MUC5B deficient mice had 
impaired bacterial functions and accumulation of bacterial species in the lungs while MUC5B 
overexpressing mice did not have similar abnormalities and actually showed improved bacterial 
phagocytosis.[152] Therefore, our finding that FP suppresses RV-induced MUC5B at early timepoints 
may potentially be the more important effect in terms of impairment of anti-bacterial host-defence 
than the increased mucin expression observed later in the course of infection. However, these 
processes are poorly understood and firm conclusions are therefore difficult to make. 
The effect of FP on IFN responses and implications in terms of anti-viral host defence has already 
been discussed in detail in section 6.2. However, there is evidence that IFNs may also play important 
roles in anti-bacterial host defence. In contrast to the adverse effects on virus control associated 
with deficient IFN responses to primary RV infection, deficient type I IFN signalling appears to 
protect against secondary bacterial challenge as IFNAR -/- mice infected with influenza have been 
shown to have improved bacterial clearance and survival following secondary challenge with S. 
pneumoniae. [211, 415] Therefore, IFN suppression by FP might be an effect that would be expected 
to improve rather than impair subsequent bacterial infection.  
Other parameters that were suppressed by FP in the RV1B infection model include the AMP 
pentraxin-3. Levels of pentraxin-3 have been shown to be increased in the sputum of patients with 
COPD compared to control subjects following experimental infection with RV [190] and in vitro, 
corticosteroids suppress pentraxin-3 release by LPS in dendritic cells.[416] In the human model of 
experimental RV infection in COPD, secondary bacterial infection also correlated with reduced levels 
of AMPs SLPI and elafin.[190] However, we observed no effect on SLPI expression by FP and/or RV 
infection in the mouse model and were unable to measure elafin due to lack of a mouse homolog. 
Other innate anti-bacterial components that were assessed in the FP + RV model include the 
expression of PRRs. We found that TLR2 mRNA expression in lung tissue was upregulated by RV 
infection but suppressed in the presence of FP. TLR2 is a PRR that plays a key role in pattern 
recognition of gram-positive bacteria and activation of innate immune responses. A previous study 
by Saba et al showed that TLR2 was required for RV-induced proinflammatory cytokine responses, 
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since bone marrow derived macrophages treated with TLR-2 blocking antibody or taken from TLR-2 
deficient mice had impaired cytokine responses to RV1B.[417] . Therefore, the suppressive effect of 
FP on induction of TLR2 by RV1B may contribute to the suppressed inflammatory responses that 
were observed in our model and thus directly contribute to increased risk of secondary bacterial 
infection following RV infection. 
6.3.3 Evaluation of the lower respiratory microbiota in mice 
To assess our hypothesis that the lower respiratory microbiota in mice contained PPMs relevant to 
human disease, we initially attempted to perform 16S rRNA pyrosequencing in BAL samples from 
wild-type untreated mice. When samples were sequenced, we found that they were dominated by 
Herbaspirillum, a bacterial genus that is typically found in plants [382] and has not been described in 
previous studies that have assessed the airway microbiota in either humans or mice [116, 122, 355, 
356]. Using BAL performed by a more sterile technique we found that the 16S rRNA yield was 
extremely low and thus unsuitable for pyrosequencing. Studies have also reported that pooling 
multiple BAL samples or sampling the upper respiratory tract by nasal lavage can allow successful 
characterisation of the mouse airway microbiota [95, 99] but we found low 16S qPCR copy number 
for both these approaches and were thus also unable to sequence such samples. A study by 
Goulding et al successfully characterised the mouse microbiota in BAL samples by clone library 
analysis.[199] This technique is recognised to be more sensitive than 16S pyrosequencing methods 
but suffers from limitations of cloning bias and is labour intensive and relatively more 
expensive.[118] A recent study by Barfod et al described successful characterisation of the mouse 
microbiome in BAL samples using pyrosequencing. In order to circumvent the difficulties of low 
bacterial 16S rRNA content in BAL samples, they performed an additional PCR step to increase 
amplification.[355] Although this appeared to allow successful 16S pyrosequencing, the additional 
PCR step is very likely to increase the chance of contamination and the authors do not present any 
sequencing data from negative controls to rule out the possibility of universal contamination. It is 
notable that they reported the presence of several bacterial genera including Polaromona, 
Schlegella and Brochothrix that are considered to be environmental bacteria and have not been 
reported in samples from human studies.[355]  
Having observed low 16S rRNA yields in airway lavage samples from mice, we next focussed on 
harvested lung tissue samples. We found that lung tissue had a higher bacterial yield than BAL with 
~2 log increase in 16S qPCR copy numbers in lung tissue samples, regardless of the quantity of tissue 
used to extract DNA from. Although the minimum threshold of qPCR copies required to allow 16S 
pyrosequencing is currently unclear, these data suggest that use of lung tissue may be a more 
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feasible approach to characterisation of the lower respiratory tract microbiota in mice than using 
BAL samples. In the study by Barfod et al described above, successful characterisation of the 
microbiota in lung tissue was also reported, using a similar protocol to that used for BAL 
samples.[355] However, as the authors discuss, use of lung tissue samples may be complicated by 
the occurrence of non-specific binding of 16S primers due to low amounts of bacterial DNA with 
large amounts of host eukaryotic nucleic acids and this adds yet another level of complexity to this 
technique.  
6.3.4 Evaluation of bacterial loads in lung tissue following administration of FP and/or RV1B 
infection 
Although we were unable to proceed with 16S pyrosequencing of samples in the FP + RV1B model to 
directly test our hypothesis that FP administration in combination with RV1B infection would 
precipitate disturbance of the respiratory microbiome, we were able to use the 16S qPCR assay to 
assess effects on the total bacterial loads in lung tissue following these manipulations. We observed 
an early and transient fall in lung tissue bacterial loads in mice challenged with RV1B compared to 
UV–RV1B treated controls at 8h post-infection. This early effect correlates temporally with the peak 
expression of many anti-bacterial mediators following RV infection in the mouse model. Therefore, it 
is possible that, through up-regulation of these mediators, RV infection reduces bacterial loads in the 
lung. We did not, however, observe any differences between RV1B and UV-RV1B challenged mice at 
timepoints later than 8h. Molyneaux et al reported that experimental RV infection in patients with 
COPD led to a 6 fold rise in 16S copy numbers in sputum but saw no difference in bacterial loads 
associated with RV infection in healthy controls.[122] Molyneaux et al did not assess 16S qPCR 
copies at earlier timepoints than d15 post-infection [122] and so it is unclear if a similar early 
reduction in bacterial loads occurs in human models. Notably, mediators such as IL-6 and TNF-α peak 
around d9 in the human model of RV infection (P.Mallia, unpublished observations) and therefore 
assessment of bacterial loads at earlier timepoints may have demonstrated similar reductions to 
those observed in the mouse model.  
Assessment of bacterial loads following FP administration in our model revealed a trend towards a 
transient increase in bacterial loads at 8h with significant increases observed when FP was combined 
with RV infection. This raises speculation that FP suppresses anti-bacterial components of host-
defence and thus directly alters the microbiota, increasing bacterial loads in the lung. Although we 
observed no effect of FP and/or RV infection on total bacterial lung loads at later timepoints, it 
should be noted that these treatments could still be causing alterations in the bacterial community 
composition without having any effect on the total quantity of bacteria within the lungs. 
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6.3.5 Exogenous administration of S. pneumoniae to model bacterial colonisation 
Requirement of a change in sequencing platform prevented progression of work to characterise the 
lower respiratory microbiota in mice. We therefore employed an alternative strategy of instilling low 
dose S. pneumoniae to directly model bacterial lung colonisation in mice. Optimisation experiments 
to define the lowest possible infecting dose at which bacteria could be reliably recovered from lung 
tissue by culture whilst inducing a mild inflammatory response suggested that 2.5 x 105 CFU was the 
most appropriate dose. However, we found that there was a narrow threshold between rapid 
clearance of bacteria at low infecting doses of 1 x 105 CFU and systemic dissemination with mortality 
observed in a proportion of mice infected with 2.5 x 105 CFU and above. A recently published study, 
which was not available at the time we conducted our optimisation experiments has shown that a 
number of factors including the strain of S. pneumoniae, the volume in which the dose is 
administered and the strain of mouse used can all influence whether lower airways colonisation can 
be reliably established.[352] This study showed that S. pneumoniae D39, the pneumococcal strain 
used in our study, was not suitable for accurate modelling of colonisation and use of an alternative 
strain LGst215 in CBA/Ca mice led to 90% of mice infected having recoverable bacteria in the lungs 
at 7d post-infection.[352] Therefore, adopting such approaches may have enabled us to establish a 
more representative colonisation model. Other approaches such as encasing bacteria in agar beads 
to restrict in vivo phagocytosis and thus prevent rapid clearance from the airways have also been 
reported to successfully achieve a representative colonisation model [353, 354] but these 
approaches are more technically difficult. 
6.3.6 Effect of FP on low dose S. pneumoniae infection 
6.3.6.1 Bacterial loads in lung tissue and systemic dissemination 
Administration of high dose FP (1mg/kg) prior to infection with 2.5 x105 CFU S. pneumoniae led to 
significantly increased bacterial loads in lung tissue at 8h post-infection with a non-significant trend 
towards an increase also observed at 4 and 24h post-infection. We also observed a non-significant 
trend towards increased systemic dissemination (bacterial CFU counts in blood) at 24h post-
infection. Our findings suggest that ICS use could potentially lead to increased proliferation of 
existing PPMs such as S. pneumoniae in the lungs of patients with COPD who are chronically 
colonised and thus directly precipitate pneumonia. The relevance of this mechanism to human 
disease is based on the assumption that the model of low dose S. pneumoniae we used is 
representative of lower airways colonisation in COPD. However, it could be argued that our model is 
one that is more in keeping with an acute bacterial pneumonia, since systemic dissemination and 
death occurs in a proportion of infected animals. If indicative of an acute pneumonia model, then 
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our findings would actually contradict those from some human studies, which have reported that ICS 
use during established pneumonia in patients with COPD is associated with reduced pneumonia-
related complications and improved outcomes.[269, 274-276] However, these studies could not 
directly assess the effect of ICS on bacterial loads in patients with pneumonia and it is possible that 
the observed beneficial effects may be due to suppressed inflammatory responses rather than 
effects on bacteria clearance as reduced systemic inflammatory responses have been reported  with 
ICS use in community-acquired pneumonia.[418] Our finding that high dose FP increases bacterial 
loads in lung tissue is in keeping with other studies that have assessed the effect of ICS 
administration in mouse pneumonia models. Patterson et al reported that nebulised FP 
administration increased bacterial loads in lung tissue and blood following Klebsiella pneumoniae 
challenge in mice.[283] Wang et al also showed increased bacterial loads in lung tissue associated 
with nebulised budesonide following challenge with P. aeruginosa in a mouse model of ovalbumin-
induced asthma.[303] Neither of these studies accurately characterised the key underlying 
mechanism of how FP increased bacterial loads, although they report some similarities to our 
observations of suppressed anti-bacterial mediators including neutrophil chemokines, IL-6 and 
CRAMP (discussed in sections 6.3.5.2 and 6.3.5.4). 
6.3.6.2 Anti-bacterial cytokines and inflammatory cell recruitment and function 
The induction of anti-bacterial cytokines and recruitment of inflammatory cells was assessed in the 
FP + low dose S. pneumoniae mouse model. We observed suppression of the early induction of 
proinflammatory cytokines and chemokines including IL-6, TNF-α, CXCL1/KC and CXCL2/MIP-2 and 
suppression of macrophage and neutrophil numbers by FP. Studies have reported similar effects of 
corticosteroids on inflammatory responses following stimulation by bacterial products in vitro [287-
290] and following challenge with live bacteria in vivo.[283, 312] These are all components that are 
involved in the innate response to bacterial respiratory infection. IL-6 plays a role in delaying 
neutrophil apoptosis and enhances neutrophil cytotoxic function [419] and mice deficient in IL-6 
show increased lung tissue bacterial loads and impaired survival [148]. TNF-α is also a key cytokine in 
pneumococcal pneumonia and is required for neutrophil recruitment [420] and anti-TNF-α antibody 
administration in a mouse model of S.pneumoniae infection has been shown to be associated with 
reduced neutrophil counts and accelerated death [147]. The direct involvement of neutrophils in 
bacterial clearance has been demonstrated in a mouse model where selective neutrophil depletion 
increased lung tissue bacterial loads.[149] Therefore, some or all of these suppressed responses may 
contribute to the increased bacterial loads observed in our model. 
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In addition to assessment of macrophage numbers, we also evaluated the ability of alveolar 
macrophages to phagocytose FITC-labelled S. pneumoniae ex vivo to assess whether ICS had any 
effects on this function of alveolar macrophages to explain the effects on bacterial loads observed. 
We observed no significant difference in %phagocytosis or mean fluorescence intensity (indicating 
the amount of bacteria taken up by each cell) between alveolar macrophages from FP and vehicle 
treated mice, suggesting that FP does not affect phagocytosis of bacteria by macrophages. Patterson 
et al used eGFP-labelled Klebsiella to quantify the effect of FP on in vivo phagocytosis in a mouse 
pneumonia model. They observed no difference between % macrophages that had engulfed bacteria 
and a trend towards increased mean fluorescence intensity associated with FP treatment.[283] 
Other studies that have assessed the effect of corticosteroids on macrophage phagocytosis ex vivo 
report conflicting results with some showing an impairment [280, 281] and others, in keeping with 
our findings, showing no effect [170]. 
6.3.6.3 Pattern recognition receptors 
We also assessed the effect of FP on expression of PRRs by S. pneumoniae. Similar to RV infection, 
we observed that S. pneumoniae infection induced TLR2 expression, which was supressed by FP 
administration. Chu et al reported very similar findings in a mouse model of M. pneumoniae 
infection.[312] TLR2 is an important PRR that recognises lipoteichoic acid and lipoprotein 
components of the pneumococcal cell wall [138] and our finding that its expression is suppressed by 
FP is potentially important as this may lead to reduced bacterial recognition and suppressed 
initiation of anti-bacterial immune responses which could be contributing to the increased bacterial 
loads we observed in the model. The critical role of TLR2 signalling in host defence against S. 
pneumoniae infection has been highlighted in mouse strains deficient in TLR2 which show impaired 
bacterial clearance following challenge with S. pneumoniae.[139] 
6.3.6.4 Anti-microbial peptides  
The effect of FP administration on expression of a number of AMPs was also evaluated in the low 
dose S. pneumoniae model. Of those assessed, CRAMP was the only expressed AMP that was 
affected by FP administration. We observed near complete inhibition of CRAMP protein in BAL at 8h 
post-infection, which matched the temporal kinetic of increased bacterial loads we observed. 
Cathelicidins are released by neutrophils and epithelial cells [182] and therefore, our finding that FP 
suppressed levels of CRAMP in the mouse model is perhaps unsurprising as neutrophil recruitment 
was also significantly suppressed at the same timepoint. CRAMP deficient mice have been shown to 
have reduced neutrophil recruitment and impaired bacterial clearance following P.aeruginosa 
infection.[421]  




The potentially protective effects of suppressed type I and II IFN induction on virus-induced 
secondary bacterial infection were discussed previously in section 6.3.2. Similar to the RV model, we 
also observed that FP suppressed the induction of IFN-β and –γ by S. pneumoniae infection. 
However, where this effect may protect against secondary bacterial challenge following RV infection, 
the opposite relationship has been reported for primary bacterial infection. Mice that lack type type 
I IFN signalling (IFNAR -/-) have been shown to  exhibit enhanced development of bacteraemia 
following intranasal pneumococcal infection, while maintaining comparable bacterial numbers in the 
lung, an effect that may be related to changes in expression of PAFR altering transmigration of 
bacteria across the lung.[154]  
However, our finding that FP increases bacterial lung loads with only minimal effect on systemic 
dissemination perhaps suggests that the effects we observed are not mediated by suppression of 
IFN-β. In contrast, IFN-γ deficient mice have increased bacterial loads in lung tissue following 
infection with S. pneumoniae and therefore type II IFN suppression by FP may potentially be more 
important in our model.[155] Mancuso et al showed that IFNAR -/- mice had reduced survival 
following systemic challenge with S. pneumoniae.[422] We could not assess this parameter in our 
study as we limited endpoint assessment to 24h post-infection. 
6.3.6.6 Dose responsive effects of FP on bacterial infection 
As discussed in section 6.2.6, the dose of 1mg/kg FP used in the mouse model is likely to be 
considerably higher than those used in clinical practice. Observational studies have suggested that 
the risk of pneumonia associated with ICS use in COPD may be dose-dependent with higher doses 
associated with greater risk.[221, 266, 267, 270]  Additionally, a mouse model study which used the 
same method of dosing via the intranasal route as adopted in our studies, showed the opposite 
effect with reduced bacterial loads associated with administration of a lower dose of FP (10µg per 
mouse, 20 fold lower than the doses used in our study).[313] We therefore assessed whether lower 
doses of FP had differential effects on anti-bacterial responses and bacterial loads following S. 
pneumoniae infection. 
In contrast to high dose (1mg/kg) FP administration, administration of 0.1mg/kg FP prior to S. 
pneumoniae infection reduced bacterial loads in lung tissue compared to vehicle + S. pneumoniae 
treatment with a trend towards reduction also associated with 0.5mg/kg FP administration. 
However, the ability of lower doses of FP to suppress induction of anti-bacterial cytokines IL-6 and 
TNF-α and neutrophil recruitment was no different to high dose FP. A previous study reported that 
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dexamethasone enhances H. influenzae induced upregulation of TLR2 in an ear epithelial cell line 
[391] and this has led to the hypothesis that glucocorticoids may prime the innate immune system 
for rapid activation and enhancement of the acute phase response[423]. We therefore assessed 
whether lower doses of FP also increased TLR2 expression in our model but did not find this to be 
the case. In a clinical context, these data provide some mechanistic insight into how ICS may 
increase pneumonia risk in COPD and also suggest that lower doses of ICS may potentially retain 
beneficial anti-inflammatory effects without causing detrimental effects on bacterial clearance.  
6.3.7 Limitations of FP and S.pneumoniae infection mouse model 
A major limitation of the S.pneumoniae infection model was that, even at the low infecting doses 
used, it was more representative of a phenotype of severe pneumonia/sepsis rather than lower 
airways colonisation. This prevented formal testing of the hypothesis that ICS administration would 
lead to proliferation of colonising pathogenic species and thus predispose to increased risk of 
pneumonia and limits extrapolation of findings to human disease. This model also suffers from 
similar limitations regarding the differences in intranasal FP dosing method employed in mice 
compared to daily inhaled dosing in humans as previously discussed with the FP and RV1B infection 
model (see section 6.2.9).  
 
6.4 Summary / Conclusions 
 
 Four dose elastase/LPS administration in mice does not accurately model the inflammatory 
changes or anti-viral immune responses associated with RV-induced exacerbation of COPD in 
humans. 
 Single dose elastase administration in mice more accurately models the inflammatory 
changes of RV-induced exacerbation but is also not representative of the impaired virus 
control that is thought to be indicative of human disease. 
 Administration of inhaled FP impairs type I and III IFN responses to RV infection which is 
causally related to impaired virus control. 
 Administration of inhaled FP has the potentially beneficial effect of suppressing virus-
induced airway inflammation but also impairs adaptive immunity and increases mucin 
expression, which may have detrimental effects in the context of RV exacerbations of COPD. 
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 Inhaled FP suppresses a number of components of anti-bacterial host defence in the lungs 
following infection with S. pneumoniae including TLR2 expression, anti-bacterial cytokine 
and CRAMP production, airway neutrophil recruitment and type I and II IFN expression. 
 High dose FP increases 16S bacterial copy numbers in the lung of naïve mice and also 
increases lung tissue bacterial loads following challenge with S. pneumoniae. 
 Lower doses of FP have the opposite effect to high dose FP, causing reduced lung tissue 
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6.5 Future work 
6.5.1 RV-induced exacerbation of COPD model 
In chapter three, we presented an assessment of a number of different protocols for modelling RV-
induced exacerbation of COPD. Although we report a novel model of single dose elastase challenge 
in combination with RV1B infection that mimics a number of key aspects of human disease, we were 
unable to define a model that recreated all the key elements of human disease. 
6.5.1.1 Further characterisation of single dose elastase model 
There are a number of additional features of stable and exacerbated COPD that were not assessed in 
the single dose elastase model that we established that are relevant to human disease and, if 
present, would increase the clinical validity of the model. Characterisation of lymphocyte sub-
populations by flow cytometry would allow a more detailed assessment of the observed 
enhancement in lymphocytic inflammation and permit an assessment of whether the model mimics 
the increased CD8+ T cell recruitment that has been reported in the human experimental model of 
RV infection in COPD.[84] Other disease-relevant features of human COPD that could be evaluated in 
the model would include measurement of markers of oxidative stress, which have been reported in 
cigarette-smoke exposure models.[329] Additionally systemic inflammation [424] and 
extrapulmonary disease manifestations such as skeletal muscle atrophy and cardiac dysfunction are 
features that have also been reported in cigarette smoke exposure models [424-427] but not 
extensively studied in  elastase models of COPD. 
We used non-invasive lung function measurement techniques to show evidence of AHR to MCH 
challenge in the model. AHR has previously been regarded as a hallmark of asthma but is also 
observed in COPD.[428] However, we failed to demonstrate any baseline abnormalities (without 
MCH challenge) with either elastase administration alone or in combination with RV infection and 
therefore, we were unable to demonstrate the key feature of fixed airflow obstruction in our model 
of COPD. As discussed previously, invasive techniques may be more sensitive for detection of 
baseline abnormalities induced by elastase administration and would allow a more comprehensive 
assessment of single dose elastase as a model of airflow limitation. 
6.5.1.2 Alternative models of COPD exacerbation 
We were unable to define a mouse model that accurately replicated the deficient anti-viral 
responses and impaired virus control that is believed to be indicative of human disease. 
Development of such a model would be desirable to enable formal testing of our hypothesis that 
combined use of ICS in COPD leads to synergistic suppression of IFN leading to increased RV 
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replication. Additionally, such a model could also be used to test novel anti-viral therapies with the 
potential for future use in clinical practice.  
One possible explanation for our observation of reduced rather than increased virus loads in all 
models that we assessed is that the initial inflammatory response evoked by elastase administration 
primes the immune system so that when RV1B infection occurs 10d later, the virus can be cleared 
more rapidly. Other previously reported COPD exacerbation models have used increased intervals of 
up to 21d between elastase administration and bacterial challenge and shown impaired rather than 
improved pathogen clearance.[348, 349] Therefore, the model may be improved by increasing the 
interval between elastase and RV challenges to allow characterisation of a more accurate model of 
deficient anti-viral immune responses and impaired virus control in COPD.  
Finally, it may be possible that elastase-induced emphysema in mice is too severe a model to allow 
similar features to those reported in the human model of RV-induced COPD exacerbation which was 
conducted in patients with early stage disease.[35] In the absence of human experimental infection 
studies in patients with more severe disease to draw reference from, a more representative mouse 
model of early stage COPD, such as cigarette smoke exposure in combination with RV1B infection 
may potentially offer a more accurate representation of then deficient anti-viral immune responses 
reported in the existing human model of RV infection in mild COPD. Gualano et al showed that short-
term (4 days) cigarette exposure increased virus loads following challenge with H3N1 influenza A 
[341] and a similar dosing protocol could be attempted with RV1B infection. 
As discussed previously (section 6.1.3), a major limitation of the mouse model of COPD exacerbation 
is the limited validity and relevance of an acute exposure model to human disease. Therefore 
progression of previous work involving human experimental RV challenge in patients with early 
stage COPD [35] to a human infection model in more advanced disease would represent the 
optimum future approach towards characterising the precise anti-viral and inflammatory responses 
following RV infection in severe COPD.  
6.5.2 FP and RV1B infection model 
As we were unable to define an accurate model of the impaired virus control associated with human 
COPD, we used RV infection in wild type (otherwise healthy) mice as a surrogate for an acute 
exacerbation of COPD to evaluate the effects of ICS administration. However, in clinical practice, 
healthy patients who develop RV infections are not routinely treated with ICS. Therefore, to increase 
the validity of our findings to human disease, it would still be of interest to evaluate the effects of 
ICS administration in our single dose elastase model of COPD exacerbation. Although this may not 
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represent a valid approach to studying the combined effects of COPD and ICS on anti-viral immune 
responses, it may be useful for assessment of other parameters that are adversely affected by FP 
administration such as mucin expression, which was also increased in the single dose elastase + RV 
model. 
We present limited in vitro data on characterisation of the specific components of IFN signalling 
impaired by FP. It would be interesting to assess the effects of FP on IFN expression in response to 
other specific agonists of other receptors involved in initial virus sensing and induction of release of 
type IFN including TLR7 and 8 (R848) and RIG-I (5'pppdsRNA). Similarly, the effect of FP on IFN-β 
induced ISG expression in BEAS2B cells could also be evaluated to assess whether ICS also impair the 
secondary component of IFN signalling, which was suggested by evaluation of control groups from 
our in vivo recombinant IFN-β administration experiments. Use of small interfering RNAs (siRNAs) to 
knock down specific genes involved in these signalling pathways (such as adaptor molecules MAVS 
or TRIF) would further allow a more detailed characterisation of the components that are specifically 
affected by FP. Such information would be useful to give a clearer understanding of the effects of ICS 
on innate anti-viral immune responses and potentially facilitate the development of novel agents 
that preserve the beneficial anti-inflammatory effects of ICS but avoid detrimental effects on anti-
viral immune responses. Such agents could be more useful than currently available therapies for 
prevention of exacerbations and/or as treatment during an acute exacerbation. 
Our observation that FP increases RV-induced mucins in the mouse model may be of particular 
importance in clinical practice, if similar effects were to occur in humans. We were, however, unable 
to define the precise mechanism of how FP increases the late expression of MUC5AC and MUC5B 
following RV infection but showed that it was not related to the increased virus loads observed as 
the reduced virus loads associated with recombinant IFN-β administration had no impact on mucin 
expression.  Previous studies using in vitro models have shown that EGFR-dependent cascades are 
important in the upregulation of MUC5AC by RV.[368, 369] Using a similar protocol to that described 
by Hewson et al [368], NCL-H292 cells could be treated with FP and stimulated with either RV or 
specific agonists such as Poly(I:C) and effects on MUC5AC mRNA expression could be measured by 
quantitative PCR and EGFR expression assessed by Western blot analysis. A previous study has 
shown that inhibition of EGFR inhibits TLR3-mediated MUC5AC expression in vitro [369]and 
therefore, it is possible that FP may increase TLR3- or RV-mediated EGFR expression and thus 
augment MUC5AC expression. Such mechanistic studies may facilitate development of alternative 
therapies that have suppressive effects on both inflammation and mucins, which may be more 
beneficial for the treatment of COPD than existing therapies such as ICS. 
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We performed a limited assessment of the dose responsive effects of FP in the RV1B mouse model. 
We were able to identify a dose (0.5mg/kg) which had lesser effects on impairment of anti-viral 
immune responses but equivalent anti-inflammatory effects to the higher dose (1mg/kg) that was 
evaluated. However, at the lowest dose we assessed (0.1mg/kg) anti-inflammatory effects were lost. 
Therefore, future studies in the model could be aimed at performing a more extensive dose 
evaluation which may lead to identification of a specific dose that retains anti-inflammatory effects 
but has no effect on anti-viral host responses. This may suggest that similar doses exist in the 
context of ICS use in humans, although the relative ineffectiveness of these drugs in COPD due to 
reduced expression of HDAC-2 [229], with usual requirement for use of higher doses in clinical 
practice may prevent this concept being directly applicable to human disease. 
In the longer term, it would be interesting to evaluate the effects of ICS administration in a human 
model of experimental RV infection in COPD to assess whether similar effects are seen as those 
observed in the mouse model of primary RV infection. Specifically, it would be important to assess 
whether inhaled ICS at clinically relevant doses suppresses induction of type I and III IFNs and leads 
to impaired virus control. Clinically relevant endpoints that may be affected by ICS therapy that 
could be assessed in a human model would include symptom scores, lung function and airway mucin 
production. This would allow a more detailed disease-relevant evaluation of the potential adverse 
effects of ICS therapy during virus-induced exacerbations of COPD.  
6.5.3 FP and bacterial infection 
Future studies on the effects of FP on bacterial infection would focus on progression of work to 
characterise the microbiome in the FP + RV1B model and further evaluation of the effects of FP in 
the low dose S. pneumoniae model. 
6.5.3.1 Respiratory microbiota 
 Our preliminary data showed that RV infection in mice transiently reduced 16S bacterial loads while 
FP administration, alone or in combination with RV infection, transiently increased bacterial loads. 
This raises speculation that both RV infection and FP administration may have direct effects on 
bacterial communities within the lung and potentially lead to proliferation of PPMs, as we 
hypothesised. Formal characterisation of the specific composition of lung microbiota using 16S 
pyrosequencing of lung tissue samples from our model of combined FP and RV infection will allow 
detailed characterisation of the effects of these manipulations. Furthermore, it will be interesting to 
assess whether immune replacement strategies such as administration of recombinant IFN-β or 
other recombinant proteins of mediators that were found to be suppressed by FP and may be 
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relevant to virus-induced secondary bacterial infection, such as pentraxin-3 would be able to 
positively modulate the microbiota and reduce  expansion of PPMs. It would also be useful to assess 
whether single dose elastase administration models the disordered microbial communities that has 
been reported in human studies of COPD [114, 116, 429] and also assess the effects of combined FP 
and RV infection on the lower respiratory microbiota in this model as stated in our original aims. 
6.5.3.2 Effect of FP in S. pneumoniae model 
A number of future experiments could be carried out to further study the anti-bacterial effects of ICS 
in the S. pneumoniae model we established. We identified a number of potential mechanisms by 
which FP suppressed anti-bacterial innate host responses and may thereby lead to the increased 
bacterial CFUs in lung tissue observed in the model. In a similar fashion to our assessment of 
recombinant IFN-β in the FP+RV1B model, the FP + S. pneumoniae mouse model could be directly 
used to test cause and effect by assessing whether administration of ICS suppressed mediators can 
restore anti-bacterial immune responses and reduce lung tissue bacterial loads. Similar to its 
beneficial effects on virus control in the FP+RV1B model, recombinant IFN-β administration may also 
have a beneficial effect on the increased bacterial loads associated with FP administration in the S. 
pneumoniae model, especially since a recent study showed that IFN-β can reduce systemic 
dissemination of bacteria.[154] Additionally, we observed a large inhibitory effect of FP on CRAMP 
protein levels in BAL, an effect that matched the temporal kinetic of increased bacterial loads 
observed. Evaluation of the ability of recombinant CRAMP to improve anti-bacterial innate 
responses would also be of interest and such approaches have been proposed as potential 
therapeutic strategies in other conditions associated with chronic bacterial infection such as cystic 
fibrosis.[430] 
As with the FP + RV1B mouse model, we performed a limited dose assessment to evaluate the effect 
of lower doses of FP on S. pneumoniae infection. We found that lower doses of FP have opposite 
effects on bacterial control in the lungs but were unable to define by what mechanism this occurs as 
the components that we assessed were all similarly suppressed by high and lower doses of FP. A 
more detailed evaluation of the effect of lower dose FP on the other anti-bacterial components that 
were assessed with high dose FP such as ex vivo assessment of macrophage phagocytosis and 
CRAMP protein levels in BAL may allow identification of a specific component that is inhibited by 
high dose FP but enhanced by lower doses. This may also allow us to identify which of the many anti-
bacterial responses suppressed by FP is most relevant to the observed increase in bacterial lung 
loads.  
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Some studies have suggested that budesonide, the other commonly used ICS in COPD may be 
associated with lower risk of pneumonia but this finding is controversial.[222, 264, 265] A direct 
evaluation of comparable doses of budesonide and FP on anti-bacterial host defence and bacterial 
clearance in the S. pneumoniae mouse model would therefore be particularly informative. 
Additionally, a few studies have shown that LABAs such as salmeterol can also have effects on 
components of anti-bacterial host defence.[431, 432] Since ICS are frequently prescribed in 
conjunction with LABAs in COPD, it would also be interesting to assess whether co-administration of 
salmeterol with FP in our model of bacterial infection would have beneficial or detrimental effects. 
In the longer term, evaluation of the effects of commencing ICS on airway bacterial loads and the 
microbiota in patients with COPD that are colonised and non-colonised with PPMs would allow a 
more direct and disease-relevant approach. The difficulty with such a study would be identification 
of an appropriate cohort of patients who are ICS naïve. Alternatively, a recently described approach 
of experimental S.pneumoniae colonisation in healthy human subjects [433] could be adopted to 
directly study the effects of ICS administration on bacterial infection in patients with early stage 
COPD. This experimental approach would also allow other important questions and hypotheses to 
be addressed including whether bacteria can directly trigger exacerbations in COPD, which remains a 
controversial and widely debated issue [434]. 
6.5.3.3 Alternative co-infection models 
 An alternative approach to assessment of the effects of FP and/or RV1B infection on the lower 
respiratory microbiota in mice would be to directly model secondary bacterial infection by 
sequential infection with RV1B and S. pneumoniae.  We were unable to define an accurate model of 
bacterial colonisation using S. pneumoniae D39 and therefore had to limit assessment of endpoints 
to 24h post-infection. As discussed previously, a recent study demonstrated use of an alternative S. 
pneumoniae strain in CBA/Ca mice which more accurately represented lower airways 
colonisation.[352] Combination of RV infection with this model of bacterial colonisation may allow a 
more representative investigation into the effects of ICS on RV-induced secondary bacterial infection 
in COPD.  Development of such a model would require considerable optimisation with a number of 
factors to consider including the specific timing of challenge with RV and bacteria. Previous studies 
have administered H. influenzae 48h after infection with RV1B and showed delayed bacterial 
clearance in mice.[209] Alternatively, studies in influenza mouse models have administered S. 
pneumoniae at later timepoints after viral challenge.[211, 385] The majority of suppressed anti-
bacterial effects in our model of FP + RV1B infection occurred at 8-24h post-infection and therefore 
this may represent the optimum timepoint to assess, but the literature on influenza and the late 
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effects on mucin expression observed in our model might suggest that longer intervals should also 
be assessed. A virus/bacteria confection model could also be combined with our single dose elastase 
COPD model which would then allow us to directly assess the effect of ICS administration on RV-
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